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ABSTRACT 
 Glioma arises from glial cells in the brain and is a common intracranial 
neoplasm of the central nervous system. Standard treatment is surgery followed by 
radiation and chemotherapy, however, the prognosis remains poor. Presence of the 
blood brain barrier (BBB) poses a significant challenge to drug delivery due to the tight 
junctions between adjacent endothelial cells. However, studies have confirmed that 
integrity of the tight junctions in the BBB is compromised in primary and metastatic 
brain tumours.  
It is a known fact that tumour masses are hypoxic and oxygen consumption in a 
tumour is erratic. A drop in the partial pressure of oxygen changes gene expression 
mediated by the activation of hypoxia inducible factor (HIF). HIF system plays an 
important role in tumour growth by controlling the transcription of genes responsible 
for cell proliferation, angiogenesis and energy metabolism.  
Asiatic acid is a herbal extract of the plant Centella asiatica. Asiatic acid has 
been shown to possess anti-cancer activity, in addition, it also aids wound healing, 
collagen synthesis and can cross the BBB.  
Results from this study showed that asiatic acid reduced cell viability in 
comparison to the chemotherapeutic drug-cisplatin, under hypoxia. Apoptosis was 
observed under hypoxia following asiatic acid treatment, however, no significant effects 
on cell proliferation or reactive oxygen species generation were observed. 
Taken together, these results suggest that asiatic acid is a potent inducer of cell 
apoptosis under hypoxia and mainly acts via downregulation of Bcl-2, intracellular 
calcium increase and mitochondrial stress.  
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Asiatic acid is a hydrophobic compound and thus creates a challenge for its 
delivery to tumours. In addition to studying the effects of asiatic acid under hypoxia in 
this study, we have also aimed at designing a vehicular system for the delivery of asiatic 
acid into tumours. Biodegradable nanoparticles formulated with poly-ε-caprolactone 
(PCL) were prepared to investigate sustained, localised delivery of asiatic acid. 
Monodisperse blank and asiatic acid-loaded nanoparticles, that were stable for 60 days 
were prepared and ranged between 133 ± 1.8nm to 152.5 ± 2.7nm and 134.4 ± 1.5nm to 
150.2 ± 1.2nm in size, respectively. The asiatic acid-loaded nanoparticles had a drug 
loading efficiency of 28 ± 1.2% and no release of the drug in phosphate buffered saline 
at pH 7.4 following 24 hour incubation. Although nanoparticle internalisation was 
observed with the coumarin-6 loaded nanoparticles, in vitro studies did not show any 
significant effects on cell viability of SVGp12 or U87-MG cell lines. The lack of the 
particular lipase in mammals leads to a slow degradation of PCL by hydrolysis and can 
take up to 4 years for complete degradation. 
Thus, we established that asiatic acid induces apoptosis in glioblastoma cells in 
vitro and also under hypoxia. However, asiatic acid-loaded nanoparticles showed no 
differences in cell viability due to the lack of lipase in the cells.  
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1 INTRODUCTION 
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1.1 Glioma  
Glioma, a common intracranial neoplasm of the central nervous system, is a 
highly malignant brain tumour having poor prognosis due to the associated 
neovascularisation (Skog et al., 2008). Glioma arises from the glial cells in the brain 
which include astrocytes, oligodendrocytes and ependymal cells that support and 
nourish the brain (Jia et al., 2012; Toyooka et al., 2008). The World Health 
Organisation (WHO) scheme for the grading of gliomas is the classification of the 
tumours on their hypothesised line of differentiation and by the features they display 
whether of ependymal cell, astrocyte or oligodendrocyte origin. They are graded on a 
scale of I-IV depending upon the degree of malignancy (Table 1.1; Maher et al. 2001). 
Table 1.1: WHO grading system for gliomas and their incidence rate 
Tumour grade Characteristics Incidence 
I (Pilocytic Astrocytoma) Low proliferative potential, 
possibility of cure after surgery 
~2%  of all gliomas 
II (Diffuse Astrocytoma) Infiltrative, low proliferative 
potential, may recur and progress 
to higher grades of malignancy 
10-15% of astrocytic 
tumours 
III (Anaplastic 
Astrocytoma) 
Infiltrative and proliferative, 
histological evidence of 
malignancy 
30% of astrocytic 
tumours 
IV (Glioblastoma) Highly infiltrative and 
proliferative, histological evidence 
of malignancy, mitotically active, 
prone to necrosis, associated with 
rapid preoperative and 
postoperative disease progression 
and fatal outcome 
70% of astrocytic 
tumours 
Adapted from: Brain tumour staging, American Society of Clinical Oncology, reviewed, 
June 2013 and Chalmers, 2011 
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1.1.1 Glioblastoma Multiforme  
Glioblastoma multiforme (GBM) is the most aggressive and malignant form of 
glioma. GBM may be a primary neoplasm of the brain or develop from a low-grade 
astrocytoma or an oligodendroglioma. It accounts for 12-15% of all intracranial tumours 
(Bruce & Harris, 2011). GBM arises from the genetic and epigenetic alterations in the 
normally functioning astroglial cells (Fig. 1.1), and many other genetic and cytogenetic 
chromosomal alterations have been described as playing a role in the onset of the 
tumour (Haque & Ray, 2011). 
GBM may be classed as a primary or secondary tumour with the primary type 
accounting for 95% of the GBM cases; most associated with adults over 50 years of 
age. Secondary GBM, accounting for 5% of the total GBM cases, is seen in younger 
patients of less than 45 years of age, typically developing from a low-grade astrocytoma 
or an anaplastic astrocytoma with the time scale ranging from 1-10 years for its 
development (Ohgaki and Kleihues, 2013) 
1.1.2 Genetic Pathways Leading to GBM 
The development of glioma may be de novo or through the progression from a 
low grade or anaplastic astrocytoma (Kleihues and Ohgaki, 1999). Several genetic 
alterations have been identified in the malignant transformation of astrocytes; however, 
the understanding of the sequence and types of gene alterations remains incomplete. 
The existence of prominent mutations in the components of the cell cycle and the 
apoptotic pathways in glioma along with dysregulation of growth, survival and 
migration suggests the likelihood of these targets to be important in glial development 
(Maher et al., 2001). 
Comprehensive genetic screens of GBM have shown that genetic loss is 
scattered across the entire genome, affecting nearly all chromosomes at frequencies 
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ranging from 2% to 80%. Particularly common regions of loss include areas on 1p, 6q, 
9p, 10p, 10q, 13q, 14q, 15q, 17p, 18q, 19q, 22q, and Y (Kanu et al., 2009). Loss of 
heterozygosity (LOH) on chromosome 10q is the most common genetic alteration for 
primary (complete loss) and secondary GBM (partial loss), occurring in 60-90% of 
GBM cases. However, several other LOH studies have shown three distinct loci to be 
deleted, 10p14–p15, and 10q23–24, distal to 10q25. The mutation is specific for GBM 
and rarely found in other tumour grades (Bruce & Harris, 2011; Kanu et al., 2009). At 
lower frequencies, allelic losses on 1p (31%) and 7q (9-12%) have also been seen in 
GBM (Kanu et al., 2009). The tumour suppressor gene PTEN (phosphatase and tensin 
homolog) on chromosome 10q23.3 encodes the protein tyrosine phosphatase, which 
turns off signalling pathways. A mutation of this gene leads to loss of PTEN activity 
giving rise to activation of cell cycle signalling pathways (Bruce & Harris, 2011). 
Genetic alterations at the genomic level, amplifying the gene expression are 
demonstrated in GBM however, these are less frequent in comparison to loss of gene 
expression. The gain of gene expression occurs in the form of duplication of entire 
chromosomes, intra-chromosomal amplification of specific alleles, extra-chromosomal 
amplification often in the form of double minutes, and activating mutations (Kanu et al., 
2009). The most common oncogenomic event is amplification of epidermal growth 
factor receptor gene (EGFR). The EGFR gene on chromosome 7, which controls cell 
proliferation, is amplified in GBM along with the presence of truncated isoforms of the 
receptor which result due to the deletion of exons 2-7 from the extracellular domain ( 
Bruce & Harris, 2011; Kanu et al. 2009; Kleihues & Ohgaki 1999; Lang et al. 1994). 
EGFR is a 170kDa receptor tyrosine kinase member of the ErbB family consisting of 
four distinct receptors: HER1/EGFR (HER-human epidermal growth factor receptor), 
HER2, HER3 and HER4. It is formed of three major domains: the extracellular domain, 
the transmembrane domain and the cytoplasmatic domain, which harbors the tyrosine 
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kinase activity. Phosphorylation of the tyrosine kinase domain activates several 
signaling pathways, such as the phosphatidyl-inositol 3-kinase (PI3K), Akt (protein 
kinase B), mTOR (mechanistic target of rapamycin, encoded by MTOR gene), and 
Ras/mitogen-activated protein kinase (MAPK); resulting in the activation of several 
biological processes such as cell proliferation, angiogenesis, migration, survival and 
differentiation (Minniti et al., 2009; Normanno et al., 2006). The mutant EGFR thus 
confers enhanced tumourigenicity on human glioblastoma cells by increasing 
proliferation and reducing apoptosis (Kleihues and Ohgaki, 1999). EGFR amplification 
has been identified as a genetic hallmark of cancer cells including GBM (Hanahan and 
Weinberg, 2011b; Ohgaki et al., 2004). 
 
Figure 1.1: Genetic alterations involved in the progression and initiation of 
primary and secondary GBM 
The onset of GBM involves several genetic alterations such as p53 mutation, loss of 
heterozygosity and EGFR amplification. Different genetic alterations are involved at 
different grades of tumour. Source Ohgaki et al., 2004. 
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Genetic alterations such as amplification or deletion represent direct glioma-
inducing events; other alterations directly affect gliomagenesis by DNA instability. The 
overall mutation rate in somatic human cells is approximately 1.4 × 10
10
 nucleotides per 
cell division. This low spontaneous mutation rate in normal cells cannot be accountable 
for the large mutation rate observed in GBM (Ohgaki et al., 2004). Gliomagenesis 
involves errors in DNA replication and repair, chromosomal segregation, and alteration 
of signalling cascades not directly attributed to genomic mutations such as Ras and c-
Myc (Hanahan and Weinberg, 2011b). The collection of these genetic and cellular 
alterations gives rise to a tumour cell phenotype, described as a mutator phenotype. 
DNA repair mechanisms are central to this mutator phenotype (Loeb, 2001). However, 
in GBM, at least four major DNA repair pathways may go askew. This includes 
nucleotide excision repair, base excision repair, mismatch repair, and direct reversal of 
lesions in recombination. The DNA repair enzyme O
6
-methylguanine-DNA 
methyltransferase (MGMT) offers resistance towards alkylating agents where it 
specifically removes promutagenic alkyl groups from the O
6
-position of guanine in 
DNA, thus protecting cells from carcinogenesis. Loss of MGMT expression is caused 
due to methylation of promoter CpG islands (CGI) which has been observed in 
secondary (75%) and primary (36%) GBMs; where ~60% are located in CGIs (Deaton 
et al., 2011; Hegi et al., 2005). The majority of the low-grade gliomas with MGMT 
methylation contain a mutation in the tumour suppressor gene p53. The p53 gene 
encodes a protein that plays an important role in several cellular processes, including the 
cell cycle, response to DNA damage, apoptosis, cell differentiation, and 
neovascularisation (Bobustuc et al., 2010; Furnari et al., 2007; Ohgaki et al., 2004). p53 
protein functions as a stress-inducible switch to turn on alternative pathways to G1 arrest 
of the cell cycle or apoptosis (Furnari et al., 2007; Kleihues and Ohgaki, 1999). The p53 
gene has been observed to be altered or deleted in approximately 25-40% of GBMs, 
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more commonly in the secondary subtypes (Bruce & Harris, 2011; Kanu et al, 2009; 
Lang et al, 1994). 
1.2 Symptoms and Treatment  
The most common symptoms of glioma include headaches, fits and seizures. 
Other symptoms include aphasia, paresthesia, hemiparesis, and problems with the eye. 
Thus these are not considered very seriously by the patient, making the diagnosis of 
glioma very difficult. However, the initial clinical presentation is variable and depends 
on tumour localisation and size (Preusser et al., 2011). Glioma is often identified at the 
end stage when the tumour progresses to GBM. High grade glioma patients may show 
symptoms such as epilepsy, cognitive dysfunction and a high intra-cranial pressure 
(Preusser et al., 2011; Stupp et al., 2009; Verhoeff et al., 2009). 
Patients with high-grade glioma have a poor prognosis and cannot be cured 
despite a multimodality treatment with surgery, radiation and chemotherapy. The 
median survival ranges from <1 to 5 years depending on tumour grade, cytogenetic 
analysis, age and performance status at the time of diagnosis (Preusser et al., 2011). The 
primary objective of surgery is to remove as much of the tumour mass as possible 
without disturbing the neurological function (Bruce & Harris, 2011). However, high 
grade tumours have infiltrating cells making entire tumour removal very difficult 
(Kleihues and Ohgaki, 1999). Surgery can improve patient prognosis but the small 
amount of tumour that may be left behind after surgery may lead to a relapse (Jallo & 
Ramachandran, 2012). Radiation (RT) and chemotherapy on the other hand are non-
invasive but have many adverse side effects and reduce the overall immunity of the 
patient, making the cells and tissue more prone to other infections (Chamberlain et al., 
1998).  
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1.2.1 Cisplatin 
Cisplatin (cis-diamminedichloroplatinum or CDDP), is a potent 
chemotherapeutic drug widely used for cancer treatment. The discovery of cisplatin in 
the 1960’s has sparked a huge interest in the potential of platinum-II and other metal 
containing compounds in the treatment of different types of cancer (Frezza et al., 2010). 
The clinical use of cisplatin includes the treatment of sarcomas, ovarian and cervical 
cancer, cancers of the bone, soft tissue and blood; and paediatric solid tumours. Patients 
have thus obtained better prognosis. Cisplatin was first applied to a cancer patient in 
1971 and became available for clinical use in 1978 as Platinol
®
 (Bristol-Myers Squibb) 
in Canada and thereafter in the United States, followed by the rest of the world 
(Lebwohl and Canetta, 1998).  
The clinical use of cisplatin is very limited due its dose-dependent toxicity on 
normal tissue and cellular resistance (Florea and Büsselberg, 2011; Frezza et al., 2010; 
Tezcan et al., 2013). Some of the side-effects of cisplatin include nausea and vomiting, 
other cell damaging effects such as a drop in the blood cell count, platelet production in 
the bone marrow and immunosuppression. More specific side effects include 
nephrotoxicity, neurotoxicity and loss of hearing (Florea and Büsselberg, 2011; 
Momekov et al., 2006; Ramesh and Brian Reeves, 2002; Sheleg et al., 2002). Cisplatin 
is often used in combination with other drugs, so as to produce a synergistic effect and 
thus reduce the side-effect profile of the drug (Desoize and Madoulet, 2002; Momekov 
et al., 2006; Mori et al., 2003).  
The main mechanism of action of cisplatin is via DNA intercalation following a 
spontaneous aquation reaction which involves the sequential replacement of the cis-
chloro ligands of cisplatin with water molecules. Cisplatin enters cells by passive 
diffusion and induces its cytotoxicity mainly by forming DNA-protein; and DNA-DNA 
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inter-strand and intra-strand cross-links. The platinum ion of cisplatin forms bi-
functional intra-strand crosslinks with the DNA at the N
7
 purine base. Cisplatin thus 
induces a kink in DNA structure and is a critical lesion allowing biomolecular 
recognition of the cell (Baruah et al., 2002; Florea and Büsselberg, 2011; Lanjwani et 
al., 2006; Siddik, 2003; Wang and Lippard, 2005). The physical distortion of the inter-
strand platinum crosslinks facilitates the binding of various proteins (e.g. TATA box-
binding protein and high-mobility group box protein 1) to the recognised damaged 
DNA inducing apoptosis and changes in the cell cycle (Wang and Lippard, 2005).  
Upon entering cells, cisplatin binds to intracellular thiols- metallothionein and 
glutathione, in turn reducing the amount of cisplatin available to bind to DNA. 
However, a continued exposure to cisplatin escalates the amount of cellular thiols which 
increases the cell’s resistance to cisplatin (Hagrman et al., 2003; Komatsu et al., 2000).  
In mouse cells and yeast, cisplatin resistance has been shown to be due to a mutation or 
deletion of the CTR1 gene (encodes for a high affinity copper transporter), which results 
in increased cisplatin resistance and reduction of cellular platinum levels due to 
overexpression of a multidrug resistance protein MRP2 or a copper-transporting P-type 
ATPase ATP7B. Also, the exporter protein- ATP-binding cassette protein subfamily C2 
has been shown to play a role in cisplatin resistance by promoting its efflux from cells 
(Holzer et al., 2004; Ishida et al., 2002). Other mechanisms of cellular resistance of 
cisplatin include increased repair of DNA adducts, reduction in cisplatin accumulation 
by changing influx/efflux profile and the failure of apoptotic pathways (Mamenta et al., 
1994; Miyashita et al., 2003; Nakayama et al., 2002; Siddik, 2003). 
However, the absorption of cisplatin into the perifocal tumour is hindered by the 
presence of the blood brain barrier. The use of cisplatin as a chemotherapy drug is 
restricted due its high molecular weight (300Da) (Sheleg et al., 2002).  
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1.2.2 Temozolomide 
More recently, radiotherapy and concomitant temozolomide (TMZ) followed by 
adjuvant TMZ has become the standard of care for patients with glioblastoma since the 
European and Canadian randomized trial was published in 2005 (Mineo et al., 2007; 
Stupp et al., 2005; Taal et al., 2008). TMZ is a second-generation imidazotetrazine 
derivative, exerting its cytotoxic effects by the methylation of specific DNA sites, with 
the methylation of the O
6
 position of guanine bases in the DNA considered to be the 
most critical (Sheleg et al., 2002). The median survival rate was increased when RT and 
chemotherapy were combined versus chemotherapy alone (16 months versus 11 
months) (Mineo et al., 2007). The cytotoxic effects of TMZ are associated with 
intracellular levels of MGMT. The high levels of MGMT in tumour tissue cause the 
resistance of tumour cells to TMZ. Epigenetic silencing of MGMT by promoter 
methylation is directly associated with improved survival in patients treated with TMZ 
(Minniti et al., 2009). 
1.2.3 Other Treatments 
Interstitial brachytherapy with iodine (I-125), another component of standard 
therapy, has been used as an adjuvant treatment for malignant brain tumours (Zhang et 
al., 2012). While the primary radionucleotide for brachytherapy is iodine, a more recent 
move is taking place towards permanent low-activity implants from the temporary high-
activity implants (McDermott et al., 1998; Zhang et al., 2012). This technique is used to 
treat small (<4 cm), radiographically well-defined lesions with a single high-dose 
fraction of ionizing radiation in stereotactically directed narrow beams, thus providing 
an added improvement to the survival outcome to patient with glioma. Stereotactic 
brachytherapy (SB), a spatially precise stereotactic implantation technique, is used in 
patients with supratentorial tumours that do not involve the corpus callosum, brain stem, 
thalamus, intraventricular or ependymal surfaces, and are  well defined, unifocal 
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tumours of 1-4cm in diameter. SB accurately places an inflating balloon catheter 
containing radioactive isotopes or interstitial diffusion-based drug delivery systems 
within the brain tumour, without producing cytotoxic effects on normal brain structures 
(Pelloski and Gilbert, 2007; Schwarz et al., 2012; Zhang et al., 2012).  
Carmustine, a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU
®
) is a nitrosourea 
and a chemotherapeutic drug approved by the Food and Drug Administration for use in 
the treatment of GBM (Reithmeier et al., 2010; Westphal et al., 2003). Nitrosoureas are 
DNA alkylating agents characterised by high lipophilicity permitting blood-brain barrier 
penetration. Nitrosoureas such as carmustine, lomustine or nimustine were commonly 
used in the first line of treatment for GBM prior to 1999 (Weller et al., 2013). 
Intracavitary carmustine wafers are recommended as part of first-line therapy for 
patients with an intraoperative diagnosis of high-grade glioma whose tumours are 
suitable for >90% resection (Wang et al., 2002). Neurosurgical clinics in the USA use 
carmustine wafers (Gliadel
®
) in interstitial chemotherapy for incurable relapses of 
malignant brain gliomas. In a phase III clinical trial in the USA, the median survival of 
patients treated with Gliadel
®
 was 31 weeks (27 US medical centres, 222 patients with 
recurrent malignant brain gliomas) (Sheleg et al., 2002). 
Several aberrantly activated signalling pathways characterise GBM. Epidermal 
growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR) 
and platelet-derived growth factor receptor (PDGFR) are overexpressed, amplified 
and/or mutated, leading to uncontrolled cell proliferation, angiogenesis, migration, 
survival and differentiation of the glioma cells (Minniti et al., 2009; Normanno et al., 
2006). Thus, several targeted inhibitors for EGFR, VEGFR and PDGFR are being 
developed. Recently, the use of small-molecule tyrosine kinase inhibitors (TKIs) and 
monoclonal antibodies against EGFR and VEGFR were evaluated in phase II clinical 
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trials for potential use in the treatment of GBM (Minniti et al., 2009). Pre-clinical 
studies involving the murine humanised monoclonal antibody cetuximab (Erbitux
®
, 
Merck & Co) have shown that EGFR inhibition leads to reduced proliferation and 
VEGF expression in glioma cells along with cell apoptosis (Minniti et al., 2009). Two 
oral, small TKI molecules, gefitinib (Iressa
®
, AstraZeneca) and erlotinib (Tarceva
®
, Osi 
Pharmaceuticals) were also evaluated in several phase I and phase II clinical trials in 
GBM patients (Minniti et al., 2009). Phase I and II studies of gefitinib and erlotinib 
used as single agents adjuvant to RT have shown no major improvements in survival. A 
modest progression free and median survival of 8.1 and 39.4 weeks respectively has 
been shown in phase II clinical trials consisting of 53 recurrent GBM patients (Minniti 
et al., 2009; Rich et al., 2004). A similar phase II trial of erlotinib has shown a median 
progression-free survival of only 2-3 months with a 6-25% response rate (Minniti et al., 
2009; Raizer et al., 2010). New growth factor inhibitors such as lapatinib (a dual EGFR 
and ErbB-2 inhibitor) and canertinib (a pan-ErbB inhibitor) have shown the potential 
for use in the treatment of GBM. An increased suppression of tumour growth following 
canertinib administration was observed in athymic nude mice bearing xenografts of  
human SF-767 glioblastoma (Minniti et al. 2009). 
Other potentially useful agents for the treatment of GBM are represented by the 
PDGFR, mTOR and integrin inhibitors (Minniti et al., 2009). 
One of the major problems with chemotherapy is the achievement of the 
therapeutic drug concentration at the tumour site without causing undesirable effects on 
the other organs of the body. The vascular system of the tumours is highly disorganised 
and unpredictable thus making drug delivery into the tumour very difficult (Chawla and 
Amiji, 2002). 
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1.3 Blood Brain Barrier 
The blood brain barrier (BBB) is a physiological barrier and a cellular transport 
system made by the complex tight junctions between adjacent endothelial cells (Risau 
& Wolburg 1990; Abbott & Romero 1996; Abbott 2002; Fig. 1.2). 
 
Figure 1.2: Cell associations at the blood brain barrier 
The cerebral endothelial cells form TJs at their margins sealing diffusional paracellular 
pathway between cells. Pericytes distributed along the length of the cerebral capillaries, 
surrounding the endothelium, are enclosed by and contribute to the local basement 
membrane forming a distinct perivascular extracellular matrix. The properties and 
maintenance of the BBB is due to the astrocyte foot processes surrounding the 
capillaries.  
Source: (Abbott et al., 2010) 
 
The BBB maintains homeostasis of the central nervous system (CNS) by 
restricting paracellular movement of water-soluble substances from blood to the brain 
microenvironment (Colgan et al., 2007). Endothelial cells line the microvessels of the 
brain and their tight junctions force a transcellular route of the molecular traffic across 
the brain instead of the paracellular route (Hawkins and Davis, 2005; Wolburg and 
Lippoldt, 2002). These endothelial cells exhibit specialised properties such as extremely 
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low permeability, high transendothelial electrical resistance and low occurrence of 
pinocytic vesicles (Colgan et al., 2007). These cells also secrete the basal lamina, which 
surrounds the brain capillaries that decreases the capillary permeability. Furthermore, 
the capillaries of the brain are in contact with the astrocyte foot processes (astrocytes are 
glial cells), thus separating the capillaries from the neurons (Abbott et al., 2006). 
Junctional complexes between endothelial cells include adherens junctions (AJs) 
and tight junctions (TJs). In AJs, cadherin proteins span the intercellular cleft and are 
linked into the cell cytoplasm by the scaffolding proteins alpha, beta and gamma 
catenin. AJs hold cells together giving the tissue structural support and are essential for 
formation of TJs (fig. 1.3). The disruption of AJs leads to barrier disruption (Wolburg 
and Lippoldt, 2002). The barrier function of the BBB is maintained by the highly 
regulated presence of tight junctions between adjacent cells and comprise of claudins, 
occludin, junctional adhesion molecules (JAM) 1-3, cingulin, 7H6 tight junction 
associated antigen, spectrin and zona occludens (ZO) 1, 2, 3. The ZOs link the tight 
junction proteins to each other and the actin cytoskeleton (Abbott et al. 2010; Colgan et 
al. 2007). Activation of actin is initiated by a rise in intracellular calcium, e.g., resulting 
from ligand binding to B2 bradykinin receptor and may change the configuration of 
claudins and occludin thus modifying the TJ properties (Abbott et al., 2010). 
Twenty four isoforms of claudin have been described, claudin 1-24, of which 
claudin 3 and 5 are vital to the diffusion and high electrical resistance of the BBB (Fig. 
1.3). Cytoplasmic proteins ZO-1, ZO-2, ZO-3 and cingulin link the cytoskeleton protein 
actin thus maintaining the structural and functional integrity of the BBB (Ballabh et al., 
2004).  
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Figure 1.3: Structure of blood brain barrier tight junctions 
Cadherins of the AJs provide structural integrity and cell attachment, and are necessary 
for the formation of TJs. Claudins associate and bind to each other across the 
intercellular cleft. Claudins and occludins are linked to ZO-1, 2 and 3, which are in turn 
linked via cingulin dimers to the actin/myosin cytoskeletal system within the cell.  
Source: Abbott et al., 2010 
 
1.3.1 Functions of the BBB 
Apart from providing a stable environment for neural function, the BBB 
maintains an optimum ionic composition for synaptic signalling function. The BBB 
helps in keeping the peripheral and central neurotransmitter pools separate, thus 
minimising ‘cross talk’ (Bernacki, et al 2008). Presence of macromolecules, such as 
albumin, prothrombin and plasminogen in the brain, activates cascades that can cause 
seizures, glial activation, glial cell division and scarring, and cell death (Gingrich and 
Traynelis, 2000; Gingrich et al., 2000).  These are prevented from entering into the 
brain interstitial fluid by the BBB. Neurotoxic substances and xenobiotics are actively 
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pumped out of the brain by the ABC transporters (Dallas et al., 2006). Solute carriers 
allow the transport of polar nutrients such as glucose and amino acids necessary for 
metabolism (Zhang et al., 2002). 
1.3.2 Transport across the BBB 
Several potential routes for permeation across the BBB are available. These 
include passive diffusion, ATP-binding cassette (ABC) transporters, solute carriers, cell 
migration and receptor mediated (RMT) or adsorptive mediated (AMT) transcytosis. 
Lipid-soluble non-polar molecules and blood gases - oxygen and carbon dioxide 
- can diffuse through the cell membrane passively and cross the endothelium in the 
BBB (Liu et al., 2004). Bases, due to their positive charge, have an advantage over 
acids when penetrating through the BBB. It is possibly due to the cationic nature of 
these molecules and an interaction with the negatively charged glycocalyx and 
phospholipid head groups of the outer leaflet of the cell membrane that facilitate their 
entry (Abbott et al., 2010). The diffusion of most polar substances through the BBB is 
difficult and thus all cells express a large number of solute carriers in the cell membrane 
(Zhang et al., 2002). These solute carriers are essential for the transport of polar 
nutrients such as glucose and amino acids necessary for metabolism. A wide variety of 
transport proteins mediating flux into and out of the brain are expressed by the BBB 
endothelial cells (Abbott et al., 2010).  
The ABC transporters in humans are of greatest significance for efflux transport 
of P-glycoprotein, multidrug resistance-associated proteins, and breast cancer resistance 
proteins (BCRP) (Begley, 2004; Dauchy et al., 2008). These transporters also transport 
cholesterol and are associated with drug resistance (Dean et al., 2001). The ABC 
transporters intercept drugs diffusing across the cell membrane, out of the endothelial 
cells (Abbott et al., 2010). The major role of the ABC transporters in the BBB is to 
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function as active efflux pumps consuming ATP and transporting a diverse range of 
lipid-soluble compounds out of the brain capillary endothelium and the CNS thus 
removing potentially neurotoxic, endogenous or xenobiotic molecules (Dallas et al., 
2006). 
The main route of transcystosis of macromolecules such as proteins and peptides 
across the BBB is by the endocytotic mechanisms. These vesicular mechanisms involve 
either RMT or AMT. RMT requires specific binding of macromolecules to their 
receptors on the cell surface triggering an endocytotic event, whereas AMT requires a 
positively charged macromolecular interaction with cell surface to induce endocytosis 
and subsequent transcytosis (Abbott et al., 2010; Demeule et al., 2002).  
1.3.3 How is the BBB Compromised in Glioma? 
Studies have confirmed that the integrity of the BBB is compromised in primary 
and metastatic brain tumours. Alteration in the BBB architecture during the brain 
tumour includes compromised TJs, increase in perivascular space, presence of 
fenestrations in the blood capillaries and increased number and activity of pinocytic 
vesicles (Bart et al., 2000; Deeken & Löscher, 2007; Liebner et al 2000). 
Studies have shown that in GBM, there is a selective loss of claudin-3 from the 
tight junctions, but not JAM, thus leading to a loss in the integrity and the functionality 
of the BBB (Abbott et al., 2010). Liebner and colleagues reported that claudin-1 
expression was lost from nearly all microvessels in high-grade astrocytomas (Liebner et 
al., 2000). In contrast, claudin-5 and occludin expression were down regulated in 
hyperplastic vessels and ZO-1 expression was largely unaffected; suggesting the 
molecular structure of microvessel tight junctions is altered in high-grade astrocytomas 
allowing the leakage of various solutes across the BBB (Davies, 2002). 
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1.4 Apoptosis 
Apoptosis, from the Greek word “to fall off” is a programmed cell death 
mechanism, first described by Kerr et al. in 1972 (Kerr et al., 1972). Apoptosis is a 
distinctive and an important mode of “programmed” cell death, involving genetically 
determined elimination of cells (Elmore, 2007). Apoptosis plays a vital role in 
development, and aging and in sustaining tissue homeostasis to maintain the cell 
populations and has been highly conserved throughout evolution (Cheung et al., 2012; 
Elmore, 2007; Fulda et al., 2010).  
1.4.1 Morphological Changes 
 Apoptosis is morphologically characterised by cell shrinkage, blebbing of cell 
membrane, nuclear condensation, cellular fragmentation and formation of apoptotic 
bodies (Furuya et al., 1997; Ziegler and Groscurth, 2004).  
The early stages of apoptosis involve cell shrinkage and pyknosis, which can be 
visualised under the light microscope (Kerr et al., 1972). Cell shrinkage results in 
smaller cell size, denser cytoplasm and more tightly packed cell organelles. Pyknosis 
results due to chromatin condensation and is a characteristic feature of apoptosis 
(Kroemer et al., 2009; Wong, 2011). This is followed by extensive plasma membrane 
blebbing (although the plasma membrane still remains intact), karyorrhexis and 
separation of cell fragments into apoptotic bodies also called “budding”(Elmore, 2007; 
Wong, 2011).  Subsequently, phagocytosis by macrophages, parenchymal cells or 
neoplastic cells occurs, and the apoptotic bodies are degraded in the phagolysosomes 
(Elmore, 2007). In addition to this, during the early stages of apoptosis, externalisation 
of phosphatidylserine from the inner layer to the outer layer of the cell membrane 
occurs, thus allowing recognition of dead cells by macrophages (Johnson et al., 2000; 
Saraste and Pulkki, 2000; Wong, 2011). Macrophages involved in the engulfment and 
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digestion of apoptotic bodies are called the “tingible body macrophages” and are found 
in the reactive germinal centres of lymphoid follicles or sometimes in the thymic cortex 
(Elmore, 2007; Rahman et al., 2010). Phagocytosis occurs without any inflammation as 
no inflammatory cytokines are released in the process (Kurosaka et al., 2003). In 
addition, the apoptotic cells do not release any cellular constituents into the surrounding 
interstitial tissue and the rapidly occurring process prevents any tissue necrosis from 
occurring (Elmore, 2007).  
1.4.2 Biochemical Changes 
In the presence of stress stimuli such as chemotherapeutic agents, irradiation and 
oxidative stress, the “death signal” initiates a complex series of events, including the 
activation of caspases (Cheung et al., 2012; Fulda et al., 2010; Li et al., 1997).  
The two main types of biochemical changes observed in apoptosis include: 
activation of caspases, and DNA and protein breakdown. DNA breakdown into large 
50-300 kilobase pieces occurs, followed by internucleosomal cleavage of the DNA by 
endogenous DNases into double-stranded DNA fragments of 180 to 200 base pairs. 
Although a characteristic feature of apoptosis, this is not specific, as the DNA ladder is 
also observed in agarose gel electrophoresis of necrotic cells (Lee et al., 1997; Saraste 
and Pulkki, 2000). 
The activation of caspases is another specific feature of apoptosis. Caspases 
belong to the cysteine family of proteases, where the “c” of the caspases refers to the 
cysteine protease family and the “aspase” refers to the enzymes property to cleave the 
asparatic acid residues. Activation of the caspases leads to the cleavage of many cellular 
proteins and breaking up of the nuclear scaffold and cytoskeleton. These biochemical 
changes explain in part the morphological changes, however, apoptosis can also take 
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place without oligonucleosomal DNA fragmentation and can be caspase-independent 
(Roschitzki-Voser et al., 2012; Wong, 2011). 
1.4.3 Mechanism of Apoptosis 
 The mechanism of apoptosis is a highly complex and a sophisticated event, 
involving an energy-dependant cascade of molecular events. Research has shown that 
there are two main mechanisms of apoptosis: the intrinsic or the mitochondrial pathway 
and the extrinsic or the death receptor pathway (Fig. 1.4) (Chen et al., 2014; Elmore, 
2007). However, evidence suggests that the two pathways are linked and the molecules 
from one pathway may influence the other (Elmore, 2007; Igney and Krammer, 2002). 
Another pathway, involving T-cell cytotoxicity and perforin-granzyme-dependent 
killing of the cell, also takes place in apoptotic cells. This is mediated by the granzyme 
B or granzyme A. All three pathways, intrinsic, extrinsic and the granzyme-B, converge 
down on the same execution phase, which involves the activation of caspase-3, resulting 
in DNA fragmentation, cellular degradation, formation of apoptotic bodies and 
expression of ligands for recognition by phagocytic cells (Andoniou et al., 2014; 
Elmore, 2007; Wong, 2011). 
1.4.4 The Intrinsic Pathway 
 The intrinsic pathway is initiated by internal stimuli such as hypoxia, irreparable 
DNA damage, high cytosolic Ca
2+
, severe oxidative stress, radiation, toxins and viral 
infections (Elmore, 2007; Wong, 2011). 
The intrinsic pathway is the result of an increase in the mitochondrial 
permeability and the release of pro-apoptotic molecules such as cytochrome-c into the 
cytoplasm. The Bcl-2 family of proteins control and regulate the apoptotic 
mitochondrial events. The Bcl-2 family of proteins governs mitochondrial membrane 
permeability either by the pro-apoptotic (e.g., Bax, Bak, Bad, Bcl-Xs, Bid, Bik, Bim 
21 
 
and Hrk) or the anti-apoptotic (e.g. Bcl-2, Bcl-XL, Bcl-W, Bfl-1 and Mcl-1) proteins 
(Fulda et al., 2010; Wong, 2011). 
 The above mentioned stimuli result in the opening of the mitochondrial 
membrane permeability transition pore, loss of the mitochondrial transmembrane 
potential and release of two main groups of pro-apoptotic proteins from the 
intermembrane space into the cytosol (Saelens et al., 2004). The first group of proteins, 
cytochrome-c, Smac (secondary mitochondria-derived activator of caspase), DIABLO 
(direct IAP Binding protein with Low pI) and the serine protease Omi/high temperature 
requirement protein A (HtrA2), activate the caspase-dependant mitochondrial pathway 
(Elmore, 2007; Garrido et al., 2006; Guicciardi et al., 2014). Cytoplasmic release of 
cytochrome-c activates caspase 3 via the formation of a complex known as apoptosome 
which is made up of cytochrome c, Apaf-1 and caspase 9. Conversely, Smac/DIABLO 
and Omi/HtrA2 promote caspase activation by binding to IAP (inhibitor of apoptosis 
proteins), subsequently leading to the disruption in the interaction of IAPs with caspase-
3 or -9 thus leading to their activation (Kroemer et al., 2007; LaCasse et al., 2008; 
Wong, 2011).    
1.4.5 The Extrinsic Pathway 
 The extrinsic pathway initiates upon the binding of death ligands to the death 
receptor member of the tumour necrosis factor gene superfamily (TNF) and involves 
transmembrane receptor-mediated interactions. The best known death receptor is the 
TNF receptor-1 (TNFR-1) which is related to the protein Fas (CD95); their ligands are 
called TNF and FasL respectively (Chicheportiche et al., 1997; Elmore, 2007; 
Hengartner, 2001; Locksley et al., 2001; Wong, 2011). These receptors are comprised 
of cysteine-rich extracellular domains and have an 80 amino acid cytoplasmic domain, 
called the death domain, and are critical in transmitting death signal from the cell 
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surface to intracellular signalling pathways. The death domain is involved in recruiting 
adaptor proteins such as TNF receptor-associated death domain (TRADD) and Fas-
associated death domain (FADD), and cysteine proteases such as caspase-8 (Chen et al., 
2014; Schneider and Tschopp, 2000; Wong, 2011). 
 The FasL/FasR and the TNF/TNFR-1 are the best characterised models for the 
series of events that take place in the extrinsic apoptotic pathway (Elmore, 2007). Upon 
ligand binding to the receptor, cytoplasmic adaptor proteins are recruited which exhibit 
the binding of respective death domains to the receptors. The binding of FasL to FasR 
results in binding of the adaptor protein FADD, whereas, binding of TNF to TNFR 
results in binding of TRADD along with the recruitment of FADD and RIP (receptor-
interacting protein) (Elmore, 2007; Suliman et al., 2001; Wajant, 2002). Dimerisation of 
the death effector domain takes place due to the association of FADD with procaspase-
8. This results in the formation of a death inducing signalling complex (DISC), thus 
leading to auto-catalytic activation of procaspase-8. The activation of caspase-8 triggers 
the execution pathway. This type of apoptosis can be inhibited by the protein c-FLIP 
(cellular FLICE {FADD-like IL-1β-converting enzyme}-inhibitory protein) which binds 
to FADD and caspase-8, causing them to be ineffective (Elmore, 2007; Suliman et al., 
2001; Wong, 2011).  
1.4.6 The Perforin-Granzyme Pathway 
Natural killer (NK) cells and CD8
+
 cytotoxic T lymphocytes (CTL) are the most 
important hosts of the immune system. These cells exert their effects by two distinct 
mechanisms, one involves the synthesis and release of soluble mediators such as INF-γ, 
TNF-α and interleukins, while the other involves direct cell lysis and induction of 
apoptosis in target cells (Pardo et al., 2004). T-cell mediated cytotoxicity comprises of 
CD8
+
 cells that kill the antigen bearing cells via the extrinsic pathway involving the 
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FasL/FasR interaction. However, these cells can exert their effects on tumour cells and 
infected cells via a different pathway involving the secretion of transmembrane pore-
forming molecule, perforin, with a subsequent exocytosis of cytoplasmic granules 
through the pore to induce apoptosis of the target cells (Pardo et al., 2004; Trapani and 
Smyth, 2002). The most important components within the granules are the serine 
proteases granzyme A and granzyme B (Elmore, 2007; Pardo et al., 2004). 
 Granzyme B cleaves proteins at the aspartate residues. It thus initiates the 
activation of apoptosis by direct or indirect caspase activation (caspases-3  and -8) 
resulting in the disruption of mitochondrial membrane integrity, by cleaving factors like 
ICAD (Inhibitor of Caspase Activated DNAse ) or by cleaving the key structural 
proteins in the nuclear membrane or the cytoskeleton (Brunner, 2003; Elmore, 2007; 
Pardo et al., 2004). Studies have also shown that granzyme B can utilise the intrinsic 
mitochondrial pathway for amplification of the death signal by specific cleavage of Bid 
and induction of cytochrome-c release (Elmore, 2007).  
 The granzyme-A pathway activates another cascade leading to the caspase-
independent apoptotic pathway via the damage of single stranded DNA (Martinvalet et 
al. 2005). Upon entering the cell, granzyme A activates DNA fragmentation via DNase 
NM23-H1, a tumour suppressor gene product. This DNase plays an important role in 
immune surveillance to prevent cancer by inducing apoptosis of tumour cells (Fan et al., 
2003).  
A special target of granzyme A is an endoplasmic reticulum (ER-) associated 
complex called the SET complex. The SET complex consists of granzyme A activated 
DNase NM23-H1, tumour suppressor gene pp32, and three granzyme A substrates- the 
nucleosome assembly protein SET, the base excision repair enzyme Ape1/Ref-1, and 
the DNA bending protein HMG-2. The SET complex (270-420 kDa) has an important 
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role in maintaining chromatin structure and DNA repair. Following a CTL attack or 
upon the loading of granzyme A into the cells, translocation of the SET complex into 
the nucleus of the cell occurs. Granzyme A cleaves the SET complex, removing the 
inhibition of the NM23-H1 DNase, resulting in apoptotic DNA degradation (Fan et al., 
2003; Martinvalet et al., 2005).  
1.4.7 Execution Pathway 
The final pathway of apoptosis, wherein the activation/execution of the caspases 
occurs, is called the execution pathway. Execution of apoptosis occurs via the 
degradation of nuclear and cytoplasmic proteins by the activated cytoplasmic 
endonucleases and proteases. The main effector molecules of apoptosis are the 
caspases-3, -6 and -7. Activation of caspase-3 by initiator caspases-8, -9 and -10 
activates the endonuclease CaD (caspase-activated DNase) (O’Brien and Kirby, 2008; 
Yang et al., 1998). In normal proliferating cells, CaD is complexed with ICaD (inhibitor 
of CaD) (Nagata, 2000). Activated caspase-3 thus cleaves ICaD to release the CaD 
leading to DNA degradation and chromatin condensation (O’Brien and Kirby, 2008). 
The p53 gene has an important link to apoptosis and therefore to cancer. p53 
mutation occurs in the majority of human tumours and is associated with the 
advancement of the tumour and patient prognosis (Lowe and Lin, 2000). Normal 
cellular mechanisms are controlled through a mechanism which involves p53. 
Mutations or deficiencies in p53 lead to reduced apoptosis and therefore to tumour 
development. Another feature of disruption of normal cellular death programme may 
occur due to an increase in the Bcl-2 protein, as it promotes cell survival by blocking 
apoptosis (Lowe and Lin, 2000; O’Brien and Kirby, 2008).  
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Figure 1.4: Schematic representation of the three apoptotic pathways, intrinsic, 
extrinsic and perforin/granzyme 
All the three pathways, intrinsic, extrinsic and granzyme B, merge in the end to activate 
caspase-3 leading to cytoskeletal reorganisation, chromatin condensation, nuclear 
fragmentation and ultimately leading to formation of apoptotic bodies and cell death. 
Source: Biology Stack Exchange 
 
 
1.5 Difference between Apoptosis and Necrosis 
Necrosis is an alternative approach to cell death. Necrosis is considered to be a 
toxic and energy-independent process. Presence of stress stimuli such as ischemia, 
glutamate excitotoxicity in neurons, hypoxia, hypoglycaemia and exposure to DNA 
alkylating agents has been reported to trigger necrotic cell death (Fulda et al., 2010; 
Vanlangenakker et al., 2008). Death domain receptors such as TNFR1 and Toll-like 
receptors have been reported to trigger necrosis. RIP-1 (receptor-interacting protein 1), 
a serine/threonine kinase protein plays a crucial role in the initiation of necrosis induced 
by the ligand-receptor interactions. Reactive oxygen species and calcium are the main 
stimuli of a necrotic cell death (Vanlangenakker et al., 2008). The mechanisms of 
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necrosis and apoptosis differ; however, there is an overlap in the two processes. Factors 
that convert an on-going apoptotic process into a necrotic process include the depletion 
of intracellular ATP and decrease in the availability of caspases (Denecker et al., 2001; 
Elmore, 2007; Levin et al., 1999). 
The major morphological changes that take place during necrosis include swelling 
of the cell, gain in cell volume due to swelling of organelles, formation of cytoplasmic 
vacuoles, distended endoplasmic reticulum, formation of cytoplasmic blebs, disruption 
of organelle membranes, swelling or rupturing of lysosymes or mitochondria and 
eventually, disruption of cell membrane (Kerr et al., 1972; Zong et al., 2004). The loss 
of cell membrane integrity leads to the release of cytoplasmic contents into the 
surrounding tissue, sending chemotactic signals, eventually leading to recruitment of 
inflammatory cells. As opposed to apoptosis, karyolysis occurs and inflammation may 
also occur (Denecker et al., 2001; Elmore, 2007).  
 
1.6 Cell Proliferation and Cell Cycle Mechanism 
Eukaryotic cells divide by an elaborate series of events, constituting the cell cycle, 
wherein the chromosome duplicates and a copy of the duplicated chromosome passes 
into each daughter cell. The cell cycle is a very tightly regulated process which causes 
an irreversible and unidirectional change in the state of the cell. The loss of this 
regulation leads to an uncontrolled expansion in the cell population, thus giving rise to 
cancer. Cell replication is controlled mainly by two consecutive phases, nuclear DNA 
replication and mitosis (Pinheiro and Sunkel, 2012; van den Heuvel, 2005). 
Eukaryotic cell cycle can be divided into four phases: G1, S, G2 and M phase.  
The G1 phase is essential for the determination of the fate of the cell (the cell can 
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withdraw from any further proliferation and undergo differentiation in order to perform 
a specific task or enter into the S phase) and is the first stage of interphase. During 
interphase, the cell grows and there is extensive transcription and synthesis of new 
cellular components. Somatic cells begin by the replication of chromosome in the S 
(synthesis) phase. This is followed by the G2 phase where the cells undergo rapid 
growth and protein synthesis in order to prepare for mitosis or the M phase. Mitosis is 
the process of nuclear division wherein a number of activities take place in the nucleus 
of the cell and is concluded by the division of the mother cell into two daughter cells. 
This is followed by the G1 (Gap 1 or Growth) phase (Crosio et al., 2002; Pinheiro and 
Sunkel, 2012; Rieder, 2011; Tyson et al., 2002). 
The cell cycle is controlled by a family of serine/threonine protein kinases called 
the cyclin-dependant kinases (Cdks) and their corresponding cyclin regulatory subunits. 
Different cyclin/Cdk units appear and have a specific kinase activity at different time 
points in the cell cycle (Table 1.2, Fig. 1.5) (Shackelford et al., 1999; Vermeulen et al., 
2003). Cdks induce downstream signals and major cellular events such as chromosome 
condensation, DNA replication, and spindle assembly by the phosphorylation of 
selected proteins. The levels of Cdks during a cell cycle remain constant, as opposed to 
the levels of cyclins which increase and decrease thus periodically activating their 
respective Cdks (Tyson et al., 2002; Vermeulen et al., 2003). The regulation of the 
activity of Cdk is controlled by cyclin binding and cyclin-dependent kinase inhibitors 
(CKIs). The two main families of the CKIs include the Ink4 family and Cip/Kip family. 
The members of the Ink 4 family only bind to Cdk4 and 6, while the members of the 
Cip/Kip family bind to all Cdks (Berthet et al., 2003; Cerqueira et al., 2014).  
To date, 21 Cdk encoding genes and 29 cyclin encoding genes have been 
identified. Amongst these, the cyclins A, B, E and D, and cyclin-dependent kinases 1, 2, 
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4 and 6 have been identified as the major regulators of cell cycle control (Bretones et 
al., 2014). The sequential activation of Cdk4 or Cdk6 followed by Cdk2, functions in 
early to mid-G1 phase and is important for the cell to enter into the S phase from the 
G0/G1 phase. While the Cdk 4 and Cdk6 associate with the D-type cyclins, the Cdk2 
complexes with cyclin E during late G1 (Berthet et al., 2003; Hubbi and Semenza, 
2015; Yang et al., 1997). Following the activation of the G1-phase Cdks, 
phosphorylation of the retinoblastoma protein (Rb) occurs allowing the accumulation of 
E2F transcriptional factors which consists of the genes encoding the required proteins 
for S phase (Bretones et al., 2014; Nevins, 2001). The Cdk1 and 2/cyclin A complex 
functions in the S phase whereas Cdk2/cyclin B and A complexes promote the G2/M 
transition (Bassermann et al., 2014; Berthet et al., 2003; Hubbi and Semenza, 2015). 
The cyclin B1/Cdk1 complex regulates cellular entry into mitosis and through its 
cytoplasmic, nuclear and centrosomal localisation, it is able to synchronise mitotic 
events such as nuclear envelope breakdown and centrosome separation (Wang et al., 
2014). Following mitosis, Cdk7 plays an important role in cell cycle progression and 
RNA Polymerase II transcription as a component of the general transcription factor IIH. 
The catalytic subunit of Cdk7, cyclin H and a really interesting new gene (RING) finger 
protein, Mat1 form the CDK-activating kinase (CAK), which in turn activates the 
downstream Cdks by phosphorylating key threonine residues in a process known as T-
loop activation (Kelso et al., 2014; Wohlbold et al., 2006).  
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Figure 1.5: Diagrammatic representation of cyclins and cyclin dependent kinases 
involved in cell cycle regulation 
Diagram summarises cyclins and cyclin dependent kinases that are involved in the cell 
cycle progression. Source: Candela Learning 
 
Table 1.2: List of cyclin/Ckd complexes that are activated at specific time points in 
the cell cycle 
Cdk  Cyclin Cell cycle phase activity 
Cdk 4 Cyclin D1, D2, D3 G1 phase 
Cdk 6 Cyclin D1, D2, D3 G1 phase 
Cdk 2 Cyclin E G1/S phase transition 
Cdk 2 Cyclin A S phase 
Cdk 1 Cyclin A G2/M phase transition 
Cdk 1 Cyclin B Mitosis 
Cdk 7 Cyclin H CAK, all cell cycle phases 
 (CAK-Cdk activating kinases). (Vermeulen et al., 2003) 
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1.7 Oxygen Dependence 
The growth, development and internal organisation of all large animals depends 
on the maintenance of oxygen homeostasis (Maxwell et al., 2001). However, 
mitochondrial respiration proves that the mitochondria are independent of oxygen 
presence due to the presence of high affinity cytochrome c oxidase. This gives rise to 
the model of “oxygen regulation”, although this is more precisely explained by the 
“kinetic oxygen saturation” (Gnaiger, 2003). Oxygen supply to a tissue depends on the 
flow and oxygen content in the blood perfusing the tissue and; also upon the 
asymmetrical arrangement of microvessels supplying the oxygen in the surrounding 
region. This heterogeneity of microvasculature in tumours strongly influences the 
partial pressure of O2 (pO2) and thus the occurrence of hypoxic micro-regions. This 
results in the likelihood that oxygen consumption is erratic between and within tissues 
(Dewhirst et al., 1994).   
Mammalian tissue can tolerate a wide range of oxygen tension, depending on the 
organ size, function and location of tissue and can thus encounter O2 concentration 
ranging from 0.002-10%, with the ambient air O2 concentration being 21% (Liu and 
Simon, 2004; Walmsley et al., 2005). Neutrophils, a striking example of the former, 
migrate in the circulation to the inflammation site and are thus required to adapt to and 
function in an environment with lower oxygen tension than that in the circulatory 
system (Walmsley et al., 2005). Also, studies dating back almost a century have 
demonstrated that neutrophils and macrophages depend highly on anaerobic glycolysis 
as a process for the production of ATP (Levene and Meyer, 1912a, 1912b). A drop in 
the pO2 causes a complex change in gene expression which is mediated by the 
immediate activation of the hypoxia inducible factor (HIF), present in all cell types of 
higher eukaryotes (Liu and Simon, 2004). The HIF system has also been identified to 
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play an important role in the physiological challenge of achieving a balance between 
oxygen demand and supply (Maxwell et al., 2001). 
1.7.1 The HIF System 
The HIF transcriptional factor is a heterodimer comprised of alpha and beta 
subunits, both of which are PER-ARNT-SIM (PAS, a signal sensor) subfamily of the 
basic helix-loop-helix DNA binding motifs (Maxwell et al., 2001; Melillo, 2004). The 
β-subunit is also known as the aryl hydrocarbon receptor nuclear translocator (ARNT) 
and also serves as a heterodimeric partner with the aryl hydrocarbon receptor (Huang et 
al., 1998; Liu and Simon, 2004). In contrast to this, the α-subunit only functions as a 
mediator in the hypoxic response (Huang et al., 1998). From amongst the multiple 
isoforms of HIF, HIF-1α and HIF-2α are the best understood (Loboda et al., 2010).  
HIF-1α and HIF-1β mRNA are expressed in most human and rodent tissues, 
while HIF-2α, HIF-3α, HIF-2β and HIF-3β show a more controlled pattern of 
expression. Studies have shown that HIF-1α plays a general role by signalling the 
presence of hypoxia to the transcriptional machinery in the cell nucleus. On the other 
hand, HIF-2α and HIF-3α play more specialised roles in oxygen homeostasis (Semenza 
et al., 2000). Although the HIF-1 and HIF-2 α subunits are highly conserved at the 
protein level have a similar domain structure and dimerise with HIF-1β, they have 
distinct tissue specific expression patterns. HIF-1α is present ubiquitously. However, 
the expression of HIF-2α is limited to lung, kidney, heart, small intestine and 
endothelium (Gordan et al., 2007; Holmquist-Mengelbier et al., 2006; Rosenberger, 
2002). 
1.7.2 O2 Dependant HIF Degradation  
The ARNT is constitutively expressed unlike the α-subunit levels whose 
stability is mediated by a region known as the oxygen-dependant degradation domain 
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(ODDD) (Huang et al., 1998). When the O2 tension is high, (21% O2), the α subunits are 
undetectable due to their rapid degradation by the product of the tumour suppressor 
gene called the von Hippel-Lindau tumour suppressor gene (VHL). This promotes HIF-
1α degradation by the ubiquitin-26S proteasome pathway. HIF-1α inactivation and its 
capture by the VHL are dependent on the hydroxylation of two prolyl residues, Pro
402
 
and Pro
564
, in the ODDD. A further level of O2-dependent regulation is by the 
hydroxylation of an asparaginyl residue in the C terminal transactivation domain 
(Asn
803
 of HIF-1) that prevents HIF-1α interaction with CBP/p300, a transcriptional 
coactivator protein. This results in the accumulation of the HIF-1α protein (Giaccia et 
al., 2003; Kamura et al., 2000; Liu and Simon, 2004; Semenza et al., 2000; Tanimoto 
and Makino, 2000). 
Upon a reduction in O2 tension to below 6%, the α subunits are stabilized and 
translocated into the nucleus where they dimerise with the ARNT via the PAS domain 
(Fig. 1.6). This leads to an active transcription of a wide array of genes that are critical 
to adapt to hypoxia (Table 1.3). Examples include VEGFR, PDGFR and plasminogen 
activator inhibitor-1 (Giaccia et al., 2003; Liu and Simon, 2004; Maxwell, 2003; 
Semenza et al., 2000). 
1.7.3 Prolyl Hydroxylases 
The oxygen-dependant prolyl-4-hydroxylation of HIF-1α is catalysed by three 
proline hydroxylase enzymes (PHD1, PHD2 and PHD3). PHDs are 2-oxoglutarate-
dependant dioxygenases that hydroxylate key proline residues (Pro
402
 and Pro
564
) in the 
ODDD of HIF-1α. These enzymes require molecular oxygen and iron as a co-substrate 
for the reaction to take place, thus the PHD also acts as an oxygen sensor. The 
characterisation of these enzymes has shown a reduced activity under the hypoxia 
“mimics” such as iron chelators, cobaltous ions and decreased oxygen availability 
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(Bruick and McKnight, 2001; Cioffi et al., 2003; Cockman et al., 2000; Ohh et al., 
2000).  
Table 1.3: List of HIF-1 targeted genes 
Gene Fucntion 
Red blood cell production Erythropoietin 
Iron metabolism Transferrin, transferrin receptor, ceruloplasmin 
Cell proliferation, 
differentiation and viability 
Cyclin G2, caspase 9, regulated in development and 
DNA damage responses 1 (RTP801) 
Vascular architecture and 
tone 
VEGF receptor-1, endoglin, plasminogen activator 
inhibitor-1, adrenomedullin, endothelin-1. Nitric 
oxide synthase-2, heme oxygenase-1 
Matrix metabolism Prolyl-4-hydroxylase-α1 
pH regulation Carbonic anhydrase-9 
Energy metabolism Glucose transporters 1 & 3, Glyceraldehyde 
phosphate dehydrogenase, pyruvate kinase M, lactate 
dehydrogenase A 
VEGF- vascular endothelial growth factor. Maxwell, 2003; Semenza et al., 2000 
 
Additionally, the transcriptional activity of HIF-1α is regulated by dioxygen-
dependant hydroxylation of asparagine (Asn
803
) residue in the COOH-terminal 
transactivation domain (CAD) of HIF-1α. This reduces the downstream transcription of 
HIF-1α targeted genes by inhibiting the coactivator p300. An enzyme, called the FIH 
(factor inhibiting hypoxia), carries out the hydroxylation of the asparagine residue in the 
CAD region of HIF-1α and thus plays a role in preventing the transcriptional activation 
role of CAD. The reaction rates of both the enzymes, PHD and FIH, are extensively 
influenced by the oxygen level. These enzymes thus act as oxygen sensors regulating 
the stability and the activity of HIF (Cioffi et al., 2003; Epstein et al., 2001; Esteban and 
Maxwell, 2005; Lando et al., 2002). 
34 
 
 
 
 
 
Figure 1.6: Representation of the domains and regulation of HIF-1α 
(A) Diagrammatic representation of HIF-1α showing the different domains. (B) 
Regulation of HIF. At high levels of oxygen (normoxia), HIF-1α forms an inactive HIF-
1 complex, which is unstable. This occurs due to the hydroxylation of the prolyl residue 
(by PHDs) and the hydroxylation of the asparagine residue (by FIH) in the ODD 
domain of HIF. Entrapment by the VHL gene occurs and degradation of the HIF-1α 
takes place by the proteasome pathway. On the other hand, at low oxygen levels 
(hypoxia), HIF-1α is stabilised and translocates to the nucleus leading to transcription of 
genes essential to adapt to hypoxia. 
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1.8 Reactive Oxygen Species 
Reactive oxygen species (ROS) are involved in almost all biological functions. 
Hydroxyl radicals (•OH), superoxide anions (O2•
−
), singlet oxygen (
1
O2) and hydrogen 
peroxide (H2O2) are constantly generated in the mitochondria as a result of aerobic 
metabolism (Kryston et al., 2011; Matés and Sánchez-Jiménez, 2000; Song et al., 2014; 
Wiseman and Halliwell, 1996). Inflammatory cells, both- allergenic and non-allergenic, 
produce ROS (Simon et al., 2000). Persistent oxidative stress leads to destruction of the 
essential biomolecules such as DNA, proteins and lipids. ROS also function to form a 
defence mechanism against bacterial infections, thus acting as a part of defence system 
(Matés and Sánchez-Jiménez, 2000; Shen et al., 1996; Valko et al., 2006). Specialised 
enzymes in the biological system such as NADPH-oxidase, myeloperoxidase and nitric 
oxide synthase, generate reactive oxygen or nitrogen species in order to kill the harmful 
bacteria that may enter the biological systems. NADPH-oxidase is found in the plasma 
membrane of phagocytes and B lymphocytes, and participates in phagocytic activity by 
releasing superoxide radical, a primary element that ignites antibacterial defence. In this 
manner, ROS play a dual role in the biological system as they can be both harmful and 
beneficial (Matés and Sánchez-Jiménez, 2000; Valko et al., 2006; Zorov et al., 2014). 
ROS has been shown to be involved in intracellular signalling pathways such as 
inflammation, regulation of insulin production and in the activation of the hypoxia 
inducible factor. In this manner of cellular or molecular signalling, ROS production 
targets at reversible protein modifications, modulation of gene regulation and adaptive 
MAP kinase signalling activation (Bashan et al., 2009; Kikusato et al., 2015; Lu et al., 
2015; Weidinger and Kozlov, 2015). ROS has been strongly implicated in hypoxia 
wherein the activation of a number of transcription factors takes place due to ROS 
(Kolamunne et al., 2013).  
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The generation of ROS is controlled by the antioxidants present in cells such as 
reduced glutathione, catalase, and superoxide dismutase, thereby detoxifying the ROS 
(Clerici et al., 1995; Kryston et al., 2011; Simon et al., 2000). Antioxidants can be 
classified according to their mode of action as scavenging, preventative or enzymatic. 
Scavenging antioxidants prevent antioxidant stress by scavenging the radicals as they 
form. Preventative antioxidants work mainly by sequestering transition metal ions and 
those formed from Fenton reactions (Fenton’s reaction is where Fe2+ is oxidised by 
hydrogen peroxide to Fe
3+
, forming a hydroxyl radical and a hydroxide ion in the 
process). Enzymatic antioxidants comprise of systems that function by catalysing the 
oxidation of other molecules (Chapple, 1997). Superoxide dismutase has been 
considered as the most effective intracellular enzymatic antioxidant that catalyzes the 
dismutation of O2
•−
 to O2 and to the less-reactive species H2O2 (McCord and Fridovich, 
1969; Valko et al., 2006). Catalse is involved in converting hydrogen peroxide to water; 
while glutathione peroxidase is involved in reducing peroxides by forming selenoles 
(Se-OH) (Bauer and Zarkovic, 2015; Matés et al., 1999; Nishimoto et al., 2015; Valko 
et al., 2006; Yu et al., 2014). 
1.8.1 Relationship between Cancer and ROS 
ROS are a double-edged sword. The basal ROS level in cancer cells is higher than 
normal cells. This is due to the high metabolic activity of the cells and mitochondrial 
energetics. The hypoxic conditions of the cancerous cells lead to activation of HIF, as 
explained in section 1.7. Various alterations in the mitochondrial electron transfer chain 
lead to an increased possibility of the electron transfer to oxygen. Chronic 
inflammation, increased cytokine release and the activation of c-Myc protein (c-Myc is 
a member of the Janus kinase family, involved in cell proliferation and apoptosis) 
coupled with its downstream signalling proteins together lead to an increase in the ROS 
production in cancerous cells (Chiang et al., 2015; Tong et al., 2015; Vafa et al., 2002). 
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This elevated ROS level enhances cancer growth and proliferation; and is involved in 
tumour angiogenesis and promotes cancer cell invasion and metastasis (Chen et al., 
2015; Pelicano et al., 2004). 
Cellular metabolism can cause an oxidative DNA damage which has been shown 
to induce malignant transformation of normal cells in vitro (Cooke et al., 2003). ROS 
can cause both purine and pyrimidine base changes along with changes in the 
deoxyribose backbone of the DNA, single or double-stranded DNA breaks, DNA cross-
links and damage to important genes and proto-oncogenes, thus giving rise to cancer 
(Dizdaroglu et al., 2002; Wiseman and Halliwell, 1996). The DNA damage resulting 
from ROS exposure can thus cause errors in replication, transcription and translation, 
signal induction pathways (including NF-κB, activated protein-1, phospholipase A2, 
mitogen activated protein kinases and c-Jun kinase) and genomic instability, all of 
which result in carcinogenesis. It has been well established that free-radical mediated 
DNA-damage occurs in cancer tissues (Cooke et al., 2003; Valko et al., 2006). 
 
1.9 Nanoparticles 
The potential to use polymeric nanoparticles (NPs) as drug delivery vehicles for 
anti-cancer therapeutics has recently been identified and could revolutionise the future 
of cancer therapy (Ma et al., 2011). Polymeric NPs prepared from natural and synthetic 
polymers have drawn major attention due to higher stability, versatility for industrial 
manufacture and opportunity for further surface nano-engineering (Shenoy et al., 2005). 
Nanoparticles, due to their submicron-size and increased surface to mass ratio, have 
unique physicochemical properties. They can be tailor-made to achieve a controlled 
drug release and disease specific localisation by tuning polymer characteristics and 
surface chemistry (Shenoy et al., 2005). The use of NPs for drug delivery is attributed to 
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the improved pharmacokinetic profile, decreased effective dose and increased 
availability associated with it. It has been established that NPs as drug carriers can 
preferentially be concentrated in the tumour mass by virtue of the enhanced permeation 
and retention (EPR) mechanism and upon deposition, can act as drug depots thus 
providing a continuous supply of the combined therapeutic drug compound into the 
tumour mass (Feng et al., 2012; Shenoy and Amiji, 2005). 
Different synthetic polymers used for nanoparticle preparation include poly-
lactic acid (PLA), poly-ε-caprolactone (PCL), poly(lactide-co-glycolide) (PLGA) and 
poly(alkyl cyanoacrylate) (PACA) while natural polymers include chitosan, alginates, 
gelatin and albumin (Kumari et al., 2010; Yordanov, 2012). Doxorubicin-loaded lipid-
modified dextran based polymeric nano-system have shown noticeable anti-proliferative 
effects against multi-drug resistant osteosarcoma cell lines (Susa et al., 2009). A few 
drug delivery systems using nanoparticles have been approved by the FDA and are 
available for cancer treatment. These include pegylated liposomal doxorubicin (Doxil 
and Caelyx) and liposomal daunorubicin (DaunoXome). Recently, an albumin bound 
paclitaxel nanoparticle Abraxane was approved by the FDA for breast cancer treatment 
(Haley and Frenkel, 2008) 
1.9.1 Enhanced Permeation and Retention Mechanism: 
The lack of lymphatic drainage in solid tumours has two effects on drug delivery 
and retention in solid tumours. Firstly, defective lymphatic flow in solid tumours 
decreases the clearance of high-molecular-weight compounds from tumour interstitium 
(Jang et al., 2003; Maeda, 2001; Matsumura and Maeda, 1986). Secondly, this together 
with leaky tumour blood vessels, results in enhanced accumulation and retention of high 
molecular-weight compounds in solid tumours, a phenomenon recognised as the 
enhanced permeability and retention effect (Jang et al., 2003; Maeda, 2001). 
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1.9.2 Poly-ε-caprolactone: 
The synthetic polymer poly-ε-caprolactone (PCL; Fig 1.7) was selected for this 
study due to its biocompatibility and biodegradability. It is a semi-crystalline non-toxic 
polymer with neutral biodegradation end-products approved by the FDA for clinical use 
(Cho et al., 2002; Shenoy and Amiji, 2005; Tarafder et al., 2013). The applications of 
PCL include suture coatings, absorbable medical devices such as intravascular stents as 
support to vein grafts, and as external grafting material for broken bones (Sarasam, 
2001). PCL reinforced with glass fibres has been used as intramedullary fracture 
fixation pins and applied in tissue engineered constructs for craniofacial repair 
(Coombes et al., 2004). PCL is produced from crude oil and has a good resistance to 
water, oil, solvents and chlorine. PCL usually has a glass transition temperature of 
−60°C and melting point of 45°-60°C, depending on the molecular weight (Coombes et 
al., 2004; Gan et al., 1999). PCL is versatile in the sense that it allows modification of 
its physical, chemical and mechanical properties by co-polymerisation or blending with 
many other polymers efficiently (Dash and Konkimalla, 2012).  
PCL degradation is slow thus making it suitable for use as a long term drug 
delivery system (Sinha et al., 2004). The degradation of PCL in the human body can be 
affected by molecular weight, crystallinity, environment and temperature (Coombes et 
al., 2004). PCL undergoes random, non-enzymatic cleavage beginning in the 
amorphous region and is auto-catalysed by the carbonyl end groups of the fragmented 
polymeric chain; water permeability of the polymer being the rate-limiting step. This is 
followed by enzymatic surface erosion of the polymer characterised by grooves and 
cracks on the surface. These fragments are then utilised in the tricarboxylic acid (TCA) 
cycle and phagocytosed to complete the degradation (Dash and Konkimalla, 2012). 
Thus, PCL nanoparticles can serve as a biocompatible drug delivery system with 
minimal toxicity. 
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Figure 1.7: Polymeric structure of PCL 
PCL is prepared by the ring opening polymerization of ε-caprolactone to 
polycaprolactone. Source: Kumari et al., 2010 
 
1.10  Asiatic acid 
Triterpenes are terpenes consisting of six isoprene units with a molecular 
formula C30H48. These are biosynthesised in plants by cyclisation of squalene (Huang et 
al., 2011). Triterpenes are extensively distributed in composite plants, and their 
biological activities have attracted abundant attention. Many triterpenoids have proven 
promising as antineoplastic agents (Hsu et al., 2004; Huang et al., 2011). Asiatic acid 
(AA), a herbal extract of the plant Centella asiatica (family Apiaceae) (Fig 1.8), is 
native to many countries such as India, Sri Lanka, Thailand, China, Indonesia and 
Malaysia. The extracts of Centella asiatica – asiatic acid, madecassic acid and the three 
asiaticosides, asiaticoside, asiaticoside A and asiaticoside B, have been used as a 
traditional herb in both Indian and Chinese medicine to treat heart disease, rheumatism, 
nervous disorders and bronchitis (Gohil et al., 2010; Lee et al., 2012).  
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Figure 1.8: Picture of the plant Centella asiatica 
Found mostly in Asia, used as a culinary leaf and an herbal medicine. Source: (Thai 
beauty products) 
 
Asiatic acid, a pentacyclic triterpenoid (Fig. 1.9), is the active constituent of the 
plant, showing many properties such as anti-angiogenesis, wound-healing, inhibition of 
collagen production at wound site, low risk of severe side-effects, anti-ulcer, anti-
hepatofibric activity and inhibition of β-amyloid induced hepatotoxicity (Hsu et al., 
2004; Kavitha et al., 2011; Krishnamurthy et al., 2009; Singh and Rastogi, 1969). There 
has been satisfactory evidence to suggest that asiatic acid can cross the blood brain 
barrier, and is cytotoxic to many cancer lines including the U87-MG glioblastoma cell 
line (Cho et al., 2006; Kavitha et al., 2011). It has also been reported that asiatic acid 
can be neuroprotective in a mouse model of focal ischemia and preserves BBB integrity 
in a post-ischemic episode (Krishnamurthy et al., 2009; Lee et al., 2014a, 2012).  
Asiatic acid induces a time- and dose-dependent cell death of the U-87MG cell 
lines via both apoptosis and necrosis by activation of caspase-3 and caspase-9 (Cho, 
2006). Asiatic acid also exhibits cell cycle arrest in the S-G2/M phase and apoptosis in 
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breast cancer cell lines MCF-7 and MDA-MB-237 (Hsu et al., 2004). Treatment with 
AA has been reported to induce apoptotic cell death in human hepatoma and malignant 
glioma cells by enhancing intracellular calcium release (Cho et al., 2006; Lee et al., 
2002).  
Park et al. (2005) reported that asiatic acid induced apoptosis in melanoma cells 
by increasing the levels of reactive oxygen species. Asiatic acid was also shown to 
reduce H2O2-related cell death, decrease  intracellular free radical concentrations and 
regulate the metabolism of carbohydrates in diabetic rats by modulation of key 
regulatory enzymes (Lee et al., 2014b). Asiatic acid as well as Centella asiatica extract 
have also been shown to possess strong efficacy against rat colon cancer cells (Bunpo et 
al., 2005, 2004). A study by Wang et al. (2013) showed that the synthetic derivative of 
AA, A-3, markedly inhibited the growth of non-small cell lung cancer cell line A549 
and PC9/G cells via downregulation of the Ras/Raf/MEK/ERK pathway and cell cycle 
arrest at G1/S and G2/M phases. Asiatic acid has also shown cell growth inhibition in 
breast cancer cell lines by inducing S-G2/M phase arrest and apoptosis (Hsu et al., 
2004). 
 
Figure 1.9: Chemical structure of asiatic acid 
Asiatic acid is a pentacyclic triterpenoid, consisting of six isoprene units biosynthesised 
by cyclisation of squalene. Source: (Huang et al., 2011) 
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Asiatic acid inhibits VEGF and a significant improvement of oedema of lower 
limbs has been observed in previous studies (Kavitha et al., 2011). However, one major 
problem associated with administration of asiatic acid is its low solubility in aqueous 
and oil medium thus hindering dissolution causing decreased bioavailability of the drug 
(Zhao et al., 2010). 
1.10.1 Conventional Centella asiatica Preparations 
Centella asiatica is available in liquid or solid pharmaceutical forms for oral 
intake and via parenteral route for homeopathic use (Brendler et al., 2000). 
Centellase
®
 (Scharper, Italy), an extract prepared from Centella asiatica 
comprising madecassic acid (30%), asiatic acid (30%) and asiaticosides (40%), was 
available in the form of tablets (10 and 30mg), drops (10mg/ml), powder (2%) and 
ointment (1%). This preparation, however, is no longer found in German markets 
(Brinkhaus et al., 2000). 
Another Centella asiatica extract comprising of asiaticoside (40%), asiatic acid 
(29-30%), madecassic acid (29-30%), and madasiatic acid (1%), called Madecassol
®
 
(La Roche, Belgium; Bilim, Greece) is currently only available in France. Madecassol 
was marketed in the form of an ointment or cream (1%), powder (2%) and 10mg tablets 
and used for accelerating cicatrisation and grafting of wounds (Brinkhaus et al., 2000; 
Gohil et al., 2010; Jamil et al., 2007). 
Another preparation, Emdecassol
®
 ointment, containing asiaticoside (0.4g) and a 
triterpenoid acid mixture (0.6g standardized to 0.29-0.3g asiatic acid, 0.29-0.3g 
madecassic acid and a maximum of 0.1g madiasiatic acid). However, this ointment is no 
longer available due to the inadequacies in the qualitative standardisation. The ointment, 
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when applied topically on the open wounds of rats, increased collagen synthesis and 
cellular proliferation at the wound site thus accelerating wound healing (Brinkhaus et 
al., 2000; Gohil et al., 2010; Jamil et al., 2007). 
Elha-dermidyn
®
 and Ekzevowen
®
 ointment, complex homeopathic preparations, 
are indicated for the treatment of various dermatological conditions (Brinkhaus et al., 
2000).  
Centella asiatica extracts in a dose of 60mg once or twice a day are frequently 
used in modern herbal medicine (Brinkhaus et al., 2000).  
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1.11 Aims  
The aim of this project was to study the effects of asiatic acid on glioblastoma 
cells in vitro and compare these against the widely used chemotherapeutic agent, 
cisplatin. Characterisation of asiatic acid induced cytotoxicity was performed using cell 
viability assays such as apoptosis, cell cycle analysis and cell proliferation analysis. 
This project also aimed at characterising a drug delivery system for asiatic acid to 
prepare monodispersed AA-loaded NPs less than 250nm in size having a surface charge 
of -10mV to -20mV in order to allow them to move across the BBB. Characterisation of 
these NPs included measurement of parameters such as size and surface charge, analysis 
of the drug loading and drug encapsulation efficiency and drug release from AA-loaded 
NPs using the High Pressure Liquid Chromatography (HPLC) system. 
 
  
46 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
2 MATERIALS and METHODS 
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2.1 Materials 
All reagents used were of the highest grade commercially available and obtained from 
the following suppliers: 
ATCC
®
 
SVGp12 and U87-MG cell line 
Biotium 
Carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) 
Cell Signalling 
EGF-receptor antibody, anti-rabbit IgG HRP-linked antibody 
Lonza Group LTD., UK 
Eagle’s minimum essential medium (EMEM), sodium pyruvate, non-essential amino 
acids, L-glutamine, trypsin 
Fisher Scientific Ltd., UK 
Millex
®
 MCE (mixed cellulose esters) sterile 33mm 0.45µm pore size syringe driven 
filter, Sterile PES (polyethersulfone) low protein binding 0.45µm pore size Whatman
™
 
syringe driven filter, sterile plastic disposable syringe without needles 10mL and 20mL, 
acetone, methanol, acetonitrile, acetic acid, ultra-pure water, tris-HCl, glycine, 
ammonium pyrosulphate, sodium dodecyl sulphate, glycerol, bromophenol blue, 
dithiothreitol, triton X-100, HEPES buffer, sodium chloride, Amerhcam prime ECL 
Prime-chemilumiscent agent, 25cm cell scrapers, SimplyBlue
™
 SafeStain,  
ethylenediaminetetraacetic acid disodium salt dehydrate (EDTA), sodium fluoride, 
sodium deoxycholate, ponceau-S, potassium chloride, Mini-Protean Tetra Cell 10-well 
4-gel system, restore western blot stripping buffer, BCA solution, acrylamide/Bis-
acrylamide 30% solution (29:1), bovine serum albumin lyophilized powder ≥96%, 8-
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well chambered cover glass NUNC, cell culture treated 96-well plates NUNC, cell 
culture treated black walled 96-well plates NUNC, cell culture treated 6-well plates 
NUNC, T25 and T75 cell culture flasks 
GE Healthcare Life Sciences 
ECL prime western blotting detection reagent 
Invitrogen/Life Technologies
™
, UK 
Foetal bovine serum, PrestoBlue
®
, Dead Cell Apoptosis Kit with Annexin V Alexa 
Fluor
®
 488 & Propidium Iodide, MagicMark
™
 XP western protein standard 
Sigma Aldrich
®
, UK 
Polycaprolactone (Mwt ~14,000), Pluronic F-68, lipase from Pseudomonas sp. (Type 
XIII, 27units/mg), polyethylene glycol (PEG), asiatic acid, cisplatin, coumarin-6, 2’,7’ –
dichlorofluorescin diacetate (DCFDA), luperox, coumarin-6, SUPELCOSIL
™ 
LC-18 
HPLC Column 
Scientific Laboratory Supplies Ltd., UK 
Whatman
™
 Nylon membrane circles 0.45µm 90mm vacuum bench-top, protease 
inhibitor cocktail, phosphatase Inhibitor cocktail 2 
VWR
®
, UK 
Pluronic F-68 
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2.2 Cell Culture Work 
2.2.1 Cell Maintenance 
SVGp12 (human foetal astroglial cells) and U87-MG (human brain astroglial 
cell) cells were maintained in 75cm
2
 flasks containing Eagles Minimum Essential 
Media (EMEM), supplemented with 10% foetal bovine serum (FBS), 2mM L-
glutamine, 1% non-essential amino acids (NEAA) and 1mM sodium pyruvate at 37°C 
humidified atmosphere containing 5% CO2. The cells were allowed to reach a 
maximum confluence of 80% after which the monolayer was passaged by 1x 
trypsinisation. Cells were pipetted gently to ensure a single cell suspension. Cells were 
either passaged at 1:3 into freshly prepared flasks to maintain the cell line or seeded into 
multi-well plates for experimental analysis. 
Cells were seeded under normal conditions and allowed to adhere for a 
minimum of 2 hours before being transferred to 1% (1% oxygen: 5% carbon dioxide: 
94%  nitrogen) or 5% (5% oxygen: 5% carbon dioxide: 90% nitrogen) hypoxia using 
Baker Ruskinn's InvivO2 400 hypoxia workstation. 
2.2.2 Growth Curves 
In order to determine the rate of growth of the cell lines, growth curve 
measurements were performed over a period of 7 days, under normoxia and 1% 
hypoxia. Cells were seeded in triplicate, at a density of 20,000 cells per well in a 6-well 
plate. Each day, replicate wells for each cell line were trypsinised and the cell number 
determined using a haemocytometer and trypan blue exclusion. 
2.2.3 PrestoBlue® Cell Linearity Assay 
To determine a suitable working range for the cell number, a linearity assay 
using PrestoBlue
®
 at different cell numbers was performed. Cells were seeded at a 
density of 0, 50, 100, 250, 500, 1000, 5000, 10,000 and 20,000 cells/well in a volume of 
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100µl/well media in 96-well plates. Cells were incubated for 24, 48 and 72 hours. 
Following incubation, a volume of 10µl of PrestoBlue
®
 was added to each well and 
fluorescence measured after incubation for one hour. 
2.2.4 Cell Viability using Cisplatin and Asiatic acid 
In order to determine the EC50 values of cisplatin and asiatic acid, a 
concentration-dependent dose response curve was generated in both SVGp12 and U87-
MG cell lines, under normoxia. Cells were seeded at a density of 1000 cells/well at a 
volume of 90µl in a 96-well plate and cultured for 24 hours before drug treatment at 
10µl/well using the following drug concentrations: 0.1, 0.3, 1, 3, 10, 30, 100µM. Cell 
viability was measured at 24, 48 and 72 hours post treatment using PrestoBlue
®
. EMEM 
in the absence of cells was used as control. For experiments under hypoxia, cells were 
seeded and allowed to adhere to the plate before being transferred to hypoxia of either 
1% or 5%. 
2.2.5 Combination Studies 
A drug combination study of cisplatin and asiatic acid was performed on the cell 
lines, U87-MG and SVGp12. Cells were seeded at a density of 1000 cells/well at a 
volume of 90µl/well in a 96-well plate. Following 24 hours of incubation, the cells were 
treated with cisplatin and asiatic acid at 100, 30, 10, 3, 1, 0.3, 0.1µM in triplicates in 
combination with 30µM asiatic acid and 2µM cisplatin, respectively. Cell viability was 
measured using the PrestoBlue
®
 assay at 24, 48 and 72 hours respectively.  
2.2.6 Cellular Reactive Oxygen Species Detection  
A reactive oxygen species assay was performed on the SVGp12 and U87-MG 
cell line using a modified protocol from Abcam
®
. Cells were seeded at a density of 
25,000cells/well in a blacked-walled 96-well plate and allowed to adhere overnight. The 
following day, media was discarded and cells were washed with 100µl 1X PBS. Cells 
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were incubated for 45 minutes in dark at 37°C following the addition of 20µM DCFDA 
in phenol free medium. The DCFDA solution was removed and cells were treated with 
100µl/well of 2, 10 and 40µM cisplatin and 30, 50 and 70µM asiatic acid in triplicate. 
Non treated cells were used as control and a positive control using 50µM luperox was 
performed. Fluorescence was measured at an Ex/Em of 485-535nm. 
2.2.7 Effect of Nanoparticle Treatment on Cell Viability 
A nanoparticle dose response curve was generated to measure the effects of 
nanoparticles, blank and asiatic acid-loaded, on cell viability. Cells were seeded at 
100cells/well in a volume of 100µl/well in 96-well plates. Blank and asiatic acid-loaded 
nanoparticles were prepared fresh (Section 2.6.1), under sterile conditions, prior to 
treatment. Following the preparation of the nanoparticles, 1ml of the nanoparticles was 
centrifuged at 12,600 x g to remove unbound drug. The resultant supernatant was 
discarded and the pellet re-suspended in 1X PBS. The nanoparticles were added to the 
wells at a volume of 2, 6, 10, 14, 18 and 22µl/well in triplicate. The total volume in all 
wells was standardised to 122µl using 1X PBS to maintain volume consistency. 
PrestoBlue
®
 viability assay was performed following 24, 48, 72, 120 and 168 hours of 
incubation to measure cell viability. EMEM in the absence of cells, media in the 
presence of cells without any treatment and cells treated with 1X PBS were used as the 
blank, positive and vehicle control respectively. 
 
2.3 Flow cytometric analysis 
2.3.1 Apoptosis Assay using Annexin V/Alexa Fluor® 488 and Propidium Iodide 
Flow cytometry with annexin V/Alexa Fluor
®
 488 and propidium iodide staining 
was used to determine early and late apoptotic cells following their treatment with blank 
and asiatic acid-loaded nanoparticles. SVGp12 and U87-MG cells were seeded at a 
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density of 100,000cells/well in 6-well plates and incubated for 24 hours prior to 
treatment with nanoparticles and the EC50 concentrations of cisplatin and asiatic acid. 
Cells were harvested by trypsinisation and centrifuged at 1000rpm for 5 minutes to 
obtain a cell pellet, following 24, 48, 72 and 120 hours of treatment. Cells were 
maintained at 4°C, to prevent any further apoptosis, following harvesting. Nanoparticle 
suspension in 1X PBS was prepared as described in Section 2.6.1 prior to addition to the 
cells. Treatments were 10µM cisplatin, 50µM asiatic acid and 6 & 22µl blank and 
asiatic acid-loaded nanoparticles. Non-treated cells and cells with 1X PBS were used as 
the positive control and vehicle control respectively. Cell pellets were resuspended in 
binding buffer consisting of 1:100 dilution of the stock concentration of annexin V (as 
per manufacturer’s instructions) and propidium iodide at a final concentration of 
5µg/ml, and incubated at room temperature for 15 minutes prior to analysis. 
Flow cytometry was performed on the FACSAria (BD Bioscience, Franklin 
Lakes, New Jersey, USA). Relative differences in cell size were gated on the forward-
angle light scatter (FSC) while the internal complexity of the cells was detected by the 
side-angle light scatter (SSC). Detection was performed at 488nm (blue laser) and at 
407nm (violet laser) for the propidium idodide and annexin V/Alexa Fluor
®
 488 stains 
respectively. A total of 10,000 gated events were collected. 
Apoptosis assay was also performed under 1% and 5% hypoxia. Cells were 
seeded as described above and were allowed to adhere overnight prior to transfer to 
hypoxia 2 hours before the addition of 10µM cisplatin and 50µM asiatic acid. Non 
treated cells were used as controls. Flow cytometry was performed using the Guava 
easyCyte™-12HT (Merck Millipore, Merck KGaA, Darmstadt, Germany) flow 
cytometer. 
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2.3.2 Cell Proliferation Assay using CFDA-SE  
Cell proliferation using the carboxyfluorescein diacetate succinimidyl ester 
(CFDA-SE) dye was examined in both SVGp12 and U87-MG cell lines. Cells were 
seeded at a density of 100,000 cells/well in 6-well plates. 22 hours post seeding, the 
cells were treated with CFDA-SE at a final concentration of 5µM in 1xPBS and 
incubated for 30 minutes at 37°C in the dark. The CFDA-SE/PBS was discarded, 1.5ml 
of fresh media added and the plates returned to the incubator. Nanoparticle treatment, 
blank and asiatic acid-loaded, at 6 and 22µl and treatment with 10µM cisplatin and 
30µM asiatic acid was performed 24 hours after cell seeding and the plates were 
incubated for 24, 48, 72 and 120 hours before harvesting the cells. Non-treated CFDA-
SE stained and unstained cell controls were harvested by trypsinisation for analysis on 
the flow cytometer.  
Cell proliferation assay was also performed under 1% and 5% hypoxia. Cells 
were seeded as described above and allowed to adhere overnight and transferred to 
hypoxia 2 hours before the addition of 10µM cisplatin and 50µM asiatic acid. Non 
treated cells were used as controls.  
Flow cytometry was performed using the Guava easyCyte
™
-12HT flow 
cytometer. All samples were gated on the FSC versus SSC and a total of 10,000 gated 
events were recorded. The excitation and emission peaks for CFDA-SE are 492nm and 
517nm respectively.  
2.3.3 Cell Cycle Analysis 
Cell cycle analysis of SVGp12 and U87-MG cell lines, under normoxia and 
hypoxia (1% and 5%), was performed on the Guava easyCyte
™
-12HT flow cytometer. 
Cells were seeded at a density of 100,000cells/well in 6-well plates. Cells were allowed 
to adhere overnight prior to treatment with 10µM cisplatin or 50µM asiatic acid. 
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Following incubation for 24, 48, 72 and 120 hours, cells were trypsinised, centrifuged at 
1000 rpm and maintained at 4°C. The supernatant was discarded and the cell pellet re-
suspended in 1X PBS containing of 250µg/ml RNase and 5µg/ml propidium iodide. 
Cells were stained for 30 minutes at room temperature and analysed using by flow 
cytometry. Detection was performed using the Guava EasyCyte
™
-12 HT flow cytometer 
at 488nm (blue laser) for propidium idodide. Dead cells and doublets were gated out 
and a total of 10,000 gated events were collected. 
 
2.4 Microscopy  
2.4.1 Scratch/Wound Healing Assay 
An in vitro scratch assay on SVGp12 and U87-MG cell lines was performed. 
Cells were seeded at 45,000cells/well in a total volume of 0.5ml in a 24-well plate. 
Cells were allowed to adhere overnight and the cell monolayer was scraped in a single 
line using a sterile toothpick to create a scratch. Medium was replaced and cells were 
treated with 10µM cisplatin or 30µM asiatic acid. Cell imaging, for 18 hours, was 
performed on a modified Zeiss Cell Observer imaging system using a Zeiss Plan-Apo 
20 x 0.8 NA air objective. Non treated cells were used as control. 
2.4.2 Cellular Uptake of Nanoparticles using Microscopy 
Coumarin-6 loaded blank nanoparticles were prepared as described in Section 
2.6.1., immediately prior to addition to the cells.  A 0.5mg/ml stock solution of 
coumarin-6 in acetone was prepared, following which 0.625, 1.25 and 6.25ml was 
added in the organic phase to give final concentrations of 0.05, 0.1 and 0.5%, 
respectively.  1ml of the nanoparticle suspension was centrifuged at 12,600 x g to 
remove unbound coumarin-6 and the resulting supernatant discarded.  The pellet was re-
suspended in 1ml sterile EMEM and stored at 4°C until required.   
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SVGp12 and U87-MG cells were plated onto 8-well chamber slides at a density of 
20,000 cells per well in a volume of 200µl and allowed to adhere overnight.  22µl of 
coumarin-6-loaded nanoparticle suspension was added to each well and uptake into 
cells was recorded at 18 and 24 hours following addition.  Images were captured on a 
modified Zeiss Cell Observer imaging system using a Zeiss Plan-Apo 20 x 0.8 NA air 
objective.  Coumarin-6 was imaged using a GFP filter set with Ex/Em of 450-490nm 
and 500-550nm respectively.  Analysis of the images was carried out using the Zeiss 
ZEN desk imaging software. 
 
2.5 Biochemical Analysis 
2.5.1 Western Blotting 
Preparation of Cell Extracts 
Western blot analysis for EGF-receptor was performed on SVGp12 and U87-
MG cell lines. Cells were grown to 80% confluence in T25 flasks. Flasks were treated 
with 10µM cisplatin and 50µM asiatic acid for 24, 48 and 72 hours, under normoxia and 
1% hypoxia. Cells were washed with 1X PBS, scraped, re-suspended in 250µl lysis 
buffer (RIPA buffer 7.8ml [7.62gm HEPES pH 7.5, 5.61 NaCl, 20% Triton X-100 
32ml, 10% Sodium deoxycholate 32ml, 10% sodium dodecyl sulphate 6.4ml], 0.5M 
sodium fluoride 2ml, 0.5M EDTA 0.1ml, 0.1M sodium phosphate 1ml, phosphatase 
inhibitors 25µl, protease inhibitors 25µl, dH2O 0.8ml) on a rotator for 1 hour at 4°C and 
centrifuged at 13,000 rpm for 15 minutes to get rid of any cell debris. 
Protein assay was carried out using cell lysate. 10µl of cell lysate or BSA at the 
concentration of 1.8, 1.6, 1.4, 1.2, 1, 0.8, 0.6, 0.4, 0.2 mg/ml was added in each well of 
a 96-well plate, in triplicate. CuSO4:BCA (bicinchoninic acid) 1:50 solution was 
prepared fresh each time, 200µl added to the wells and incubated in the dark at room 
56 
 
temperature for 20 minutes. Absorbance was measured at an absorbance of 485nm. 
Protein concentration in each sample was calculated using the standard curve generated. 
Immunoblotting 
Proteins were separated on a 10% sodium dodecyl sulphate-polyacrylamide gel 
and transferred to polyvinylidene difluoride (PVDF) membranes. Semi-dry transfer 
using Bio-Rad Trans-Blot
®
 SD transfer cell was performed at 15V for 20 minutes. 
Following transfer, membranes were blocked for 1 hour at room temperature with 5% 
skimmed milk in Tris-buffered saline-0.1% Tween 20 (TBS-tween). Membranes were 
then incubated with EGF-receptor antibody (1:1000 dilution) overnight at 4°C with 
gentle shaking. Membranes were washed three times with TBS-tween and twice with 
1xPBS, incubated with anti-rabbit IgG, HRP-conjugated secondary antibody (1:2000 
dilution) at room temperature for 1 hour and washed again in TBS-tween and 1X PBS. 
Immunoreactive proteins were detected by enhanced chemiluminescence using ECL 
reagent, Bio-Rad. Results were quantified by measuring the relative intensity compared 
to the non-treated controls using Bio-Rad Molecular Imager ChemiDoc
™
 XRS+ System 
with Image Lab
™
 Software, UK. Data was normalised to the amount of β-actin 
measured in the respective blots. 
 
2.6 Nanoparticle Preparation 
2.6.1 Protocol for Nanoparticle Preparation 
Blank NPs were prepared by a modified solvent displacement method as 
described by Chawla & Amiji (2002). PCL (500mg) along with PEG (5g) was dissolved 
in acetone (25ml) in a sonicating bath maintained at 40°C. The aqueous phase consisted 
of Pluronic F-68 (150mg) dissolved in distilled water (50ml) using moderate magnetic 
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stirring. The organic phase was added to the aqueous phase over magnetic stirring 
leading to instant nanoparticle formation.  Nanoparticles were centrifuged at 12,600 x g 
for one hour, the supernatant discarded and the pellet re-suspended in distilled water to 
a total volume of 20ml. Nanoparticles were filtered through 0.45µm Millex
®
 syringe 
driven filter unit, 5ml of nanoparticle suspension was injected through each filter, and 
stored at either room temperature or 4
o
C. Asiatic acid-loaded nanoparticles were 
prepared using the same protocol 20mg of drug was dissolved in the organic phase 
along with PCL and PEG. 
2.6.2 Other Techniques for Nanoparticle Preparation 
Nanoparticles were also prepared by the solvent displacement method and were 
ultra-sonicated or homogenised to give an improved particle size. Ultra-sonification was 
carried out under ice cooling for 5 minutes at 70% amplitude in a pulse regime (1 
minute sonication, 15 second pause) using a SONICS
®
 Vibra Cell sonicator. 
Homogenisation under ice cooling was carried out for 20 minutes at speed 4, using the 
IKA
®
 Ultra-Turrax T8 homogeniser. Weight of all the compounds remained constant; 
however, the amount of acetone used was 50ml. NPs were also prepared by the 
magnetic stirring process as mentioned in Section 2.6.1 and were stored at room 
temperature to obtain a direct comparison. 
2.6.3 Nanoparticle Filtration Studies 
Nanoparticles were prepared as described in Section 2.6.1. and filtered using 
sterile PES (polyethersulfone) low protein binding 0.45µm pore size Whatman
™
 syringe 
driven filter, Millex
®
 MCE (mixed cellulose esters) sterile 33mm 0.45µm pore size 
syringe driven filter or Whatman
™
 Nylon membrane circles 0.45µm 90mm vacuum 
bench-top filters. A set of non-filtered samples was analysed for comparison. 
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2.7 Nanoparticle Characterisation 
2.7.1 Size and Surface Charge Measurement 
The size, surface charge and polydispersity index (PDI) of each set of 
nanoparticle formulations, blank and asiatic acid-loaded, was measured using the 
Malvern Zetasizer
®
 Nano-ZS. The instrument was equipped with appropriate software 
for size and surface charge analysis. Prepared nanoparticles were measured over a 
period of 60 days to monitor stability. An aliquot of 1ml into a 12mm square 
polystyrene cuvette was used for size measurement and a disposable capillary cell 
containing a volume of 800µl of sample was used for performing surface charge 
measurements. 
2.7.2 Effect of Storage Temperature on Blank-Nanoparticles 
Blank nanoparticles (Section 2.6.1) were maintained at room temperature and at 
4°C. Size and surface charge measurements were undertaken for a period of 60 days or 
until precipitation was observed. Precipitation was determined by the presence of large 
aggregates at the bottom of the vials the nanoparticles were stored in.  
2.7.3 Maximisation of Nanoparticle Yield 
To maximise nanoparticle yield, the ratio of aqueous phase to organic phase, 
volume of Pluronic F-68, temperature of the organic phase before addition to the 
aqueous phase, duration of magnetic stirring and use of filters were altered. 
Nanoparticle yield was measured using High Pressure Liquid Chromatography (HPLC). 
2.7.4 Drug Loading Efficiency of Asiatic acid-loaded Nanoparticles 
The percentage loading and the amount of drug loaded per milligram of the 
polymer was determined by injecting the nanoparticle suspension through the HPLC. 
Prior to performing drug loading studies, a calibration curve for the drug was prepared. 
The calibration curve of asiatic acid in methanol/water (1:1, v/v) was constructed from 
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the peak area ratio of asiatic acid versus 8 nominal asiatic acid concentrations (100, 50, 
25, 17.5, 10, 7.5 and 5μg/ml). The reproducibility of linearity was confirmed by 
analysing three series of standard solutions of asiatic acid. A calibration curve for PCL 
was performed in a similar fashion. The calibration curve for PCL in acetonitrile was 
constructed from the peak area ratio of PCL versus 8 nominal PCL concentrations (200, 
150, 120, 100, 80, 60 and 50μg/ml). The different concentrations used for the 
calibration of asiatic acid and PCL reflect the amount of asiatic acid and PCL used in 
the formulation. 
Analytical separation of the compounds was undertaken on the instrumentation 
consisting of Jasco
™
 PU-1580 Intelligent HPLC Pump, a Jasco
™
 LG-1580-02 Ternary 
Gradient Unit and a Waters
™
 486 Tunable Absorbance Detector. A SUPELCOSIL
™
 
LC-18 (25cm x 4.6mm, 5µm) analytical column with a Phenomenex
®
 C-18 (4 x 3mm, 
5µm) guard column was used. Mobile phase consisted of methanol, acetonitrile and 
0.1% acetic acid solution in the ratio of 5:65:30 (v/v/v).  Flow rate was maintained at 
1ml/min with the injection volume being 25µl. Column temperature was maintained at 
25°C, run time was 15 minutes and detection was performed at a wavelength of 217nm. 
Chromatographic data were recorded and processed using Azur HPLC software version 
5.0.10.0. 
Asiatic acid-loaded nanoparticles were prepared as described in Section 2.6.1. 
nanoparticles were re-suspended in distilled water and a 500µl aliquot centrifuged at 
12,600 x g for 5mins. The pellet and the supernatant were injected through the HPLC. 
The amount of drug recorded in the pellet provided the amount of drug that was 
entrapped within the nanoparticles whereas the amount recorded in the supernatant was 
the amount of free drug in the nanoparticle suspension. The drug loading efficiency in 
milligrams was calculated using the equation generated from the HPLC calibration 
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curve of asiatic acid. The percentage drug loading was calculated as the total amount of 
asiatic acid present in the formulation from the initial amount of asiatic acid added 
while preparing the NPs. 
 
2.8 Drug Release Studies 
2.8.1 Drug Release in PBS in the Absence and Presence of Lipase 
Asiatic acid-loaded nanoparticles containing 20mg of asiatic acid were prepared 
as previously described (Section 2.6.1). Nanoparticles were re-suspended in 1X PBS, 
pH 7.4 in the absence and presence of lipase (45units/l). The suspension was maintained 
at a constant temperature of 37°C on a rocker kept inside an incubator. 500µl samples 
were collected every 1 hour for 3 hours and then at 24 hours following NP preparation. 
The samples were re-centrifuged at 12,600 x g for 5 min and the supernatant and pellet 
injected into the HPLC using the method described in Section 2.7.4. The amount of 
drug recorded in the supernatant represented the amount of drug released by the 
nanoparticles while the amount recorded in the pellet was the amount of drug 
encapsulated within the nanoparticles.  
2.8.2 Drug Release in Cell Culture Medium 
Nanoparticles were prepared as described in Section 2.6.1.  and re-suspended in 
20ml EMEM supplemented with 10% foetal bovine serum, 2mM L-glutamine, 1% non-
essential amino acids  and 1mM sodium pyruvate. NPs were maintained in a 37°C 
humidified atmosphere containing 5% CO2. 500µl samples were collected every 1 hour 
for 3 hours and then at 24, 48 and 72 hours following nanoparticle preparation. The 
samples were re-centrifuged at 12,600 x g for 5 min and the supernatant was injected 
into the HPLC using the method described in Section 2.7.4. The amount of drug 
recorded in the supernatant represented the amount of drug released by the nanoparticles 
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while the amount recorded in the pellet was the amount of drug encapsulated within the 
nanoparticles. 
2.8.3 Effect of pH on Drug Release from Asiatic acid-loaded Nanoparticles 
Asiatic acid-loaded NPs containing 20mg asiatic acid (Section 2.6.1) were re-
suspended in 1X PBS, pH 5.5. The suspension was maintained at 37°C on a rocker 
placed in an incubator. Sample aliquots of 500µl were collected at every 1 hour for 3 
hours and then at 24 hours.  Samples were centrifuged at 12,600 x g for 5mins. The 
pellet and the supernatant were injected through the HPLC as described in Section 
2.7.4. The amount of drug recorded in the supernatant represented the amount of drug 
released by the nanoparticles while the amount recorded in the pellet was the amount of 
drug encapsulated within the nanoparticles. 
 
2.9   Freeze-Drying of the Nanoparticles 
Blank nanoparticles prepared using the protocol in Section 2.6.1 were freeze-
dried in the absence and presence of 1% and 10% sucrose using a Christ
®
 LCG freeze 
dryer. The equipment consisted of a small freeze-drying chamber containing a 
temperature-controlled stage and a vacuum pump to ensure evacuation. Prior to freeze-
drying, 5ml samples, stored in a 50ml beaker, were frozen overnight at -18°C. Samples 
were then placed on the shelf of the freeze-dryer and main drying was performed at -
20°C for 3.5 hours, 1mbar pressure. Final drying was performed at -76°C and a pressure 
of 0.0010mbar for 10 hours. Sample beakers, prior to freeze-drying, were sealed with 
parafilm and perforated using a 9 gauge needle to allow water sublimation during the 
freeze-drying process. Freeze-dried samples were stored in the refrigerator at 4°C until 
further analysis. Samples were re-hydrated using 5ml distilled water and size and 
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surface charge measurements were performed to record any changes in the 
nanoparticles after the freeze-drying process. 
 
2.10 Visualisation of Surface Morphology using Scanning 
Electron Microscopy  
For scanning electron microscopy (SEM) analysis of the freeze-dried 
nanoparticles, a random sample was mounted on an aluminium sample mount and 
sputter-coated with gold at 30mA for 4 min. SEM analysis was performed using an FEI 
Quanta 200 ESEM
™
, USA, scanning electron microscope at a working distance of 
10mm and an accelerating voltage of 20kV. 
 
2.11 Statistical Analysis 
Statistical analysis of data was carried out using one-way and two-way ANOVA 
with Bonferroni’s post-test as described in the GraphPad software Prism version 5.00 
for Windows (GraphPad Software, San Diego California USA, www.graphpad.com). 
Significant differences were accepted for p < 0.05 and have been represented as *p < 
0.05, **p < 0.01, ***p < 0.001. . All results have been expressed as mean ± SEM. 
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CHAPTER 3 
3 Effect of Asiatic acid on Cell Death 
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3.1 Introduction 
Alterations in gene expression, including amplification or deletion, take place in 
glioma. The alteration of genes such as EGFR, MTOR and VEGF result in the activation 
or changes in cell growth and apoptosis (Kanu et al., 2009; Minniti et al., 2009; 
Normanno et al., 2006). 
It is known that a wide range of oxygen tension can be tolerated by mammalian 
tissue, and this depends on the type, function and location of the tissue (Liu and Simon, 
2004; Walmsley et al., 2005). The rate and pattern of growth of cells under different 
oxygen conditions causes complex changes in gene expression mediated by HIF and 
this also affects the mechanism of action of all drugs (Koch et al., 2003; Liu and Simon, 
2004; Maxwell et al., 2001; Yao et al., 2005). 
In addition, different cell types exhibit different growth durations and patterns. 
In this study, we chose the U87-MG cell line because it is a grade IV astrocytoma cell 
line. We chose SVGp12, an immortalised human foetal glial cell line, as our control. 
Both these cell lines are established cell lines used widely for research purposes. 
The cytotoxic effects of drugs depend upon the pattern of growth of cells thus 
also affecting cell viability and apoptosis following drug treatments. In order to be able 
to correctly drug treat cells, it would be important to understand the lag, log and 
stationary phases of cell growth of individual cell lines. As cell growth, viability and 
apoptosis would be affected by hypoxia-associated genetic alterations, we also 
examined the effects of hypoxia on these factors. 
Under any given condition, cell death either takes place via apoptosis or 
necrosis. Although apoptosis is a highly programmed mechanism; necrosis is an energy-
independent process usually occurring due to stress such as hypoxia and 
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hypoglycaemia. The failure of many chemotherapeutic drugs is due to the inability of 
these drugs in inducing apoptosis  (Elmore, 2007; Fulda et al., 2010; Kerr et al., 1972; 
Shah and Schwartz, 2001; Vanlangenakker et al., 2008). In addition to this, cell death is 
quite often mediated by the generation of reactive oxygen species (Cheung et al., 2012; 
Fulda et al., 2010; Li et al., 1997; Vanlangenakker et al., 2008). Thus, we measured the 
amounts of cellular reactive oxygen species generated following various drug 
treatments. 
Objectives: We established the effects of hypoxia on cell growth, viability, generation 
of reactive oxygen species and mode of cell death using fluorescent dyes. 
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3.2 Results  
3.2.1 Growth Curve 
Growth curves were performed to study the growth pattern, rate of growth and 
identify the lag and the log phases of SVGp12 and U87-MG cells lines.  
Normoxia 
Both cell lines showed an increase in growth for duration of approximately 6 
days following which, the cells reached a stationary phase in their growth (Fig. 3.1).  
The population doubling time of the two cell lines was identified to be 48 hours for 
SVGp12 (38,000 ± 1667) and 24 hours for the U87-MG (39,333 ± 1347) cell line. 
Significant differences were observed between the rate of growth of SVGp12 and U87-
MG cell lines on day 5 (SVGp12 114,700 ± 2457, U87-MG 205,300 ± 1644; p < 0.001), 
day 6 (SVGp12 133,300 ± 962, U87-MG 312,700 ± 15261; p < 0.001) and day 7 
(SVGp12 155,300 ± 839, U87-MG 367,000 ± 11259; p < 0.001). 
1% hypoxia 
Both cell lines showed an increase in growth for duration of approximately 6 
days following which, the cells reached a stationary phase in their growth (Fig. 3.1).  
The population doubling time of the two cell lines was identified to be 60 hours for 
SVGp12 (40,813 ± 1299) and 36 hours for the U87-MG (39,750 ± 1721) cell line. 
Significant differences were observed between the rate of growth of SVGp12 and U87-
MG cell lines on day 5 (SVGp12 105,400 ± 11261, U87-MG 201,000 ± 3108; p < 
0.001), day 6 (SVGp12 129,900 ± 1431, U87-MG 309,600 ± 3877; p < 0.001) and day 
7 (SVGp12 140,800 ± 2666, U87-MG 340,300 ± 5632; p < 0.001). 
A significant difference in the doubling time of SVGp12 and U87-MG cell lines 
was observed under hypoxia (p < 0.01). 
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Figure 3.1: Growth curve for SVGp12 and U87-MG cell lines 
Cell proliferation, for an initial seeding density of 20,000 cells/well, was determined by 
haemocytometer and trypan blue exclusion for a period of 7 days. Under normoxia (A), 
SVGp12 and U87-MG cell lines demonstrated a doubling time of 48 and 24 hours 
respectively. Under 1% hypoxia (B), SVGp12 and U87-MG cell lines demonstrated a 
doubling time of 60 and 36 hours respectively. Significant differences were observed 
between SVGp12 and U87-MG cells under normoxia and hypoxia on days 5, 6, and 7. 
Values represent mean ± S.E. for three experiments in triplicate. 
 
A 
B 
 ***  ***  *** 
 ***   *** 
 *** 
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3.2.2 PrestoBlue® Cell Linearity Assay 
To carry out future viability studies, we decided to the dye PrestoBlue
®
. As this 
is a fluorescent dye, it was important to establish the saturation point of the dye using 
different cell densities. 
The linearity between cell number and the associated fluorescence (Fig. 3.2) was 
studied using the PrestoBlue
®
 cell viability reagent at increasing cell densities in a 96-
well plate. Following an incubation of 24 hours, a linear relationship between the cell 
number and the fluorescence was observed in both the cell lines (R
2
=0.97 for SVGp12 
and R
2
=0.98 for U87-MG). After 48 hours of incubation, fluorescence was linear up to 
5000 cells/well (R
2
=0.92 for both cell lines), following which there was saturation in the 
fluorescence measured. The saturation point, however, reduced to 2500 cells/well 
following 72 hours of incubation in both two cell lines. From the results obtained, 
subsequent experiments were undertaken using a cell density of 1000 cells/well in 96-
well plate, for both, SVGp12 and U87-MG cell lines.  
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Figure 3.2: Effect of different cell concentrations on fluorescence using the 
PrestoBlue
®
 reagent 
A linearity assay, to establish the relationship between cell number and fluorescence in 
SVGp12 (A) and U87-MG (B) cell lines after 24, 48 and 72 hours of incubation, was 
performed using the PrestoBlue
®
 reagent. Saturation in fluorescence was observed at 
2500 cells/well for both cell lines at 72 hours. Values represent mean ± S.E. for three 
experiments in triplicate. 
A 
B 
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3.2.3 Effect of Cisplatin and Asiatic acid on Cell Viability 
To assess the effect of cisplatin and asiatic acid on SVGp12 and U87-MG cell 
line viability, concentration-dependant dose response curves were performed. In 
addition, it was also important to establish the EC50 values of cisplatin and asiatic acid 
for further experiments and obtain a standard for direct comparison. 
Normoxia 
Cisplatin showed a reduction in cell viability in a time and dose dependent 
manner. EC50 values obtained for cisplatin on SVGp12 cell line were 33, 11 and 5µM at 
24, 48 and 72 hours, respectively. EC50 values obtained for asiatic acid on SVGp12 cell 
line were 29, 61 and 57µM at 24, 48 and 72 hours, respectively (Fig. 3.3, Table 3.1). 
EC50 values for U87-MG cell line following cisplatin treatment were 94, 7.3 and 
4.6µM at 24, 48 and 72 hours, respectively. EC50 values for asiatic acid treatment on 
U87-MG cell line were 36, 47 and 42µM at 24, 48 and 72 hours, respectively (Fig. 3.4, 
Table 3.1).  
Based on these results, an average EC50 value over the period of 72 hours, for 
both cell lines, was calculated and used for all further experiments. The EC50 value for 
cisplatin was calculated as 10µM and for asiatic acid was 50µM. 
5% hypoxia 
Under 5% hypoxia, cisplatin showed gradual decrease in the cell viability of 
SVGp12 cell line. EC50 values obtained for cisplatin on SVGp12 cell line were 159, 115 
and 61µM at 24, 48 and 72 hours, respectively. It wasn’t possible to fit a line of best 
curve through the asiatic acid treatments on the graph (Fig. 3.5, Table 3.1). 
 A reduction in cell viability of U87-MG cell line was observed with cisplatin 
(Fig. 3.6, Table 3.1). EC50 values for U87-MG cell line following cisplatin treatment 
were 11450, 210 and 131µM at 24, 48 and 72 hours, respectively. It wasn’t possible to 
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fit a line of best curve through the asiatic acid treatments at 24 and 72 hours on the 
graph. EC50 value for asiatic acid at 48 hours, however, was calculated to be 82µM.  
1% hypoxia 
Under 1% hypoxia, a gradual decrease in the cell viability of SVGp12 cell line 
was shown by cisplatin (Fig. 3.7, Table 3.1). EC50 values obtained for cisplatin were 34, 
22 and 11 µM at 24, 48 and 72 hours, respectively. It wasn’t possible to fit a line of best 
curve with asiatic acid treatment at 24 hours, however, EC50 values at 48 and 72 hours 
were 109 and 105µM, respectively.  
EC50 values obtained for cisplatin in U87-MG cell line were 123 and 232µM at 
24 and 48 hours, respectively. It wasn’t possible to fit a line of best curve at 72 hours 
for cisplatin (Fig. 3.8, Table 3.1). EC50 values obtained for asiatic acid were 84 and 
81µM at 48 and 72 hours, respectively. It wasn’t possible to fit a line of best curve at 72 
hours for asiatic acid. 
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Table 3.1: EC50 values for cisplatin and asiatic acid under normoxia and hypoxia 
(1% and 5%) 
Normoxia  Cisplatin 
(µM) 
Asiatic acid 
(µM) 
 24 hours 48 hours 72 hours 24 hours 48 hours 72 hours 
SVGp12 32 11 5 29 61 57 
U87-MG 94 7 5 36 47 42 
 
5% 
hypoxia  
Cisplatin 
(µM) 
Asiatic acid 
(µM) 
 24 hours 48 hours 72 hours 24 hours 48 hours 72 hours 
SVGp12 159 115 61 NA NA NA 
U87-MG 11450 210 131 NA 82 NA 
 
1% 
hypoxia 
Cisplatin 
(µM) 
Asiatic acid 
(µM) 
 24 hours 48 hours 72 hours 24 hours 48 hours 72 hours 
SVGp12 34 22 11 NA 109 105 
U87-MG 123 232 NA NA 84 83 
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Figure 3.3:  Data illustrating the effect of concentration dependent treatment of 
cisplatin and asiatic acid on SVGp12 cell line, under normoxia 
Cell viability was performed using the PrestoBlue
®
 reagent on SVGp12 cell line 
following 24, 48 and 72 hours of incubation with cisplatin (A) and asiatic acid (B). A 
time and concentration dependent reduction in cell viability was observed with 
cisplatin, asiatic acid mainly showed its effects at 100 and 30µM. Values represent 
mean ± S.E. for three experiments in triplicate. 
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Figure 3.4: Data illustrating the effect of concentration dependent treatment of 
cisplatin and asiatic acid on U87-MG cell line, under normoxia 
Cell viability was measured using the PrestoBlue
®
 reagent on U87-MG cell line 
following 24, 48 and 72 hours of incubation with cisplatin (A) and asiatic acid (B). A 
time and concentration dependent reduction in cell viability was observed with 
cisplatin, asiatic acid mainly showed its effects at 100 and 30µM. Values represent 
mean ± S.E. for three experiments in triplicate. 
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Figure 3.5: Data illustrating the effect of concentration dependent treatment of 
cisplatin and asiatic acid on SVGp12 cell line, under 5% hypoxia 
Cell viability was performed using the PrestoBlue
®
 reagent on SVGp12 cell line 
following 24, 48 and 72 hours of incubation with cisplatin (A) and asiatic acid (B).. 
Values represent mean ± S.E. for three experiments in triplicate. 
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Figure 3.6: Data illustrating the effect of concentration dependent treatment of 
cisplatin and asiatic acid on U87-MG cell line, under 5% hypoxia 
Cell viability was performed using the PrestoBlue
®
 reagent on U87-MG cell line 
following 24, 48 and 72 hours of incubation with cisplatin (A) and asiatic acid (B). 
Values represent mean ± S.E. for three experiments in triplicate. 
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Figure 3.7: Data illustrating the effect of concentration dependent treatment of 
cisplatin and asiatic acid on SVGp12 cell line, under 1% hypoxia 
Cell viability was performed using the PrestoBlue
®
 reagent on SVGp12 cell line 
following 24, 48 and 72 hours of incubation with cisplatin (A) and asiatic acid (B). 
Values represent mean ± S.E. for three experiments in triplicate. 
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Figure 3.8: Data illustrating the effect of concentration dependent treatment of 
cisplatin and asiatic acid on U87-MG cell line, under 1% hypoxia 
Cell viability was performed using the PrestoBlue
®
 reagent on U87-MG cell line 
following 24, 48 and 72 hours of incubation with cisplatin (A) and asiatic acid (B). 
Values represent mean ± S.E. for three experiments in triplicate. 
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3.2.4 Apoptosis Assay using Annexin V/Alexa Fluor 488® and Propidium Iodide 
Cell death under any condition, is mediated either by apoptosis or necrosis. To 
assess the relative percentage of cells that were undergoing apoptosis and necrosis 
following respective treatments with cisplatin and asiatic acid, an apoptosis assay was 
performed on the flow cytometer using fluorescent dyes Annexin V/Alexa Fluor 488
®
 
and propidium iodide staining.  
Normoxia 
Cisplatin and asiatic acid showed an increase in the number of apoptotic and 
necrotic cells over time. In the SVGp12 cell line, significant decrease was observed 
with cisplatin treatment at 48 hours in the early apoptotic population (control 17 ± 2.9%, 
cisplatin 5.8 ± 0.6%; p < 0.05), (Figs. 3.9 & 3.10). Following 120 hours of cisplatin 
treatment, significant decrease was observed in live (control 73.5 ± 0.4%, cisplatin 53.7 
± 3.3%; p < 0.05), significant increase in the early apoptotic (control 0.2 ± 0.05, 
cisplatin 19.6 ± 1.7%, p < 0.001), significant increase in the late apoptotic (control 0.6 ± 
0.2%, cisplatin 13.8 ± 2.5%; p < 0.001) and significant decrease in the necrotic (control 
25.7 ± 0.5%, cisplatin 12.9 ± 1.4%; p < 0.05) populations. Significant decrease 
following 24 hours of asiatic acid treatment was observed in the live (control 57.6 ± 
2.4%, asiatic acid 9.7 ± 2.7%; p < 0.001), significant decrease in the early apoptotic 
(control 25.0 ± 2.1%, asiatic acid 8.3 ± 2.4%; p < 0.001) and significant increase in the 
late apoptotic (control 11.9 ± 0.4%, asiatic acid 65.7 ± 5.0%, p < 0.001). Significant 
decrease following 120 hours of asiatic acid treatment was observed in live (control 
73.5 ± 0.4%, asiatic acid 49.5 ± 6.1%; p < 0.001), significant increase in the early 
apoptotic (control 0.2 ± 0.05%, asiatic acid 44.6 ± 7.2%; p < 0.001) and significant 
decrease in the necrotic (control 25.7 ± 0.5%, asiatic acid 2.7 ± 0.8%; p < 0.001). 
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In the U87-MG cell line, cisplatin treatment showed a significant decrease in the 
live cell population following 48 (control 95.9 ± 1.5%, cisplatin 81 ± 2.1%; p < 0.001) 
and 120 (control 95.4 ± 0.1%, cisplatin 82.7 ± 1.3%; p < 0.001) hours of treatment 
(Figs. 3.9 & 3.11). Asiatic acid showed a significant decrease following 24 hours of 
treatment on the live (control 92.1 ± 1.4%, asiatic acid 5.8 ± 2.1%; p < 0.001), 
significant increase in the late apoptotic (control 1.7 ± 0.5%, asiatic acid 66.0 ± 7.6%; p 
< 0.001) and significant increase in the necrotic (control 0.8 ± 0.1%, asiatic acid 13.6 ± 
0.1%; p < 0.05) populations. Significant decrease following 120 hours of asiatic acid 
treatment was observed in live (control 95.4 ± 0.1%, asiatic acid 48.6 ± 3.8%; p < 
0.001) and significant increase in the early apoptotic (control 0.3 ± 0.1%, asiatic acid 
47.9 ± 5.0%; p < 0.001) populations.  
Significant differences were also observed between SVGp12 and U87-MG cell 
lines. Cisplatin showed a significant difference in the live cell population following 24 
(SVGp12 64.9 ± 0.9%, U87-MG 86.7 ± 0.5%; p < 0.001) and 48 (SVGp12 60.8 ± 2.1%, 
U87-MG 81.0 ± 2.12%; p < 0.001) hours of treatment. A significant difference was also 
observed in the early apoptotic population of both cell lines following 24 (SVGp12 23.8 
± 1.1%, U87-MG 8.0 ± 0.4%; p < 0.01) and 120 (SVGp12 19.6 ± 1.8%, U87-MG 3.8 ± 
0.3%; p < 0.001) hours of treatment. Asiatic acid did not show any significant 
differences between the two cell lines.  
5% hypoxia 
Cisplatin did not show any significant differences in the cell populations of 
SVGp12 cells over the period of 72 hours (Figs. 3.12 & 3.13). Asiatic acid showed a 
significant reduction in the live cell population only at 24 hours (control 63.3 ±0.9%, 
asiatic acid 55.5 ± 0.7%; p < 0.01). It can be noted from the graphs that a very small 
fraction of cells underwent necrotic cell death (data for 72 hours, control 6.5 ± 2.1%, 
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cisplatin 8.1 ± 2.4%, asiatic acid 5.1 ± 1.0%) and the majority of the dead SVGp12 cells 
were in the early (data for 72 hours, control 27 ± 5.2%, cisplatin 26.8 ± 4.6%, asiatic 
acid 21.7 ± 4.1%) or late phases of apoptosis (data for 72 hours, control 22.3 ±0.7%, 
cisplatin 24.1 ± 0.7%, asiatic acid 26.6 ± 0.2%). 
Cisplatin, again, did not show any significant differences in the cell population 
of U87-MG cells over the period of 72 hours. A small change was seen with the asiatic 
acid treatment (Figs. 3.12 % 3.13). A significant decrease was observed with 48 hours 
of asiatic acid treatment on the live (control 69.5 ± 4.8%, asiatic acid 53.2 ± 7.8; p < 
0.001) and significant increase in the early apoptotic (control 11.9 ± 3.8%, asiatic acid 
24.9 ± 4.9%; p < 0.001) populations. A significant increase was also observed in the 
early apoptotic population of cells following 72 hours of asiatic acid treatment (control 
11.3 ± 2.1%, asiatic acid 26.5 ± 4.4%; p < 0.01). An overall reduction in the percentage 
of live cells was observed in the U87-MG cell line. It can be noted that a very small 
fraction of cells underwent necrotic cell death (data for 72 hours, control 3.5 ± 0.5%, 
cisplatin 3.1 ± 0.7%, asiatic acid 2.5 ± 0.4%) and the majority of the dead U87-MG 
cells were in the early (data for 72 hours, control 11.3 ± 2.1%, cisplatin 14.6 ± 2.2, 
asiatic acid 26.5 ± 4.4%) or late (data for 72 hours, control 26.6 ± 6.7%, cisplatin 25.8 ± 
6.1%, asiatic acid 19.2 ± 2.3%) phases of apoptosis. 
Between SVGp12 and U87-MG cell lines, significant differences were observed 
for cisplatin treatment in the live cell population at 24 hours only, (SVGp12 61.3 ± 
1.4%, U87-MG 75.9 ± 1.8%; p < 0.05). Asiatic acid treatment did not show any 
significant differences in the two cell lines. 
1% hypoxia 
 Although an increase in the apoptotic population of cells was observed upon 
cisplatin treatment on the SVGp12 cell line, no significant differences compared to the 
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control were observed until 72 hours of treatment with cisplatin (Figs. 3.14 & 3.15). 
Following 72 hours of treatment with cisplatin, significant decrease was observed in the 
live (control 30.9 ± 1.7%, cisplatin 21.9 ± 1.9%; p < 0.01) and late apoptotic (control 
37.6 ± 1.5%, cisplatin 21.9 ± 1.9%; p < 0.05) populations. Asiatic acid treatment 
showed a significant increase in the late apoptotic population of cells following 24 
(control 35.9 ± 2.3%, asiatic acid 51.6 ± 0%; p < 0.05) and 48 (control 40.0 ± 2.6, 
asiatic acid 46.8 ± 4.9%, p < 0.05) hours of treatment. It can be noted, from the figures, 
that a very small fraction of cells underwent necrotic cell death (data for 72 hours, 
control 8.4 ± 1.6%, cisplatin 6.1 ± 0.9%, asiatic acid 7.0 ± 1.0%) and the majority of the 
dead SVGp12 cells were in the early (data for 72 hours, control 23.1 ± 2.6%, cisplatin 
26.7 ± 1.6%, asiatic acid 25.1 ± 1.8) or late (data for 72 hours, control 37.6 ± 1.5%, 
cisplatin 45.3 ± 2.5%, asiatic acid 42.8 ± 2.1%) phases of apoptosis. 
Again, cisplatin showed significant differences compared to the control 
following 72 hours of treatment on the U87-MG cell line (Figs. 3.14 & 3.15). This 
difference was seen in the late apoptotic population of cells (control 37.1 ± 2.2%, 
cisplatin 25.2 ± 0.7%; p < 0.05). Significant decrease was observed with asiatic acid 
treatment on the U87-MG cell line following 24 hours of treatment in the live (control 
50.8 ± 2.9%, asiatic acid 25.9 ± 3.3; p < 0.001) and significant increase in the late 
apoptotic (control 27.1 ± 1.1%, asiatic acid 46.7 ± 1.3%; p < 0.001) populations. 
Following 48 hours of asiatic acid treatment, a significant decrease was observed in the 
live cell population of U87-MG cell line (control 43.1 ± 4.6%, asiatic acid 18.9 ± 0.9; p 
< 0.0.5). Significant decrease was also observed following 72 hours of asiatic acid 
treatment in the live (control 45.6 ±3.8%, asiatic acid 27.1 ± 0.2%; p < 0.001) and 
significant increase in the early apoptotic (control 11.2 ± 1.3%, asiatic acid 26.6 ± 1.6%; 
p < 0.01) populations. 
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Significant differences were observed, at 24 hours, between the two cell lines in 
the live cell population of non-treated controls (SVGp12 30.4 ± 1.8%, U87-MG 50.8 ± 
2.9%; p < 0.001). Cisplatin showed a significant difference in the live cell population of 
the two cell lines at 24 (SVGp12 32.3 ± 1.8%, U87-MG 52.9 ± 2.1%; p < 0.001), 48 
(SVGp12 24.6 ± 2.6%, U87-MG 49.4 ± 3.7%; p < 0.001) and 72 hours (SVGp12 21.9 ± 
1.9, U87-MG 52.4 ± 3.2; p < 0.001). 
In the SVGp12 cell line under 5% hypoxia, showed a significant increase in the 
live (normoxia 8.1 ± 2.7%, 5% hypoxia 55.5 ± 0.7%; p < 0.001) and early (normoxia 
8.3 ± 2.5%, 5% hypoxia 24.3 ± 3.2%; p < 0.01) and a significant decrease in the late 
apoptotic (normoxia 65.7 ± 5.0%, 5% hypoxia 16.4 ± 1.9%; p < 0.001) populations of 
cells, following 24 hours of asiatic acid treatment. Following 48 hours of asiatic acid 
treatment under 5% hypoxia, significant increase was observed in the live cell 
population of SVGp12 cells (normoxia 21.6 ± 1.1%, 5% hypoxia 59.2 ± 7.7%; p < 
0.001). Non-treated SVGp12 cells showed significant decrease under 5% hypoxia in the 
live (76.0 ± 2.2%, 5% hypoxia 44.2 ± 3.9; p < 0.001) and a significant increase in the 
early apoptotic (normoxia 2.1 ± 0.6%, 5% hypoxia 27.0 ± 5.2%; p < 0.01) population of 
cells, following 72 hours of incubation. Cisplatin did not show any significant 
differences on SVGp12 cell line between the two conditions. Non-treated U87-MG cell 
line under 5% hypoxia showed a significant decrease in the live cell population at 24 
(normoxia 92.1 ± 1.4%, 5% hypoxia 76.0 ± 1.6%; p < 0.001), 48 (normoxia 95.9 ± 
1.9%, 5% hypoxia 69.5 ± 4.8%; p < 0.001) and 72 (normoxia 96.9 ± 0.9%, 5% hypoxia 
58.6 ± 8.5; p < 0.01) hours. Asiatic acid treatment, under 5% hypoxia, showed a 
significant increase in the live cell population in U87-MG cells following 48 (normoxia 
13.2 ± 4.3%, 5% hypoxia 53.2 ± 7.8%; p < 0.001) and 72 (normoxia 26.1 ± 4.1%, 5% 
hypoxia 51.8 ± 6.1%; p < 0.001) hours of treatment. Under 5% hypoxia, asiatic acid 
treatment showed a significant decrease in the early apoptotic population of cells 
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following 48 (normoxia 54.3 ± 6.3%, 5% hypoxia 24.9 ± 4.9%; p < 0.001) and 72 
(normoxia 68.6 ± 4.4%, 5% hypoxia 26.5 ± 4.4%; p < 0.001). Cisplatin did not show 
any significant differences. 
In the SVGp12 cell line under 1% hypoxia, a significant decrease was observed 
in the live cell population non-treated cells following 24 (normoxia 57.6 ± 2.4%, 1% 
hypoxia 30.4 ± 1.8%; p < 0.01), 48 (normoxia 61.6 ± 5.1%, 1% hypoxia 26.8 ± 2.1%; p 
< 0.001) and 72 (normoxia 76.0 ± 2.2%, 1% hypoxia 30.9 ± 1.7%; p < 0.001) hours of 
incubation. A significant increase was also observed in the late apoptotic population of 
non-treated cells at 24 (normoxia 11.9 ± 0.4%, 1% hypoxia 35.9 ± 2.3%; p < 0.001), 48 
(normoxia 12.3 ± 2.1%, 1% hypoxia 40.0 ± 6%; p < 0.001) and 72 (normoxia 4.8 ± 
0.9%, 1% hypoxia 37.6 ± 1.5%; p < 0.001) hours. Cisplatin treated cells showed a 
significant decrease in the live cell population following 24 (normoxia 64.9 ± 0.9%, 1% 
hypoxia 32.3 ± 1.8%; p < 0.01), 48 (normoxia 60.8 ± 2.1%, 1% hypoxia 24.6 ± 2.6%; p 
< 0.01) and 72 (normoxia 42.9 ± 1.4%, 1% hypoxia 21.9 ± 1.9%; p < 0.05) hours of 
treatment. Asiatic acid showed a significant increase in the live population of cells 
following 24 (normoxia 9.7 ± 2.7%, 1% hypoxia 22.1 ± 2.7%; p < 0.001) and a 
significant decrease at 48 (normoxia 21.6 ± 1.1%, 1% hypoxia 16.3 ± 0.9; p < 0.05) 
hours of treatment. A significant difference was also observed with asiatic acid in the 
late apoptotic population of cells following 24 (normoxia 65.7 ± 5.0%, 1% hypoxia 51.6 
± 0%; p < 0.05) and 48 (normoxia 37.1 ± 0.5%, 1% hypoxia 46.8 ± 4.9%; p < 0.001) 
hours of treatment. In the U87-MG cell line under 1% hypoxia, a significant decrease 
was observed in the live cell population of non-treated cells at 24 (normoxia 92.1 ± 
1.4%, 1% hypoxia 50.8 ± 2.9%; p < 0.001), 48 (normoxia 95.9 ± 1.9, 1% hypoxia 43.1 
± 4.6%; p < 0.001) and 72 hours (normoxia 96.9 ± 0.9%, 1% hypoxia 45.6 ± 3.8; p < 
0.001).  A significant increase was also observed in the late apoptotic population of 
cells following 24 (normoxia 1.7 ± 0.5%, 1% hypoxia 27.1 ± 1.1%; p < 0.001), 48 
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(normoxia 0.9 ± 0.4%, 1% hypoxia 34.0 ± 3.1%; p < 0.001) and 72 (normoxia 0.7 ± 
0.2%, 1% hypoxia 37.1 ± 2.2%; p < 0.001) hours of incubation. Cisplatin treatment 
showed a significant decrease in live cell percentage following 24 (normoxia 86.7 ± 
0.5%, 1% hypoxia 52.9 ± 2.1%; p < 0.01), 48 (normoxia 81.0 ± 2.1%, 1% hypoxia 49.4 
± 3.7%; p < 0.01) and 72 (normoxia 74.3 ± 0.8%, 1% hypoxia 52.4 ± 3.2%; p < 0.05) 
hours of treatment. Asiatic acid showed a significant increase in the live (normoxia 5.8 
± 2.1%, 1% hypoxia 25.9 ± 3.3%; p < 0.001) and a significant decrease in the late 
apoptotic (normoxia 66.0 ± 7.6%, 1% hypoxia 46.7 ± 1.3%; p < 0.001) population of 
cells following 24 hours of treatment.  
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Figure 3.9: Flow cytometric plots showing cell apoptosis using Annexin V/Alexa 
Fluor 488
®
 and propidium iodide on SVGp12 and U87-MG cell lines following 120 
hours of incubation, under normoxia 
 (A, D) Non-treated cells, (B, E) cisplatin and (C, F) asiatic acid. Cisplatin and asiatic 
acid showed a higher number of apoptotic cells compared to control. 
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Figure 3.10: Data illustrating the effect of cisplatin and asiatic acid treatments on 
SVGp12 cell line using Annexin V/Aelxa Fluor 488
®
 and propidium iodide, under 
normoxia 
Cell apoptosis study was performed on SVGp12 cell line following 24 (A), 48 (B) and 
72 (C) and 120 (D) hours of treatment. Data shows relative proportions of live 
(colourless), necrotic (light grey), early apoptotic (dark grey) and late apoptotic cells 
(black). Cisplatin did not show any differences in cell populations compared to control, 
however, asiatic acid showed a higher proportion of dead cells than control. Significant 
differences for live cell population, in comparison to control, have been displayed. 
Values represent mean ± S.E. for three experiments in triplicate.  
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Figure 3.11: Data illustrating the effect of cisplatin and asiatic acid treatments on 
U87-MG cell line using Annexin V/Aelxa Fluor 488
®
 and propidium iodide, under 
normoxia 
Cell apoptosis study was performed on U87-MG cell line following 24 (A), 48 (B) and 
72 (C) and 120 (D) hours of treatment. Data shows relative proportions of live 
(colourless), necrotic (light grey), early apoptotic (dark grey) and late apoptotic cells 
(black). Cisplatin did not show any differences in cell populations compared to control, 
however, asiatic acid showed a higher proportion of dead cells than control. Significant 
differences for live cell population, in comparison to control, have been displayed. 
Values represent mean ± S.E. for three experiments in triplicate.  
  
C 
A B 
D 
 *** 
 *** 
 *** 
 ***  ***  *** 
89 
 
   
   
   
      
Figure 3.12: Flow cytometric plots showing cell apoptosis using Annexin V/Alexa 
Fluor 488
®
 and propidium iodide on SVGp12 and U87-MG cells following 72 
hours of incubation, under 5% hypoxia 
Flow cytometry was performed on SVGp12 and U87-MG cell lines on non-treated (A, 
D), cisplatin (B, E), asiatic acid (C, F) treated cells. 
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Figure 3.13: Data illustrating the effect of cisplatin and asiatic acid treatments on 
SVGp12 and U87-MG cell line using Annexin V/Aelxa Fluor 488
®
 and propidium 
iodide, under 5% hypoxia 
Cell apoptosis study was performed on SVGp12 and U87-MG cell lines following 24 
(A & D), 48 (B & E) and 72 (C & F) hours of treatment. Data shows relative 
proportions of live (colourless), necrotic (light grey), early apoptotic (dark grey) and 
late apoptotic cells (black). Cisplatin did not show any differences in cell populations 
compared to control, however, asiatic acid showed a higher proportion of dead cells 
than control. Significant differences for live cell population, in comparison to control, 
have been displayed. Values represent mean ± S.E. for three experiments in triplicate. 
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Figure 3.14: Flow cytometric plots showing cell apoptosis using Annexin V/Alexa 
Fluor 488
®
 and propidium iodide on SVGp12 and U87-MG cells following 72 
hours of incubation, under 1% hypoxia 
Flow cytometry was performed on SVGp12 and U87-MG cell lines on non-treated (A, 
D), cisplatin (B, E), asiatic acid (C, F) treated cells. 
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Figure 3.15: Data illustrating the effect of cisplatin and asiatic acid treatments on 
SVGp12 and U87-MG cell line using Annexin V/Aelxa Fluor 488
®
  and propidium 
iodide under 1% hypoxia 
Cell apoptosis study was performed on SVGp12 and U87-MG cell lines following 24 
(A & D), 48 (B & E) and 72 (C & F) hours of treatment. Data shows relative 
proportions of healthy (colourless), necrotic (light grey), early apoptotic (dark grey) and 
late apoptotic cells (black). Significant differences for live cell population, in 
comparison to control, have been displayed. Values represent mean ± S.E. for three 
experiments in triplicate. 
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3.2.5 Cellular reactive oxygen species assay 
ROS play an important role in cell signalling pathways and contribute towards 
cellular apoptosis and necrosis. To measure the amount of ROS generated in the two 
cell lines following treatment with cisplatin and asiatic acid, a ROS assay using the 
fluorescent dye DCFDA was performed.  
Normoxia 
 Cisplatin treatments at 2, 10 and 40µM showed 136.9 ± 6.4%, 137.8 ± 6.7 and 
150.7 ± 8.4% of ROS activity on the SVGp12 cell line. Asiatic acid treatments at 30, 50 
and 70 µM showed 148.8 ± 5%, 153.9 ± 8.5% and 148.9 ± 6.2% activity in ROS on 
SVGp12 cell line (Fig. 3.16). No significant differences (p > 0.05) between any two 
groups of data, at any given time were observed. 
  Cisplatin treatments at 2, 10 and 40µM showed 132.4 ± 6%, 132.3 ± 8.5% and 
147.9 ± 8.9% of ROS activity on the U87-MG cell line. Asiatic acid treatments at 30, 50 
and 70 µM showed 135.8 ± 7.3%, 147.2 ± 4.7% and 142 ± 6.3% activity in ROS on 
U87-MG cell line (Fig. 3.16). No significant differences (p > 0.05) between any two 
groups of data, at any given time were observed. 
1% hypoxia 
 The results obtained for ROS assay under 1% hypoxia were similar to the results 
obtained for normoxia. Cisplatin treatments at 2, 10 and 40µM showed 155.3 ± 7.4%, 
166.9 ±1.4% and 133.7 ±2.4% of ROS activity on the SVGp12 cell line. Asiatic acid 
treatments at 30, 50 and 70 µM showed 148.5 ± 1.9%, 150.5 ± 2% and 145.4 ± 1.6% 
activity in ROS on SVGp12 cell line (Fig. 3.17). No significant differences (p > 0.05) 
between any two groups of data, at any given time were observed. 
  Cisplatin treatments at 2, 10 and 40µM showed 154.7 ± 3.2%, 148.9 ± 3.9% and 
160.7 ± 4.2% of ROS activity on the U87-MG cell line. Asiatic acid treatments at 30, 50 
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and 70 µM showed 155.1 ± 2.1%, 151.5 ±7.7% and 160.1 ± 2.7% activity in ROS on 
U87-MG cell line (Fig. 3.17). No significant differences (p > 0.05) between any two 
groups of data, at any given time were observed. 
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Figure 3.16: Data illustrating the effect of different concentration of cisplatin and asiatic acid treatments on SVGp12 and U87-MG cell line 
using DCFDA dye for intracellular ROS detection, under normoxia 
Cellular ROS study was performed on SVGp12 (A) and U87-MG (B) cell lines using 2, 10 and 40µM cisplatin and 30, 50 and 70µM asiatic acid. Data 
shows percentage increase in ROS activity, which was similar for all three treatments. No significant differences were observed. Values represent 
mean ± S.E. for three experiments in triplicate. 
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Figure 3.17: Data illustrating the effect of different concentration of cisplatin and asiatic acid treatments on SVGp12 and U87-MG cell line 
using DCFDA dye for intracellular ROS detection, under 1% hypoxia 
Cellular ROS study was performed on SVGp12 (A) and U87-MG (B) cell lines using 2, 10 and 40µM cisplatin and 30, 50 and 70µM asiatic acid. Data 
shows percentage increase in ROS activity, which was similar for all three treatments. No significant differences were observed. Values represent 
mean ± S.E. for three experiments in triplicate. 
A B 
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3.3 Discussion  
Growth Curves 
SVGp12 is an immortalised human foetal glial cell line. It was generated in 
1985 by transfecting primary foetal brain cells with a plasmid containing an origin-
defective mutant of simian virus 40 (SV40) (Henriksen et al., 2014; Lou et al., 2014). 
The U87-MG cell line, originated in 1966, is a highly aberrant human cell line and the 
most commonly studied brain cancer cell line. It is classified as a grade IV (as of 2007) 
astrocytoma cell line (Clark et al., 2010).  
Growth curve analysis of the two cell lines demonstrated U87-MG to have a 
higher proliferation rate compared to the SVGp12 cell line (Fig. 3.1). Arguably, the 
most imperative trait of a cancer cell is its sustained and chronic proliferation. The 
production and release of growth promoting molecules in normal cells is kept under 
check by various mechanisms that promote the normal maintenance of tissue 
architecture and function. However, cancer cells are capable of deregulating these 
systems, thus becoming masters of their own destiny (Hanahan and Weinberg, 2011a; 
Macheret and Halazonetis, 2015). Thus, a higher proliferation in the U87-MG cells was 
observed, compared to the SVGp12 cells. 
Growth curve analysis under hypoxia showed a significantly slower growth of 
SVGp12 and U87-MG cell lines (Fig. 3.1). Hypoxia slows the rate of cell growth, in all 
cells, due to p21
WAF/Cip1
 and p27
kip1
, and has been explained in detail further in this 
chapter (Maddika et al., 2007). 
PrestoBlue
®
 Cell Linearity Assay 
PrestoBlue
®
 is a ready to use, cell permeable resazurin-based solution allowing 
the quantitative determination of the cell viability. PrestoBlue
®
 reagent, when added to 
living cells, is modified in the reducing environment of the viable cells and changes 
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colour from blue to red (absorbance 570 nm), thus becoming highly fluorescent 
(excitation 535 nm/emission 612 nm). The amount of fluorescence can be detected 
using a spectrophotometer. Although PrestoBlue
®
 can also be measured using 
absorbance; florescence is a more sensitive method of detection and is also 
recommended by the company (information from Life Technologies, UK). 
PrestoBlue
®
 linearity assay established that the fluorescence produced was 
directly proportional to population doubling time of the two cell lines (Fig. 3.2). Taking 
into consideration these results, an initial cell density of 1000 cells/well would be 
enough to carry out further cell viability assays following an incubation of 24 hours or 
more. 
Assessment of Cisplatin and Asiatic acid Cytotoxicity 
Cisplatin demonstrated a decrease in cell viability of the two cell lines, SVGp12 
and U87-MG, in a concentration and time dependent manner (Figs. 3.3 & 3.4).  
Cisplatin is a chemotherapeutic drug and shows an early effect on cell viability 
only at higher concentrations, such as 100µM (Figs. 3.3 & 3.4). SVGp12 cells showed a 
smaller proportion of dead cells with cisplatin as compared to U87-MG cells (p < 0.05). 
Cisplatin enters the cells by passive diffusion. Upon entering, cisplatin 
undergoes an aquation reaction which makes it more reactive to cellular targets. 
Although cisplatin can induce structural changes in cells, it mainly works via DNA 
intercalation causing anomalies in cell replication, ultimately  leading to apoptosis 
(Florea and Büsselberg, 2011; Jiang et al., 2004; Qin and Ng, 2002; Wang and Lippard, 
2005).  Due to these reasons, the effects of cisplatin on cell viability can only be seen 
after at least 48 hours of incubation with the drug.  
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Cisplatin showed a decrease in cell proliferation over time and cell death was 
mainly due to apoptosis and not necrosis (Figs. 3.9-3.11). Cisplatin causes transient cell 
cycle arrest in the early S phase leading to a final G2/M phase arrest and ultimately 
apoptosis (Sorenson et al., 1990). Hence, as the cells proliferate, an additive cytotoxic 
effect is seen, which in turn reduces the rate of proliferation of cisplatin treated cells 
(results for this have been shown further in the study). Prolonged exposure of cells to 
cisplatin leads to mainly apoptotic cell death, however a small proportion of cells may 
undergo necrosis. Apoptosis due to cisplatin occurs via the mitochondrial signalling 
pathway through activated caspase-3 (Cummings and Schnellmann, 2002; Florea and 
Büsselberg, 2006; Jiang et al., 2004). Some of the factors that initiate resistance in 
cisplatin treated cells include increased efflux and decreased influx of the drug, 
increased cellular glutathione and metallothionein levels, increased DNA repair, and 
oncogene expression (Gonzalez et al., 2001). Thus, due to the mechanism of action of 
cisplatin, the number of apoptotic cells increased in a time dependent manner. Also, it 
can be noted from the results that cisplatin is not selective for cancer cells and exerts its 
effects on non-cancerous cells too. This encourages the need for the investigation of 
drugs that are selective to cancerous cells. 
Asiatic acid treatment on both cell lines showed a significant reduction in cell 
viability, compared to control at only the highest concentration (100µM). At 30µM, a 
gradual decrease in cell viability was observed over 72 hours, in both cell lines (Figs. 
3.3 & 3.4).  All other concentrations of asiatic acid did not show any significant 
differences in cell viability over time.  
Asiatic acid has a reputation of being a putative anticancer agent in many cancer 
types. It has been reported that the carboxylic polar group at C-28 position is essential 
for the pharmacological activities of asiatic acid (Li et al., 2014). The molecular targets 
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of asiatic acid include GRP-78, calpain and cleaved caspase-3 in U87-MG tumours 
(Kavitha et al., 2015). 
Annexin V is a calcium-dependent phospholipid binding protein with high 
affinity for PS, whereas PI is a DNA stain. Annexin V binding to the PS on the outer 
membrane of cells was observed following asiatic acid treatment (Figs. 3.9-3.11), 
however a small population of cells stained positive for propidium iodide too. Asiatic 
acid thus showed cell death mainly via apoptosis although a smaller fraction of cell 
death was via necrosis. Apoptosis assay using asiatic acid did not show any significant 
differences in the two cell lines, thus asiatic acid induced apoptosis in both cell lines.  
Asiatic acid induces a loss of PS asymmetry in a concentration-dependent 
manner that results in the PS being exposed on the outer cell membrane and also causes 
DNA fragmentation (Cho et al., 2006; Hsu et al., 2004). Asiatic acid-mediated cell 
death is cell-type specific in the U87-MG cell line and involves caspase-9 and -3 
activation (Bunpo et al., 2004; Cho et al., 2006; Kavitha et al., 2015). However, there 
are other mechanisms of asiatic acid-mediated cell death and this has been shown by the 
use of pan-caspase inhibitor, zvad-fmk. The use of this inhibitor, in a study on 
glioblastoma cell line by Cho et al., (2006), demonstrated that zvad-fmk did not 
significantly block AA-mediated cell death in the glioblastoma cell line. 
Asiatic acid causes endoplasmic reticulum (ER) stress (a result of activated 
GRP-78) and an increase in the intracellular calcium level. It is due to this that cell 
death occurs; thus decreasing the mitochondrial membrane potential. Furthermore, 
asiatic acid treatment reduces Bcl-2 expression in cells and it has been speculated that 
asiatic acid mediated increase in intracellular calcium is partially via the inhibition of 
Bcl-2 expression in the ER. (Bunpo et al., 2004; Cho et al., 2006; Kavitha et al., 2014;  
Wang et al., 2009). 
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Intracellular calcium release is a mediator of chemical-induced cytotoxicity and 
apoptotic cell death. The two major pathways leading to increase in intracellular 
calcium are influx from extracellular space and release from internal source. However, 
with the use of calcium channel blockers, studies have confirmed that asiatic acid 
mediated cell death is only due to intracellular calcium release and not due to the 
extracellular calcium store (Hsu et al., 2004). This release in intracellular calcium 
triggers a biochemical cascade leading to calpain activation. Upon activation, calpain 
degrades cell membrane, cytoplasmic and nuclear substrates, subsequently leading to 
the breakdown of cellular architecture and cell death (Momeni, 2011).  
Asiatic acid treatment also showed a smaller population of cells undergoing 
necrosis (Figs. 3.9-3.11). Necrosis is characterised by the release of the enzyme lactate 
dehydrogenase (LDH). A rapid release in LDH indicates traumatic cell death, i.e., 
necrosis, whereas a slow release indicates apoptosis (Cho et al., 2006; Scaffidi et al., 
2002).  
Thus, it can be speculated that asiatic acid mediates glioblastoma cell death due 
to caspase activation via intrinsic apoptosis and also necrosis. This is seen in the results 
obtained in this study where a small number of necrotic cell population was observed 
following asiatic acid treatment, however, cell death occurred mainly due to apoptosis.  
Decrease in oxygen supply to the cells leads to biochemical changes that can 
either result in cells adaptation to hypoxia or cause cell death. HIF-1α is an important 
transcription factor and regulator of gene products under hypoxia. An initial moderate 
increase in HIF-1α is important for cells adaptation to hypoxia (Strese et al., 2013). 
In this state, cancer cells respond to hypoxia via angiogenesis stimulation by 
VEGF, apoptosis inhibition via Bcl-2, modifying the cellular metabolism of glucose, 
adapting to extracellular acidic pH and up-regulation of proteins involved in metastasis 
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(Bogenrieder and Herlyn, 2003; Graeber et al., 1996; Vander Heiden, M. G., Cantley, 
L.C., Thompson, 2009; Zhou et al., 2006). 
A slower rate of proliferation is observed under hypoxia, due to p21
WAF/Cip1
, 
p27
kip1
 and the increased distance of the cells from the blood vessel. These defects in 
cell cycle regulation, proliferation and apoptosis cause a reduction in the efficacy of 
anticancer/chemotherapeutic drugs (Maddika et al., 2007). From the results obtained in 
this study, a reduced effect of cisplatin and asiatic acid can be observed under hypoxia. 
Cell apoptosis assay under hypoxia has shown a higher number of live cells and smaller 
apoptotic population even after prolonged treatment with cisplatin and asiatic acid 
(Figs. 3.12-3.15). 
A reduction in the activity of p53 under hypoxia causes inhibition of cell 
apoptosis, and cells are more likely to undergo restoration following DNA injuries. 
Hypoxia increases the expression of MDR1 gene encoding membrane-resident P-gp that 
belongs to a family of ATP-binding cassette transporters. P-gp acts to increase 
chemoresistance towards a variety of drugs by acting as an efflux pump, in various 
types of cancers, including glioma (Comerford et al., 2002; Gottesman, 2002; Liu et al., 
2008). Various studies have reported, that hypoxia increases chemo resistance (Koch et 
al., 2003; Rohwer et al., 2010; X. Song et al., 2006). Studies have shown that cell 
viability of U87-MG cells can be compromised to facilitate apoptosis in a caspase-
dependent/p53 independent mechanism via the inhibition of HIF-1α transactivation (Dai 
et al., 2003). Hypoxia also reduces cell-senescence due to chemotherapeutic drugs 
(Sullivan et al., 2008).  
Mitochondria, the ‘power house’ of the cell, play an important role in cell 
viability and the initiation of intrinsic apoptotic pathway (Galluzzi et al., 2008). It has 
been established previously that HIF can reduce mitochondrial activity of the cell, 
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acting once again, in a chemoresistant manner. HIF-1α suppresses the TCA cycle by 
inhibiting pyruvate shuttling into mitochondria via inactivation of PDH (pyruvate 
dehydrogenase), the enzyme that catalyses the transformation of pyruvate into acetyl-
CoA. In this manner, HIF-1α suppresses mitochondrial activity, initiates mitophagy 
(mitochondrial autophagy) and also suppresses mitochondrial biogenesis. This leads to 
reduced cell death and increased drug resistance under hypoxia (Kim et al., 2006; 
Papandreou et al., 2006; Zhang et al., 2007). 
Cell viability for cisplatin and asiatic acid under hypoxia showed more number 
of viable cells at the same drug concentrations when compared to normoxia (Figs. 3.5-
3.8). Growth curve analysis of the two cell lines showed a significantly slower rate of 
growth of cells under hypoxia when compared to normoxia (Fig. 3.1). These results 
suggest that hypoxia alters cellular metabolism, cell growth is slowed and cell apoptosis 
is reduced. Thus, as apoptosis is suppressed, this again provides an explanation for the 
reduced effect of drugs that was observed under hypoxia on the two cell lines. Also, as 
cell growth is important for the cytotoxic effects of drugs; due to the slower growth of 
cells under hypoxia, the cytotoxic effect of drugs was reduced.  
Results from the apoptosis assay showed a large number of apoptotic SVGp12 
and U87-MG cells following 24 hours of incubation with cisplatin and asiatic acid 
under hypoxia (Figs. 3.12-3.15). However, this number did not change at the end of 72 
hours suggesting that the apoptotic percentage of cells observed was not necessarily due 
to the drug treatments, but it could be due to the cells becoming acclimatised to 
hypoxia.  
An estimated 50-60% of all tumours contain hypoxic or anoxic regions. These 
regions only develop as a result of an imbalance between oxygen supply and 
consumption in proliferating tumours. A study by Grayson et al., 2006 revealed that 
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hMSC cells underwent an initial acclimatisation period where they did not proliferate, 
thus extending their lag phase. This can be seen in Fig. 3.1 where a significantly slower 
growth of cells, under hypoxia, is observed and also an increase in the doubling time for 
both cell lines. 
The hydration of carbon dioxide to carbonic acid is catalysed by carbonic 
anhydrase IX (CAIX), (transcription gene located on vHPL of HIF-1α). It contributes to 
the acidification of the extracellular tumour environment thus maintaining the normal 
pH in tumour cells. In this manner, CIAX allows acclimatisation of cells under hypoxia 
and a blockade or slow release results in cell death under hypoxia (Korkolopoulou et al., 
2007; Pantuck et al., 2003; Yamagata et al., 1998). 
Hypoxia creates an environment of stress and during the acclimatisation period, 
it can induce DNA damage, cell cycle arrest and ultimately cell death. However, as 
discussed previously, hypoxia also selects cells with a decreased p53 activity, thus 
reducing their apoptosis and allowing them to proliferate. 
It has been widely accepted that ROS play a crucial role in tumour metastasis 
and gene regulation in a variety of cell types (Ma et al., 2009). ROS show an increased 
basal level in cancer cells than in normal cells and are involved in the activation of HIF, 
whereby the transcription of various genes promoting tumour proliferation takes place 
(Section 1.8) (Kolamunne et al., 2013). Some studies have described an increase in ROS 
generation under hypoxia, while others have observed a decrease in ROS under hypoxia 
(Huang et al., 2008). 
Results from in this study, a basal level of 100% ROS activity was observed. 
Neither cisplatin, nor asiatic acid treatments showed an increase or decrease in the ROS 
activity in SVGp12 or U87-MG cells, at the concentration used (Figs. 3.16 & 3.17).  
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Hypoxia down regulates mitochondrial activity (Kim et al., 2006; Papandreou et 
al., 2006; Zhang et al., 2007). Mitochondria is the main site of ROS generation due to 
aerobic respiration. However, in a tumour cell, anaerobic glycolysis generating lactic 
acid as a source of energy takes place, instead of glucose (Fig. 3.18). This shift in lactate 
production in cancer cells, even in the presence of oxygen, is termed as the Warburg 
effect (Kim and Dang, 2006; Warburg, 1956). It is due to this that a downregulation in 
ROS production from the mitochondria is seen in tumours. 
 
Figure 3.18: Diagrammatic representation of aerobic respiration in the 
mitochondria of the cell 
Glycolysis is the first step in aerobic respiration. In the presence of NAD
+
 and ATP, 
glucose is converted to pyruvate, transported into the mitochondria and converted into 
acetyl CoA. NADH and FADH2, from the TCA/Krebs cycle, convert ADP to ATP in 
the inner mitochondrial membrane. Creation of H
+
 concentration gradient drives the 
production of more ATP. A total of 38 ATP are produced via aerobic respiration as 
opposed to 2 ATP in anaerobic respiration. The end product of anaerobic respiration is 
either ethanol or lactic acid, and it takes place in the cell cytosol. Source: Tumour 
Metabolom
®
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ROS production not only occurs in the mitochondria; other sources of ROS 
production in tumour cells include chronic inflammation, increased cytokine release and 
activation of the c-Myc protein (Biroccio et al., 2001; Kim and Dang, 2006). 
Cisplatin induces ROS generation which partially mediates apoptosis (Pelicano 
et al., 2004). This was shown in a study by Berndtsson et al., (2007) using ROS 
scavengers, that apoptosis at 24 hours was inhibited. However, massive cell death due 
to cisplatin induced ROS generation mainly occurs in c-Myc low-expressing cells. This 
is consistent with other findings that ROS are potent inducers of apoptosis. It has also 
been speculated that ROS production occurs only in cells unable to recover from 
cisplatin induced damage by c-Myc down-regulation (Biroccio et al., 2001). 
Asiatic acid, on the other hand, has been shown to suppress ROS production due 
to UVA irradiation in human keratinocytes (Soo Lee et al., 2003). A study by Tang et 
al., (2009) shows that asiatic acid causes interference with the mitochondrial membrane 
potential, in colon cancer cells, thereby stimulating cytochrome c release and initiating 
caspase signalling pathways. Apoptosis and cell death in multiple cell lines is preceded 
by the elevation of cytochrome c (encoded by a nuclear gene) and cytochrome c oxidase 
subunit II (encoded by a mitochondrial gene) levels. Both of these proteins are involved 
in the mitochondrial respiratory chain. Transcription and up-regulation of cytochrome c 
results in its translocation from cytosol into mitochondria and this does not depend on 
mitochondrial respiration or mitochondrial protein synthesis. In contrast, mitochondrial 
cytochrome c release involves dynamic changes in Bcl-2 proteins, opening of 
permeability transition pore and loss of mitochondrial membrane potential. This 
overexpression of cytochrome c enhances caspase activation and apoptosis; while the 
downregulation of Bcl-2 promotes cell death via c-Myc (Chandra et al., 2002; O’Brien 
and Kirby, 2008). As explained earlier, asiatic acid mediated glioblastoma cell death is 
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mainly due to intracellular calcium release and reduction in Bcl-2 expression in cells. 
This suggests a mechanism for asiatic acid effects on cell apoptosis and necrosis in 
glioblastoma cell lines and can be investigated in the future. 
In conclusion, the down regulation of mitochondrial activity occurs in hypoxia 
and anaerobic mode of glycolysis in tumour cells suggests a reason behind a stable level 
in the ROS activity observed in this study. Thus, although asiatic acid mediates cell 
apoptosis through ROS production, this may not necessarily be the major contributor 
towards cell apoptosis and other mechanisms such as Bax/Bcl-2, intracellular calcium 
release and caspase activation may be involved. 
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CHAPTER 4 
4 Effect of Hypoxia on Cell Proliferation and Cell Cycle 
  
 
109 
 
4.1 Introduction  
Eukaryotic cell cycle progression and proliferation are tightly regulated, 
irreversible and cause unidirectional changes in the state of the cell. Cell cycle is 
controlled by cyclin-dependent kinases and has a specific activity at every stage of the 
cell cycle, such as chromosome condensation, DNA replication and spindle assembly. 
Cell proliferation occurs due to cell cycle progression of the cell and cell cycle 
associated checkpoints regulate the entry into cell cycle. Thus, cells with deleterious 
mutations in their DNA are not allowed to progress into the cell cycle and apoptosis 
takes place (Crosio et al., 2002; Pinheiro and Sunkel, 2012; Rieder, 2011; Shackelford 
et al., 1999; Tyson et al., 2002; van den Heuvel, 2005; Vermeulen et al., 2003). 
Cell proliferation is thus an important factor in the assessment of cytotoxicity of 
drugs. Also, tumour cells generally show increased rates of proliferation due to genetic 
mutations and hence the assessment of the rate of proliferation of cells is an important 
factor in assessing drug induced cytotoxicity (Kanu et al., 2009; Minniti et al., 2009). 
Cell apoptosis and cell cycle are intimately related processes, and this is evident by the 
presence of p53 in cell cycle progression and the induction of apoptosis (Shah and 
Schwartz, 2001). 
In addition, the relative expression of various receptors, including EGFR 
expression, is modified under hypoxia and also due to drug treatments (Kanu et al., 
2009; Minniti et al., 2009).  
Cell migration is central to a variety of physiological processes including tissue 
repair and regeneration. Abnormal wound healing is a characteristic of tumour cells and 
an important factor determining the malignancy of tumour cells. Cell migration is 
regulated by EGFR expression, which is up-regulated in glioma (Gough et al., 2011; 
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Lalloo et al., 2006; Natarajan et al., 2006). We thus studied the effects of asiatic acid on 
cell migration and performed a wound healing assay over a period of 18 hours. 
Biochemical synergy has been the rationale behind combination therapies. 
Combination therapies also help in overcoming drug resistance due to the additive 
and/or synergistic effects. Cisplatin is chemotherapeutic drug whereas asiatic acid is a 
herbal compound. By choosing chemotherapeutic drugs with different mechanisms of 
action, different biochemical targets were assessed (DeVita et al., 1975; Shah and 
Schwartz, 2001).  
Objectives: Following the results obtained from apoptosis and reactive oxygen species 
generation of the two cell lines, we performed cell proliferation and cell cycle analysis. 
We also assessed the relative expression of EGFR on the two cell lines, using western 
blotting and performed combination studies using cisplatin and asiatic acid.   
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4.2 Results  
4.2.1 Cell Proliferation Assay 
The proliferation rates of cell lines vary following drug treatments and also due 
to oxygen conditions. The rate of proliferation of cells is an important factor in 
determining cytotoxicity of drugs. In order to assess this, cell proliferation assay using 
CFDA-SE was performed in SVGp12 and U87-MG cell lines, under normoxia and 
hypoxia (1% and 5%), following their treatments with cisplatin and asiatic acid. A 
reduction in CFDA-SE fluorescence indicated an increase in cell proliferation. 
Normoxia 
In SVGp12 cell line, reduction in fluorescence to 45 ± 2.5% at 24 hours and to 
1.2 ± 0.1% at the end of 120 hours was observed. Following 24 hours of incubation, 
cisplatin treatment on SVGp12 cells showed a reduction to 45 ± 2.6%; this reduced to 
1.6 ± 0.1% at the end of 120 hours, which means that cisplatin treated cells proliferated 
at a similar rate to non-treated cells (Figs. 4.1-4.3). However, cisplatin showed a 
significant increase in CFDA fluorescence at 48 hours (control 16.3 ± 0.2%, cisplatin 
21.6 ± 1.1%; p < 0.01). Treatment with asiatic acid showed a reduction in fluorescence 
to 42.3 ± 1.0% at 24 hours and 1.5 ± 0.1% at the end of 120 hours. Asiatic acid 
treatment did not show any significant differences. 
Similar results were obtained for U87-MG cell line. In U87-MG cell line, a 
reduction in fluorescence to 31.9 ± 6.0% at 24 hours and to 1 ± 0.1% at the end of 120 
hours was observed. Following 24 hours of incubation, cisplatin treatment on U87-MG 
cells showed a reduction in fluorescence to 39.7 ± 7.6%; this reduced to 2 ± 0.5% at the 
end of 120 hours, which means that cisplatin treated cells proliferated at a similar rate to 
non-treated cells . However, cisplatin treatment showed a significant increase in CFDA 
fluorescence at 48 hours (and control 14.1 ± 3.5%, cisplatin 24.5 ± 5.1%, p < 0.01), as 
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observed in Figs. 4.1-4.3. Treatment with asiatic acid showed a reduction in 
fluorescence to 36.5 ± 6.5% at 24 hours and 1.2 ± 0.2% at the end of 120 hours. Asiatic 
acid treatment did not show any significant differences. 
Significant differences were also observed between SVGp12 and U87-MG cell 
lines in the non-treated controls following 24 hours of incubation (SVGp12 39.2 ± 
3.8%, U87-MG 28.5 ± 2%; p < 0.05). Cisplatin showed significant increase in CFDA 
fluorescence at 48 (SVGp12 2.4 ± 0.2%, U87-MG 3.3 ± 0.5; p < 0.05) and 72 hours 
(SVGp12 1.8 ± 0.3%, U87-MG 4.2 ± 0.8%; p < 0.05). Asiatic acid treatment did not 
show any significant differences. 
5% hypoxia 
 In SVGp12 cell line, a reduction in fluorescence to 55.8 ± 3.0% at 24 hours and 
to 1.5 ± 0.3% at the end of 120 hours was observed. Following 24 hours of incubation, 
cisplatin treatment on SVGp12 cells showed a reduction in fluorescence to 61.9 ± 5.2%; 
this reduced to 15.8 ± 5.6% at the end of 120 hours (Figs. 4.4-4.6). Cisplatin treatment 
appeared to slow the rate of cell proliferation when compared to non-treated cells, 
although these differences were non-significant at any of the measured time points. 
Treatment with asiatic acid showed a reduction in fluorescence to 56.9 ± 4.9% at 24 
hours and 1.1 ± 0.2% at the end of 120 hours. Thus, the SVGp12 cell line proliferated at 
a similar rate with or without any treatment. Statistical analysis of the data did not show 
any significant differences in the rate of proliferation of SVGp12 cells. 
 Similar results were obtained for U87-MG cell line. Cells proliferated to 43 ± 
5.3% at 24 hours and to 2.2 ± 0.4% at the end of 120 hours. Following 24 hours of 
incubation, cisplatin treatment on U87-MG cells showed a reduction in fluorescence 
49.3 ± 8.5%; this reduced to 15.9 ± 3.4% at the end of 120 hours (Figs. 4.4-4.6). 
Cisplatin showed a decreased proliferation rate in the U87-MG cell line compared to 
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control, although these differences were found to be non-significant upon being 
analysed statistically. Treatment with asiatic acid showed a fluorescence reduction to 
41.4 ± 4.2% at 24 hours and 2.1 ± 0.3% at the end of 120 hours. Asiatic acid did not 
show any differences in the rate of proliferation of cells compared to the control. Based 
on these observations, the U87-MG cell line proliferated at a similar rate with or 
without any treatment.  
 No significant differences were observed between the two cell lines following 
incubation with any of the treatments. 
1% hypoxia 
 In SVGp12 cell line, reduction in fluorescence by 230.8 ± 97.7% at 24 hours and 
to 21.8 ± 8.5% at the end of 120 hours was observed. SVGp12 cells showed a reduction 
in fluorescence to 251.9 ± 96.4% following 24 hours of incubation with cisplatin and 
this reduced to 9 ± 2.6% at the end of 120 hours (Figs. 4.7-4.9). Asiatic acid showed a 
fluorescence reduction to 82.3 ± 16.1% at 24 hours and 6.8 ± 1.8% at the end of 120 
hours. No significant differences in the rate of proliferation of asiatic acid or cisplatin 
treated cells were observed (Figs. 4.7-4.9). Thus, the SVGp12 cell line proliferated at a 
similar rate with or without any treatment, under 1% hypoxia.  
 Similar results were obtained for U87-MG cell line. U87-MG cells showed a 
reduction in proliferation to 365.1 ± 100.8% at 24 hours and to 11.3 ± 5.3% at the end 
of 120 hours. Following 24 hours of incubation with cisplatin, U87-MG cells showed a 
fluorescence reduction to 934 ± 489.2%; this reduced to 33.4 ± 9.5% at the end of 120 
hours (Figs. 4.7-4.9). Asiatic acid showed a reduction in fluorescence to 813.1 ± 
424.7% at 24 hours and 22.3 ± 6.4% at the end of 120 hours. Statistical analysis of the 
data did not show any significant differences in the rate of proliferation of U87-MG 
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cells. Based on these observations, the U87-MG cell line proliferated at a similar rate 
with or without any treatment, under 1% hypoxia. 
 No significant differences were observed between the two cell lines following 
incubation with any of the treatments. 
  
115 
 
  
  
Figure 4.1: Flow cytometric plots showing cell proliferation using CFDA-SE on 
SVGp12 cell line under normoxia 
24 hours (A), 48 hours (B), 72 hours (C), 120 hours (D). Non-treated (black), cisplatin 
(red), asiatic acid (green). No significant differences in the rate of proliferation of 
SVGp12 cell line were observed. 
  
A B 
C D 
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Figure 4.2: Flow cytometric plots showing cell proliferation using CFDA-SE on 
U87-MG cell line under normoxia 
24 hours (A), 48 hours (B), 72 hours (C), 120 hours (D). Non-treated (black), cisplatin 
(red), asiatic acid (green). No significant differences in the rate of proliferation of U87-
MG cell line were observed.  
 
 
  
A B 
C D 
117 
 
0 24 48 72 120
0
20
40
60
80
100
Time (hours)
C
F
D
A
 f
lu
o
re
sc
e
n
ce
(%
 o
f 
C
o
n
tr
o
l)
 
0 24 48 72 120
0
20
40
60
80
100
Time (hours)
C
F
D
A
 f
lu
o
re
sc
e
n
ce
(%
 o
f 
C
o
n
tr
o
l)
 
Figure 4.3: Data illustrating the effect of cisplatin and asiatic acid on SVGp12 and 
U87-MG cell line using CFDA-SE, under normoxia 
Cell proliferation assay on SVGp12 (A) and U87-MG (B) cell lines following 24, 48, 72 
and 120 hours of incubation with non-treated (clear), cisplatin (light grey) and asiatic 
acid (dark grey) was performed using CFDA-SE. A decrease in fluorescence indicates a 
higher rate of cell proliferation. Cisplatin showed a significant reduction in proliferation 
at 48 hours, while asiatic acid showed no significant difference; differences were 
compared to control. Values represent mean ± S.E. for three experiments in triplicate. 
A 
B 
** 
** 
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Figure 4.4: Flow cytometric plots showing cell proliferation using CFDA-SE on 
SVGp12 cell line under 5% hypoxia 
24 hours (A), 48 hours (B), 72 hours (C), 120 hours (D). Non-treated (black), cisplatin 
(red), asiatic acid (green). No significant differences in the rate of proliferation of 
SVGp12 cell line were observed. 
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Figure 4.5: Flow cytometric plots showing cell proliferation using CFDA-SE on 
U87-MG cell line under 5% hypoxia 
24 hours (A), 48 hours (B), 72 hours (C), 120 hours (D). Non-treated (black), cisplatin 
(red), asiatic acid (green). No significant differences in the rate of proliferation of U87-
MG cell line were observed. 
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Figure 4.6: Data illustrating the effect of cisplatin and asiatic acid on SVGp12 and 
U87-MG cell line using CFDA-SE, under 5% hypoxia 
Cell proliferation assay on SVGp12 (A) and U87-MG (B) cell lines following 24, 48, 72 
and 120 hours of incubation with non-treated (clear), cisplatin (light grey) and asiatic 
acid (dark grey) was performed using CFDA-SE. A decrease in fluorescence indicates a 
higher rate of cell proliferation. No significant differences were observed in the rate of 
proliferation of either of the cell lines with any of the treatments. Values represent mean 
± S.E. for three experiments in triplicate. 
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Figure 4.7: Flow cytometric plots showing cell proliferation using CFDA-SE on 
SVGp12 cell line, under 1% hypoxia 
24 hours (A), 48 hours (B), 72 hours (C), 120 hours (D). Non-treated (black), cisplatin 
(red), asiatic acid (green). No significant differences in the rate of proliferation of 
SVGp12 cell line were observed. 
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Figure 4.8: Flow cytometric plots showing cell proliferation using CFDA-SE on 
U87-MG cell line under 1% hypoxia 
24 hours (A), 48 hours (B), 72 hours (C), 120 hours (D). Non-treated (black), cisplatin 
(red), asiatic acid (green). No significant differences in the rate of proliferation of U87-
MG cell line were observed. 
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Figure 4.9: Data illustrating the effect of cisplatin and asiatic acid on SVGp12 and 
U87-MG cell line using CFDA-SE under 1% hypoxia 
 Cell proliferation assay on SVGp12 (A) and U87-MG (B) cell lines following 24, 48, 
72 and 120 hours of incubation with non-treated (clear), cisplatin (light grey) and asiatic 
acid (dark grey) was performed using CFDA-SE. A decrease in fluorescence indicates a 
higher rate of cell proliferation. No significant differences were observed in the rate of 
proliferation of either of the cell lines with any of the treatments. Values represent mean 
± S.E. for three experiments in triplicate. 
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4.2.2 Scratch/wound healing assay 
Cell migration is an important factor in determining the malignancy of a 
tumorous mass. The in vitro scratch assay is a way of studying cell migration. When a 
cell monolayer is wounded or scratched, the cell monolayer responds to the cell-cell 
disruption by an increased amount of growth factors at the wound site and ultimately 
results in healing of the wound through cell proliferation and migration. We studied the 
effects of cisplatin and asiatic acid on the migration of SVGp12 and U87-MG cell lines. 
Normoxia 
The scratch assay on non-treated SVGp12 and U87-MG cell lines showed a 
complete closure of the wound after 18 hours (Figs. 4.10-4.12). Cisplatin showed a 
partial closure of the wound (from 631.07 ± 41.52µm to 333 ± 28.04 µm in SVGp12 
and from 574.2 ± 28.72 µm to 233.7 ± 6.69 µm in U87-MG). Asiatic acid treated cells, 
too, showed a partial closure of wound (from 696.11 ± 30.89 µm to 388.04 ± 9.67 µm in 
SVGp12 and from 539.28 ± 38.68 µm to 199.52 ± 15.31 µm in U87-MG) following 18 
hours of incubation. Statistical analysis of the data could not be performed. 
1% hypoxia 
The results obtained for cisplatin and asiatic acid under hypoxia were similar to 
the results obtained under normoxia, however, even the non-treated cells only showed a 
partial closure of the wound (Figs. 4.13 & 4.14). Wound healing on SVGp12 cells was 
recorded as 296.46 ± 86.90 µm from an initial 666.28 ± 35.66 µm for the non-treated 
cells, 205.45 ± 60.07 µm from an initial 676.10 ± 37.23 µm for cisplatin treatment and 
454.85 ± 39.22 µm from an initial 740.27 ± 67.80 µm for asiatic acid treatment. Wound 
healing on U87-MG cells was recorded as 84.65 ± 48.87 µm from an initial 821.01 ± 
25.82 µm for the non-treated cells, 250.06 ± 22.14 µm from an initial 742.52 ± 23.00 
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µm for cisplatin treatment and 483.12 ± 41.62 µm from an initial 869.58 ± 110.85 µm 
for asiatic acid treatment. No significant differences were observed. 
No significant differences were observed between the two cell lines under 1% 
hypoxia. 
Significant difference was observed in the non-treated control of SVGp12 cell 
line (normoxia 0µm, 1% hypoxia 253.94 ± 48.87 µm; p < 0.05).  
Due to the experiment being subjective, we faced difficulties in quantifying the 
data.  
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Figure 4.10: Time course imaging of U87-MG cell line showing wound healing over 
a period of 18 hours, under normoxia 
A complete closure of the wound for non-treated U87-MG cells was observed under 
normoxia at 18 hours. 
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Figure 4.11: Microscopy images showing the scratch/wound healing in SVGp12 
and U87-MG cell line following treatment with cisplatin and asiatic acid, under 
normoxia 
Ctrl-control, Cis-cisplatin and AA-asiatic acid. Complete closure of the non-treated 
SVGp12 and U87-MG cells was observed at 18 hours. Cisplatin showed a partial 
closure of the wound, whereas asiatic acid did not show any wound healing at all. No 
significant differences with cisplatin and asiatic acid treatments were observed. 
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Figure 4.12: Data showing the wound distance measured in SVGp12 and U87-MG 
cell line following treatments with cisplatin and asiatic acid, under normoxia 
Non treated (clear), cisplatin (light grey) and asiatic acid (dark grey). Data shows the 
wound distance before adding any treatments, followed by 18 hours of incubation with 
the desired drug. Complete closure of the non-treated SVGp12 (A) and U87-MG (B) 
cells was observed at 18 hours. Partial wound closure was observed. Statistical analysis 
of this data could not be performed. Values represent mean ± S.E. for three experiments 
in triplicate.  
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Figure 4.13: Microscopy images showing the scratch/wound healing in SVGp12 
and U87-MG cell line following treatment with cisplatin and asiatic acid, under 
1% hypoxia 
Ctrl-control, Cis-cisplatin and AA-asiatic acid. Partial closure of the wound was 
observed with the non-treated and cisplatin treated cells, asiatic acid treatment did not 
show any wound healing at all. No significant differences with cisplatin and asiatic acid 
treatments were observed. 
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Figure 4.14: Data showing the wound distance measured in SVGp12 and U87-MG 
cell line following treatments with cisplatin and asiatic acid, under 1% hypoxia 
Non treated (clear), cisplatin (light grey) and asiatic acid (dark grey). Data shows the 
wound distance at 0 hours (pre-treatment), followed by 18 hours of incubation with the 
desired drug (post-treatment). Partial closure of the wound was observed. No significant 
differences with cisplatin and asiatic acid treatments were observed. Values represent 
mean ± S.E. for three experiments in triplicate.  
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4.2.3 Immunoblotting for EGFR 
Amplification of EGFR gene is a frequent genetic mutation associated with 
GBM, and results in the activation of EGFR receptor on cell surfaces.  It has been 
confirmed by previous studies that EGFR amplification results in increased proliferation 
and invasiveness of GBM cells and is an important factor in determining patient 
prognosis (Montano et al., 2011). In order to assess the changes in the level of EGFR 
expression following drug treatments, a western blot analysis using immunoblotting was 
performed on SVGp12 and U87-MG cell lines. 
Normoxia 
 EGFR expression increased in SVGp12 following cisplatin treatment (Fig. 
4.15). EGFR expression in cisplatin treated SVGp12 cells was 75.77 ± 6.28% at 24 
hours and 125.97 ± 7.76% at the end of 72 hours. EGFR expression for asiatic acid 
treated cells increased from 92.83 ± 14.84% at 24 hours to 160.58 ± 24.42% at 48 hours 
and reduced to 70.78 ± 20.78% at the end of 72 hours. No significant differences were 
observed. 
In the U87-MG cell line, EGFR expression in cisplatin treated U87-MG cells 
was 184.57 ± 13.37% at 24 hours to 107.63 ± 14.98% at the end of 72 hours (Fig. 4.15). 
EGFR expression for asiatic acid treated cells increased from 62.91 ± 12.14% at 24 
hours to 180.22 ± 26.03% at 72 hours. No significant differences were observed. 
No significant differences were observed between the two cell lines. 
1% hypoxia 
 EGFR expression in cisplatin treated SVGp12 cells decreased from 79.49 ± 
16.07% at 24 hours to 74.33 ± 18.56% at the end of 72 hours (Fig. 4.16). EGFR 
expression for asiatic acid treated cells decreased from 153.39 ± 63.35% at 24 hours to 
136.99 ± 3.92% at the end of 72 hours. No significant differences were observed. 
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Cisplatin showed a decrease in EGFR expression over time on U87-MG cell line 
(Fig. 4.16). EGFR activity in cisplatin treated U87-MG cells decreased from 123.76 ± 
13.52% at 24 hours to 42.79 ± 7.81% at the end of 72 hours. EGFR activity for asiatic 
acid treated cells increased from 21.19 ± 3.04% at 24 hours to 74.28 ± 6.47% at the end 
of 72 hours. No significant differences were observed. 
No significant differences were obtained between normoxia and hypoxia. 
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Figure 4.15: Data showing relative levels of EGF receptor expression following 24, 
48 and 72 hour treatment with cisplatin and asiatic acid on SVGp12 and U87-MG 
cell line, under normoxia  
(A) Blot images for SVGp12 and U87-MG, (B) SVGp12, (C) U87-MG.  
EGF-R expression remained unchanged following cisplatin treatment in SVGp12 cell 
line, however, a small increase with asiatic acid was observed at 48 hours. Cisplatin 
showed a small decrease in EGF receptor activity over time on U87-MG cell line, 
however, no change was observed with asiatic acid. Values represent mean ± S.E. for 
three experiments in triplicate. 
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Figure 4.16: Data showing relative levels of EGF receptor expression following 24, 
48 and 72 hour treatment with cisplatin and asiatic acid on SVGp12 and U87-MG 
cell line, under 1% hypoxia 
(A) Blot images for SVGp12 and U87-MG, (B) SVGp12, (C) U87-MG. 
Cisplatin and asiatic acid showed a reduction in expression of EGF receptor in SVGp12 
cell line whereas asiatic acid showed an increase following 72 hours of treatment. A 
decrease in EGF receptor expression was observed with cisplatin, however, asiatic acid 
showed an increase in EGF receptor expression following 72 hour treatments in U87-
MG cell line. Values represent mean ± S.E. for three experiments in triplicate.  
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4.2.4 Cell Cycle Analysis 
Cell death due to drug treatments can take place via apoptosis, necrosis or due to 
cell cycle arrest. Cell cycle progression is a highly controlled phenomenon and various 
check-points in the cell cycle assure the entry of only healthy cells into the cell cycle 
and thus its proliferation. To investigate whether cisplatin and asiatic acid had any 
effects on cell cycle arrest in SVGp12 and U87-MG cell lines, a cell cycle analysis of 
was performed under normoxia and hypoxia (1% and 5%).  
Normoxia 
Cell cycle analysis of SVGp12 and U87-MG cell lines under normoxia showed 
differences in the cell cycle stages following drug treatments. Significant increase in 
G2/M population of cisplatin treated cells were observed at 24 (control 54.8 ± 1.7%, 
cisplatin 61.5 ± 1.4%; p < 0.001) and 48 (control 49.2 ± 1.1%, cisplatin 60.1 ± 2.8%; p 
< 0.001) while a significant decrease at 120 (control 49.8 ± 1.6%, cisplatin 44.1 ± 0.6%; 
p < 0.001) hours was observed (Figs. 4.17 & 4.18). Treatment with asiatic acid showed 
a higher percentage of cells in the S-G2/M transition of the cell cycle. Significant 
decrease was observed in G2/M cell population following 72 hours of asiatic acid 
treatment (control 48.5 ± 0.6%, asiatic acid 45.0 ± 0.6%; p < 0.05). 
Cisplatin treatment on U87-MG cell line, when compared to control, showed a 
high percentage of cells in the G2/M phase of cell cycle (control 46.5 ± 2.1%, cisplatin 
50.8 ± 0.7%, p < 0.05) following 24 hours of treatment (Fig. ). Significant decrease was 
observed with cisplatin treatment in the G0/G1 phase of cell cycle following 24 (control 
39.4 ± 2.5%, cisplatin 30 ± 1.4%; p < 0.01), 48 (control 46.9 ± 2.1, cisplatin 25.3 ± 5.8; 
p < 0.001), 72 hours (control 48.4 ± 0.8, cisplatin 31.8 ± 6.5; p < 0.05) and 120 (control 
49.0 ± 1.4%, cisplatin 41.8 ± 2.2%; p < 0.01) hours. Following 48 hours of treatment, a 
significant increase was also observed in the G2/M population of cells (control 38.9 ± 
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1.7, cisplatin 61.1 ± 5.9%; p < 0.001). Treatment with asiatic acid showed a high 
number of cells in the G0/G1 phase and the G2/M phase of the cell cycle. Asiatic acid, 
at 24 hours, showed 37.7 ± 1.9% cells in the G0/G1 phase and 47.3 ± 1.0% cells in the 
G2/M phase. Following 120 hours of incubation with asiatic acid, the G0/G1 population 
increased to 50.6 ± 1.7%, whereas the G2/M population reduced to 35.4 ±1.4%.  Asiatic 
acid did not show any significant differences.  
Cisplatin also showed significant increase in the U87-MG cell line following 24 
hours treatment in the G0/G1 (SVGp12 17.1 ±8%, U87-MG 30.0 ± 1.4%; p < 0.001) 
and a significant decrease in the G2/M (SVGp12 61.5 ± 1.4%, U87-MG 50.8 ± 0.7%; p 
< 0.001) population of cells (Figs. 4.13-4.15). A significant increase was also observed 
following 120 hours of cisplatin treatment in G0/G1 population of cells (SVGp12 25.4 
±9%, U87-MG 41.8 ± 2.2%; p < 0.001). Asiatic acid showed a significant increase U87-
MG cells in the G0/G1 population following 24 (SVGp12 22.4 ± 0.7%, U87-MG 37.7 
±1.9%; p < 0.001), 48 (SVGp12 27.4 ± 0.9%, U87-MG 43.2 ± 2.3%; p < 0.001), 72 
(SVGp12 29.1 ± 0.8%, U87-MG 47.8 ± 1.0%; p < 0.001) and 120 (SVGp12 25.9 ± 
0.9%, U87-MG 50.6 ± 1.7; p < 0.001) hours of incubation. A significant decrease was 
observed in the G2/M population of cells with asiatic acid treatment at 24 (SVGp12 
55.8 ± 1.0%, U87-MG 47.3 ± 1.0%; p < 0.01) and at 120 (SVGp12 45.9 ± 2.0%, U87-
MG 35.4 ± 1.1; p < 0.001). 
5% hypoxia 
 Cisplatin treatment on SVGp12 (Figs. 4.20 & 4.21) cells under 5% hypoxia 
showed a large number of cells in the S phase of the cell cycle (46.1 ± 2.6% at 24 
hours). This was also the case for control (49.6 ± 2.1% at 24 hours) and asiatic acid 
treated cells (47.3 ± 1.3% at 24 hours). A gradual decrease in the percentage of cells in 
the S phase was observed by the end of 120 hours. At the end of 120 hours, control, 
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cisplatin and asiatic acid treated cells showed 29.8 ± 3.5%, 16.9 ± 2.3% and 29.7 ± 
3.3% of the total cell population in the S phase. The decrease of the cell population in S 
phase was directly related to the apoptotic population of cells at the same time and 
increased over time from 19.8 ± 2.6% at 24 hours to 59 ± 7.3% at 120 hours for 
cisplatin treatment. Similar was the case for asiatic acid treated cells, 21.6 ± 0.9% at 24 
hours to 33.4 ± 4.3% at 120 hours. Statistical analysis of the data did not show any 
significant differences (p > 0.05) in the cell populations of cisplatin or asiatic acid 
treated cells at any given time. 
 Cell cycle analysis of U87-MG cell line under 5% hypoxia showed a high 
percentage of cells in the G0/G1 and S phase of the cell cycle (Figs. 4.20 & 4.22). An 
increase in the population of cells in the G0/G1 phase, over time, was observed for 
control, cisplatin and asiatic acid treatments, which correlated directly to a decrease in 
the S phase population of cells. At 24 hours, non-treated, cisplatin and asiatic acid 
treatments showed 47 ± 3.3%, 47.6 ± 3.4% and 46.8 ±3.3% cells respectively in the 
G0/G1 phase. This percentage of cells increased, at the end of 120 hours, to 50.6 ± 2.7% 
and 55.6 ± 2.6% for control and asiatic acid respectively. Cisplatin showed a decrease in 
the population of cells, at 120 hours, in G0/G1 phase to 33.8 ± 6.8%; however this was 
due to the high number of apoptotic cells that were observed. The S phase showed 43.8 
± 3.4%, 40.8 ± 3.2% and 43.2 ± 3.1% cells for control, cisplatin and asiatic acid 
treatments at 24 hours, respectively. A decrease in the population of cells in the S phase 
was observed at the end of 120 hours. Control, cisplatin and asiatic acid showed 29.6 ± 
1.7%, 26.3 ± 2.6% and 26.7 ± 1.6% of cells in the S phase at 120 hours, respectively. 
Statistical analysis of the data showed significant reduction in the S phase population of 
cisplatin treated cells 24 hours (control 43.8 ± 3.4%, cisplatin 40.8 ± 3.2%; p < 0.05) 
and also in the G0/G1 phase of cell population 120 hours (control 50.6 ± 2.7%, cisplatin 
33.8 ± 6.8%; p < 0.01). 
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 A significant increase in U87-MG cells was observed in the G0/G1 population 
of cells with cisplatin treatment following 24 (SVGp12 27.1 ± 0.6%, U87-MG 47.6 ± 
3.4%; p < 0.001), 48 (SVGp12 22.2 ± 2.6%, U87-MG 51.9 ±1.9%; p < 0.001), 72 
(SVGp12 23.8 ± 3.8%, U87-MG 50.6 ± 3.1%; p < 0.001) and 120 (SVGp12 19.0 ± 
4.2%, U87-MG 33.8 ± 6.8; p < 0.001) hours of incubation. A significant increase was 
observed in the S phase population of cells following 120 hours of treatment with 
cisplatin (SVGp12 16.9 ± 2.3%, U87-MG 26.3 ± 2.6%; p < 0.05). Asiatic acid showed a 
significant increase in the G0/G1 population of cells following 24 (SVGp12 26.2 ± 
0.7%, U87-MG 46.8 ± 3.3%; p < 0.001), 48 (SVGp12 31.3 ± 2.2%, U87-MG 52.7 ± 
2.0%; p < 0.001), 72 (SVGp12 29.7 ± 2.5%, U87-MG 58.6 ± 2.3%; p < 0.001) and 120 
(SVGp12 30.9 ± 1.3%, U87-MG 55.6 ± 2.6; p < 0.001) hours of incubation. 
1% hypoxia 
 A large number of SVGp12 cells were observed in the G2/M phase of cell cycle 
under 1% hypoxia (Figs. 4.23 & 4.24). An increase in the cell population was observed 
in the G0/G1 phase from 24 to 72 hours. Control, cisplatin and asiatic acid treatments 
showed 31 ±.9%, 18.9 ± 1.0% and 31.8 ± 1.2% cells, respectively, in the G0/G1 phase 
at 24 hours which increased to 35 ± 1.0%, 34.9 ± 1.3% and 35.2 ± 1.1%, respectively, at 
the end of 72 hours. A decrease in the cell population from G0/G1 phase to 20.6 ± 
0.6%, 26 ± 0.7% and 23.1 ± 0.2% was observed at 120 hours, for control, cisplatin and 
asiatic acid respectively. This decrease in the population correlated directly, to an 
increase in the apoptotic cell percentage at the end of 120 hours. On the other hand, 
cisplatin showed a decrease in the population of cells in G2/M phase from 62.3 ± 1.0% 
at 24 hours to 50.4 ± 0.9% at 120 hours. Control and asiatic acid treatments showed 50 
± 0.7% and 51.3 ±.6% cells, respectively, in the G2/M phase at 24 hours and 55.6 ± 
1.1% and 50.4 ± 0.9% cells, respectively, at the end of 120 hours. A significant decrease 
was observed with cisplatin treatment in the G0/G1 phase of cell cycle following 24 
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(control 31.0 ± 1.9%, cisplatin 18.9 ± 1.0%; p < 0.001) while a significant increase was 
observed following 120 (control 20.6 ± 0.6%, cisplatin 26.0 ± 0.7%; p < 0.01) hours of 
incubation. A significant increase with cisplatin treatment was observed in the G2/M 
population of cells following 24 (control 50.0 ± 0.7%, cisplatin 62.3 ± 1.0%; p < 0.001) 
while a significant decrease was observed following 120 (control 55.6 ± 1.1%, cisplatin 
49.8 ± 1.7%; p < 0.001) hours of incubation. Asiatic acid treatments showed no 
significant differences (p > 0.05) at any cell cycle phase at any given time. 
 Cell cycle analysis of U87-MG cell line showed a high number of cells in the 
G0/G1 and G2/M phase of cell cycle (Fig. 4.23 & 4.25). Cisplatin treatment showed an 
increase in the cell population of G0/G1 phase from 43.8 ± 1.6% at 24 hours to 48.2 ± 
1.0% at 120 hours. However, control and asiatic acid treatments showed a decrease in 
the cell population from 24 hours to 120 hours in the G0/G1 phase, 57.4 ± 0.7% to 53.3 
± 1.7% for control and 54.5 ± 2.9% to 52.1 ± 0.8% for asiatic acid. This decrease in the 
cell population correlated to an increase in the G2/M phase of the cell population. 
Asiatic acid showed 30.2 ± 0.2% cells at 24 hours with an increase to 35 ± 0.1% at 120 
hours in the G2/M phase. On the contrary, cisplatin showed a decrease in the cell 
population of G2/M from 40.4 ± 1.0% at 24 hours to 37.3 ± 0.4% at 120 hours. A 
significant decrease was observed following cisplatin treatment in the G0/G1 phase of 
cell cycle at 24 (control 57.4 ± 0.7%, cisplatin 43.8 ± 1.6; p < 0.001), 48 (control 57.3 ± 
1.2%, cisplatin 49.1 ± 3.2%; p < 0.01), 72 (control 54.2 ± 0.9, cisplatin 51.9 ± 1.9; p < 
0.01) and 120 (control 53.3 ± 1.7, cisplatin 48.2 ± 1.0%; p < 0.001) hours. A significant 
increase was observed following cisplatin treatment in the G2/M phase at 24 (control 
30.9 ± 0.1%, cisplatin 40.4 ± 0.1%; p < 0.001), 48 (control 31.2 ± 0.8%, cisplatin 39.8 ± 
2.615; p < 0.001), 72 (control 32.3 ± 0.8%, cisplatin 34.8 ± 1.0%; p < 0.01) and 120 
(control 34.6 ±8%, cisplatin 37.3 ± 0.4%; p < 0.05) hours. Asiatic acid treatments 
showed no significant differences (p > 0.05) in any cell cycle phase at any given time. 
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Under 1% hypoxia, a significant increase was seen in U87-MG cell line in the 
G0/G1 population of cells with cisplatin treatment following 24 (SVGp12 18.9 ± 1.0%, 
U87-MG 43.8 ± 1.6%; p < 0.001), 48 (SVGp12 28.9 ± 1.3%, U87-MG 49.1 ± 3.2%; p < 
0.001), 72 (SVGp12 34.9 ± 1.3%, U87-MG 51.5 ± 1.9%; p < 0.001) and 120 (SVGp12 
26.0 ± 0.7%, U87-MG 48.2 ± 1.0%; p < 0.001) hours of incubation. A significant 
reduction was observed in the G2/M phase of the cell cycle with cisplatin treatment 
following 24 (SVGp12 62.3 ± 1.0%, U87-MG 40.4 ± 1.0%; p < 0.001), 48 (SVGp12 
56.5 ± 1.5%, U87-MG 39.8 ± 2.6%; p < 0.001) and 72 (SVGp12 47.7 ± 0.7%, U87-MG 
34.8 ± 1.0%; p < 0.05) hours of incubation. A significant increase with asiatic acid 
treatment in the G0/G1 phase of cell cycle was observed following 24 (SVGp12 31.8 ± 
1.2%, U87-MG 54.5 ± 2.9%; p < 0.001), 48 (SVGp12 36.0 ± 1.7%, U87-MG 59.5 ± 
0.9%; p < 0.001), 72 hours (SVGp12 35.2 ± 1.1%, U87-MG 55.6 ± 0.8%; p < 0.001) 
and 120 (SVGp12 23.1 ± 0.2%, U87-MG 52.1 ± 0.8%; p < 0.001) hours of incubation. 
Asiatic acid also showed significant reduction in the G2/M population of cells following 
24 (SVGp12 51.3 ± 0.6%, U87-MG 30.2 ±0.2%; p < 0.001), 48 (SVGp12 48.1 ± 1.2, 
U87-MG 28.5 ± 0.7%; p < 0.001), 72 (SVGp12 46.8 ± 1.1%, U87-MG 31.5 ± 0.7%; p < 
0.01) and 120 (SVGp12 50.4 ± 0.9, U87-MG 35.0 ± 0.1%; p < 0.01) hours of 
incubation. 
Statistical analysis of the data at 5% hypoxia revealed significant reduction with 
cisplatin treatment in the G2/M population of SVGp12 cell line. These differences were 
observed following 24 (normoxia 61.5 ±1.4%, 5% hypoxia 7 ± 1.1%; p < 0.001), 48 
(normoxia 60.1 ± 2.8%, 5% hypoxia 4.7 ± 0.3%; p < 0.001), 72 (normoxia 47.6  ± 
1.2%, 5% hypoxia 5.9 ± 0.2%; p < 0.001) and 120 (normoxia 44.1 ± 0.6%, 5% hypoxia 
5.0 ± 1.0%; p < 0.001) hours of incubation. A significant increase was observed in the S 
phase population of cisplatin treated cells following 24 (normoxia 7.1 ± 0.4%, 5% 
hypoxia 46.1 ± 2.6%; p < 0.001), 48 (normoxia 6.2 ± 0.2%, 5% hypoxia 41.2 ± 3.9%; p 
141 
 
< 0.001) and 72 (normoxia 7.6 ± 0.4%, 5% hypoxia 24.5 ± 1.4; p < 0.01) hours of 
incubation. Asiatic acid treatment showed significant increase in S phase population of 
SVGp12 cells following 24 (normoxia 6.8 ± 0.2%, 5% hypoxia 47.3 ± 1.3%; p < 0.001), 
48 (normoxia 8.9 ± 0.9%, 5% hypoxia 28.1 ± 1.3%; p < 0.001), 72 (normoxia 8.8 ± 
0.6%, 5% hypoxia 25.6 ± 1.8; p < 0.001) and 120 (normoxia 7.5 ± 0.5%, 5% hypoxia 
29.7 ±3.3%; p < 0.001) hours of incubation. A significant decrease was observed in the 
G2/M population of SVGp12 cells with asiatic acid treatment following 24 (normoxia 
55.8 ± 1.0%, 5% hypoxia 5.1 ± 0.2%; p < 0.001), 48 (normoxia 45.4 ± 0.8%, 5% 
hypoxia 4.7 ± 0.4%; p < 0.001) 72 (normoxia 45.0 ± 0.6%, 5% hypoxia 4.6 ± 0.3%; p < 
0.001) and 120 (normoxia 45.9 ± 0.2%, 5% hypoxia 6.0 ± 0.7%; p < 0.001) hours of 
incubation. Cisplatin showed a significant increase in the S phase population of U87-
MG cells following 24 (normoxia 10.8 ± 1.8%, 5% hypoxia 40.8 ± 3.2%; p < 0.001), 48 
(normoxia 6.2 ± 0.4%, 5% hypoxia 36.5 ± 1.2%; p < 0.001), 72 hours (normoxia 6.8 ± 
0.6%, 5% hypoxia 30.3 ± 1.2%; p < 0.001) and 120 hours (normoxia 6.4 ± 0.4%, 5% 
hypoxia 26.3 ± 2.6%; p < 0.001) hours of incubation. A significant decrease was 
observed in the G2/M population of cisplatin treated U87-MG cells following 24 
(normoxia 50.8 ± 0.7%, 5% hypoxia 7.3 ± 0.5%; p < 0.001), 48 (normoxia 61.1 ± 5.9%, 
5% hypoxia 7.4 ± 0.7%; p < 0.001), 72 (normoxia 51.6 ± 5.7%, 5% hypoxia 8.0 ± 0.9%; 
p < 0.001) and 120 (normoxia 37.6 ± 1.4%, 5% hypoxia 10.1 ± 0.7%; p < 0.001) hours 
of incubation. Asiatic acid showed a significant increase in the S phase population of 
U87-MG cells following 24 (normoxia 7.7 ± 0.7%, 5% hypoxia 43.2 ± 3.1%; p < 
0.001), 48 (normoxia 6.4 ± 0.4%, 5% hypoxia 35.3 ± 1.4%; p < 0.001), 72 (normoxia 
7.4 ± 0.4%, 5% hypoxia 26.1 ± 0.8%; p < 0.001) and 120 (normoxia 6.1 ± 0.4%, 5% 
hypoxia 26.7 ± 1.6%; p < 0.001) hours of incubation. A significant decrease was also 
observed in the G2/M population of asiatic acid treated U87-MG cells following 24 
(normoxia 47.3 ± 1.0%, 5% hypoxia 6.8 ± 0.6%; p < 0.001), 48 (normoxia 42.5 ± 2.4%, 
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5% hypoxia 6.9 ± 0.1%; p < 0.001), 72 (normoxia 37.2 ± 1.3%, 5% hypoxia 5.4 ± 0.4%; 
p < 0.001) and 120 (normoxia 35.4 ± 1.1, 5% hypoxia 5.6 ± 0.6%; p < 0.001) hours of 
incubation.  
Statistical analysis of the data at 1% hypoxia revealed a significant increase with 
cisplatin treatment in the G0/G1 population of U87-MG cell line. These differences 
were observed following 24 (normoxia 30.0 ± 1.4%, 1% hypoxia 43.8 ± 1.6%; p < 
0.01), 48 (normoxia 25.3 ± 5.8%, 1% hypoxia 49.1 ± 3.2; p < 0.001) and 72 (normoxia 
31.8 ±.5%, 1% hypoxia 51.9 ± 1.5%; p < 0.001) hours of incubation. Cisplatin also 
showed a significant decrease in the G2/M population of U87-MG cells following 48 
(normoxia 61.1 ± 5.9%, 1% hypoxia 49.1 ±3.2%; p < 0.001) and 72 (normoxia 51.6 ± 
5.7%, 1% hypoxia 34.8 ± 1.0%; p < 0.001) hours of incubation. Asiatic acid showed a 
significant increase in the G0/G1 population of U87-MG cells following 24 (normoxia 
37.7 ± 1.9%, 1% hypoxia 54.5 ± 2.9%; p < 0.001) and 48 (normoxia 43.2 ± 2.3%, 1% 
hypoxia 59.5 ± 0.5%; p < 0.001) hours of incubation. A significant decrease with asiatic 
acid treatment was observed in the G2/M population of U87-MG cells following 24 
(normoxia 47.3 ±1.0%, 1% hypoxia 30.2 ± 0.2%; p < 0.001) and 48 (normoxia 42.5 ± 
2.4%, 1% hypoxia 28.5 ± 0.7%; p < 0.01) hours of incubation. 
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Figure 4.17: Flow cytometric plots showing cell cycle analysis using RNase and 
propidium iodide on SVGp12 and U87-MG cell lines following 120 hours of 
incubation, under normoxia 
Flow cytometry analysis of SVGp12 (A-C) and U87-MG (D-F) cells on non-treated (A, 
D), cisplatin (B, E) and asiatic acid (C, F). Cisplatin showed G2/M phase arrest on both 
cell lines, asiatic acid showed S-G2/M arrest on SVGp12 and G0/G1 arrest on U87-MG 
cells.  
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Figure 4.18: Data illustrating the effect of cisplatin and asiatic acid treatments on 
the cell cycle progression of SVGp12 cell line under normoxia  
Cell cycle study was performed on SVGp12 cell line following 24 (A), 48 (B), 72 (C) 
and 120 (D) hours of treatment. Data shows relative proportions of cells in G0/G1 phase 
(black), S phase (dark grey), G2/M phase (light grey) and apoptotic population 
(colourless). Cisplatin showed G2/M phase arrest while asiatic acid showed G0/G1 
arrest on SVGp12 cells. Statistical analysis did not show any differences in the G0/G1 
phase of the cell cycle for any treatments. Values represent mean ± S.E. for three 
experiments in triplicate. 
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Figure 4.19: Data illustrating the effect of cisplatin and asiatic acid treatments on 
the cell cycle progression of U87-MG cell line under normoxia 
Cell cycle study was performed on U87-MG cell line following 24 (A), 48 (B), 72 (C) 
and 120 (D) hours of treatment. Data shows relative proportions of cells in G0/G1 phase 
(black), S phase (dark grey), G2/M phase (light grey) and apoptotic population 
(colourless). Cisplatin showed G2/M phase arrest while asiatic acid showed S-G2/M 
arrest on U87-MG cells. Significant differences in the G0/G1 population of cells have 
been displayed. Values represent mean ± S.E. for three experiments in triplicate. 
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Figure 4.20: Flow cytometric plots showing cell cycle analysis using RNase and 
propidium iodide on SVGp12 and U87-MG cell lines following 120 hours of 
incubation, under 5% hypoxia 
Flow cytometry analysis of SVGp12 (A-C) and U87-MG (D-F) cells on non-treated (A, 
D), cisplatin (B, E) and asiatic acid (C, F). A transient S phase arrest was observed for 
SVGp12 cell line while U87-MG cell line showed a large population of cells under 
G0/G1 phase. 
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Figure 4.21: Data illustrating the effect of cisplatin and asiatic acid treatments on 
the cell cycle progression of SVGp12 cell line under 5% hypoxia 
Cell cycle study was performed on SVGp12 cell line following 24 (A), 48 (B), 72 (C) 
and 120 (D) hours of treatment. Data shows relative proportions of cells in G0/G1 phase 
(black), S phase (dark grey), G2/M phase (light grey) and apoptotic population 
(colourless). A transient S phase arrest was observed for SVGp12 cell line. No 
significant differences were observed. Values represent mean ± S.E. for three 
experiments in triplicate. 
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Figure 4.22: Data illustrating the effect of cisplatin and asiatic acid treatments on 
the cell cycle progression of U87-MG cell line under 5% hypoxia 
Cell cycle study was performed on U87-MG cell line following 24 (A), 48 (B), 72 (C) 
and 120 (D) hours of treatment. Data shows relative proportions of cells in G0/G1 phase 
(black), S phase (dark grey), G2/M phase (light grey) and apoptotic population 
(colourless). A large population of cells was observed in the G0/G1 phase. Significant 
differences in the G0/G1 population of cells have been displayed. Values represent 
mean ± S.E. for three experiments in triplicate.  
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Figure 4.23: Flow cytometric plots showing cell cycle analysis using RNase and 
propidium iodide on SVGp12 and U87-MG cell line following 120 hours of 
incubation, under 1% hypoxia 
Flow cytometry analysis of SVGp12 (A-C) and U87-MG (D-F) cells on non-treated (A, 
D), cisplatin (B, E) and asiatic acid (C, F). Cisplatin showed G2/M phase arrest on both 
cell lines, asiatic acid showed G0/G1 arrest on SVGp12 and S-G2/M arrest on U87-MG 
cells.  
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Figure 4.24: Data illustrating the effect of cisplatin and asiatic acid treatments on 
the cell cycle progression of SVGp12 cell line under 1% hypoxia 
Cell cycle study was performed on SVGp12 cell line following 24 (A), 48 (B), 72 (C) 
and 120 (D) hours of treatment. Data shows relative proportions of cells in G0/G1 phase 
(black), S phase (dark grey), G2/M phase (light grey) and apoptotic population 
(colourless). Cisplatin showed G2/M phase arrest while asiatic acid showed G0/G1 
arrest on SVGp12 cells. Significant differences in the G0/G1 population of cells have 
been displayed. Values represent mean ± S.E. for three experiments in triplicate. 
  
A 
D C 
B 
*** 
** 
151 
 
C
on
tr
ol C
is
A
A
0
20
40
60
80
100
120
P
o
p
u
la
ti
o
n
 S
iz
e
(%
 o
f 
T
o
ta
l)
C
on
tr
ol C
is
A
A
0
20
40
60
80
100
120
P
o
p
u
la
ti
o
n
 S
iz
e
(%
 o
f 
T
o
ta
l)
C
on
tr
ol C
is
A
A
0
20
40
60
80
100
120
P
o
p
u
la
ti
o
n
 S
iz
e
(%
 o
f 
T
o
ta
l)
C
on
tr
ol C
is
A
A
0
20
40
60
80
100
120
P
o
p
u
la
ti
o
n
 S
iz
e
(%
 o
f 
T
o
ta
l)
 
Figure 4.25: Data illustrating the effect of cisplatin and asiatic acid treatments on 
the cell cycle progression of U87-MG cell line under 1% hypoxia 
Cell cycle study was performed on U87-MG cell line following 24 (A), 48 (B), 72 (C) 
and 120 (D) hours of treatment. Data shows relative proportions of cells in G0/G1 phase 
(black), S phase (dark grey), G2/M phase (light grey) and apoptotic population 
(colourless). Cisplatin showed G2/M phase arrest while asiatic acid showed S-G2/M 
arrest on U87-MG cells. Significant differences in the G0/G1 population of cells have 
been displayed. Values represent mean ± S.E. for three experiments in triplicate. 
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4.2.5 Combination studies 
The EC25 values generated from earlier experiment (Section 3.2.3) was used in 
combination with cisplatin or asiatic acid to study any synergistic effects that may be 
involved following drug treatment of the two cell lines. 
Cisplatin and asiatic acid showed a similar response, as described earlier, on 
SVGp12 and U87-MG cell lines (Section 3.2.3). The combination treatments of both, 
2µM cisplatin and asiatic acid, or 30µM asiatic acid and cisplatin, did not seem to affect 
the viability, except at the highest concentration of the two drugs in combination with 
the other (Fig. 4.26).  
SVGp12, cell viability decreased from 11 ± 1.76% at 24 hours to 3.33 ± 0.51% 
at 72 hours upon treatment with 30µM asiatic acid and 100µM cisplatin. A reduction in 
cell viability from 65.67 ± 0.69% at 24 hours to 25 ± 2% at 72 hours was observed upon 
treatment with 2µM cisplatin and 100µM asiatic acid (Fig. 4.26). Significant differences 
were observed only with 100µM asiatic acid treatment on cell viability at each time 
point against all three other treatments (p < 0.05).  
On U87-MG, cell viability decreased from 8 ± 0.88% at 24 hours to 1.67 ± 
0.19% at 72 hours upon treatment with 30µM asiatic acid and 100µM cisplatin. A 
reduction in cell viability from 85.33 ± 1.07% at 24 hours to 31.33 ± 0.77% at 72 hours 
was observed upon treatment with 2µM cisplatin and 100µM asiatic acid (Fig. 4.26). 
Significant differences were observed with 100µM asiatic acid treatment on cell 
viability (p < 0.05). 
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Figure 4.26: Data illustrating the effect of concentration dependent treatment of 
cisplatin and asiatic acid in combination on SVGp12 and U87-MG cell lines. 
Cisplatin ( ), asiatic acid ( ), 30µM asiatic acid-cisplatin ( ) and 2µM cisplatin-asiatic 
acid ( ) on SVGp12 and U87-MG cell lines. Cell viability was measured using the 
PrestoBlue
®
 reagent following 24 (A and D), 48 (B and E) and 72 (C and F) hours of 
incubation with respective treatments. Values represent mean ± S.E. for three 
experiments in triplicate. 
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4.3 Discussion  
As explained earlier, an initial moderate increase in HIF-1α is important for 
cell’s adaptation to hypoxia and cells respond through VEGF stimulation, apoptotic 
inhibition and modification of glucose metabolism (Bogenrieder and Herlyn, 2003; 
Graeber et al., 1996; Strese et al., 2013; Vander Heiden, Cantley, Thompson, 2009; 
Zhou et al., 2006). 
Cell proliferation is an important factor for the anti-cancer effects of cisplatin. 
As explained previously (Section 3.3), cisplatin shows its anti-tumour effects through 
DNA intercalation. In this manner, cisplatin slows the rate of cell proliferation by 
binding to the DNA and causing anomalies in the cell. This effect of cisplatin on cell 
proliferation has been confirmed from the results obtained, where a significant effect on 
proliferation of SVGp12 and U87-MG was seen (Figs. 4.1-4.3).  
Asiatic acid however, works through cell death which is either via apoptosis or 
necrosis (Section 3.3). It is due to the mechanism of action of asiatic acid that no 
significant effect on cell proliferation of SVGp12 or U87-MG cells was observed (Figs. 
4.1-4.3).  
Hypoxic cells are usually distant from blood vessels and are thus not adequately 
exposed to anti-cancer drugs. This distance from blood vessels also causes a reduction 
in the rate of cell proliferation (Brown and Wilson, 2004). Another reason for the 
slower cell proliferation is the cyclin-dependent kinase inhibitor p27
Kip1
 (inhibits the 
activation of cyclin E-Cdk2 or cyclin D-Cdk4 complexes thus controlling cell cycle 
progression at G1), which is induced under hypoxic conditions (Wartenberg et al., 
2003). Cellular senescence caused by DNA-damage response due to drugs results in a 
cell cycle arrest (Chang et al., 1999; d’Adda di Fagagna, 2008). In a study performed by 
Sullivan and co-workers, it was demonstrated that hypoxia can decrease cell-senescence 
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caused due to drug treatments, explaining another mode of chemoresistance due to 
hypoxia (Sullivan et al., 2008). Thus, cytotoxic effect of an anti-cancer drug is greater in 
rapidly proliferating cells, as opposed to slowly proliferating tumour cells under 
hypoxia (Figs. 4.4-4.9). Hypoxia also selects cells with low p53 expression, thus 
reducing or inhibiting p53-induced apoptosis in hypoxic cells. Upon exposure to 
hypoxia, a post-translational modification of the p53 gene occurs, thus making it active 
and in turn promoting transcription of cell cycle regulating or apoptotic genes (Brown 
and Wilson, 2004; Graeber et al., 1996; Zhou et al., 2006). DNA injuries caused to the 
cells under normoxic environment are higher and more permanent than in a hypoxic 
environment, where cellular restoration may occur. Another cause for reduced drug 
cytotoxicity under hypoxia is the MDR (multi-drug resistance) gene and over 
expression of the gene product P-glycoprotein (P-gp), which has been identified to be 
involved in multidrug resistance (Wartenberg et al., 2003).  
A significant reduction in cell proliferation was observed for non-treated U87-
MG cells following 24 hours of incubation under hypoxia. Cisplatin, however, did not 
show any significant differences in the rate of cell proliferation between normoxia and 
hypoxia, for either of the cell lines. The growth curve data for normoxia and hypoxia of 
both cell lines showed a significantly slower rate of growth (Fig. 3.1). The scratch assay 
revealed similar results (Fig. 4.10-4.14), and a significant difference was observed in the 
wound healing of non-treated SVGp12 and U87-MG cells under 1% hypoxia (p < 0.05).  
Cisplatin activity under hypoxia has been shown to be lower than under 
normoxic conditions. However, the anti-cancer activity of a drug under hypoxia 
depends largely on the cell type and may increase or decrease accordingly (Koch et al., 
2003; Yao et al., 2005).  Cisplatin works by forming DNA adducts in the cell. Thus, in 
order for cisplatin to show its effects on cells, cell proliferation is important. However, 
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as cell proliferation decreases under hypoxia, the efficacy of cisplatin decreases too 
(Figs. 4.4-4.9). Three other studies have confirmed the findings of this research wherein 
a reduced efficacy of cisplatin was observed under hypoxia (Koch et al., 2003; Rohwer 
et al., 2010; X. Song et al., 2006).  
As the cells proliferate slowly under hypoxia, a failure of the wound healing was 
observed under microscopy, at the end of 18 hours. However, this was not the case 
under normoxia, where a complete closure of the wound was observed for non-treated 
cells and partial closure was observed for cisplatin treated cells (Figs. 4.10-4.14). These 
findings confirm the slower rate of growth and proliferation of the two cell lines under 
hypoxia. Cisplatin causes DNA interlinks and thus retards the cell migration over time. 
It is due to this that a partial closure of the wound was observed following cisplatin 
treatment. Asiatic acid, on the other hand, did not show any wound healing under 
hypoxia, but instead showed rounded cells, a characteristic of cell death. Thus, it 
suggests that asiatic acid does not affect cell proliferation but instead causes cell death 
only. 
However, keeping this in mind, it should be noted that cell proliferation assay 
under 1% hypoxia did not generate very reliable results due to the fact that the cells 
seemed to take longer to hydrolyse CFDA-SE. A shift in the CFDA-SE fluorescence to 
towards the right (indicating an increase in fluorescence which correlates to increased 
hydrolyses of CFDA-SE) was observed following 24 hours of staining. An individual 
experiment to confirm this phenomenon was performed; however, the data has not been 
shown. 
Cell cycle analysis of cisplatin treated cells under normoxia showed a G2/M 
phase arrest, as would be expected of cisplatin (Figs. 4.17-4.19) (O’Brien and Brown, 
2006). Under hypoxia, a transient S phase arrest was seen for SVGp12 cells, however, 
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the U87-MG cells showed a large population under G0/G1 phase which shifted towards 
the apoptotic population at 120 hours (Figs. 4.20-4.25). This is due to the fact that under 
hypoxic conditions, cells accumulate p53 through a HIF-1α-dependent mechanism, and 
cause an arrest at the G0/G1 phase in the cell cycle through a non-p53-mediated 
pathway (Shannon et al., 2003). According to an article published by Amellem et al., 
(1994), hypoxia results in a slower cell cycle progression whereas extreme hypoxia (e.g. 
1%) induces pre-DNA-synthetic (pre S-phase) arrest in cells, while cells in the other 
phases of cell cycle progress to late G1 phase before they are arrested. This transient 
arrest in G1 phase has been described as a possible mechanism to protect the cells from 
proceeding into the S phase, where they are more sensitive to hypoxia related DNA 
injuries (Graeber et al., 1994). This may also explain the reason for a direct increase in 
apoptotic population of cells with a decrease in the S phase population as the cell cycle 
progressed.  
 Under normoxia, asiatic acid treatment on SVGp12 cells showed an arrest in the 
S-G2/M phase of the cell cycle whereas the U87-MG cell line showed a G0/G1 phase 
arrest. These differences were noted to be significant between the two cell lines. S-
G2/M phase arrest of the cell cycle was also observed for U87-MG cells under 1% 
hypoxia (Figs. 4.23 & 4.25). In a study performed by Hsu et al., (2004), S-G2/M phase 
arrest of the cell cycle was observed in breast cancer cell lines MCF-7 and MDA-MB-
231, following asiatic acid treatment. They found that asiatic acid decreased the 
expression of cyclin B1 (regulates cell entry into mitosis), cyclin A (contributes to the 
G1/S transition, S phase progression, and G2/M transition), Cdc25c (involved in G2 
phase), and Cdk2 (involved in G1/S transition), whereas it increased the amount of 
p21/WAF1 (Cdk inhibitor) and phosphorylation of Cdk2, as well as phospho-Cdc25c. 
Cdc25c is an M phase inducer and causes de-phopshorylation of cyclin B-Cdk1 
complex, triggering cell’s entry into mitosis. However, in a DNA damaged cell, Cdc25c 
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does not reach its peak hyper-phosphorylated state (Shackelford et al., 1999). This 
suggests that asiatic acid does not induce cell cycle arrest or cell death due to DNA 
damage, but other pathways may be involved and should be investigated. 
In addition to this, asiatic acid also showed G0/G1 phase arrest under normoxia 
in U87-MG cells; under 5% hypoxia in SVGp12 and U87-MG cells; and under 1% 
hypoxia in SVGp12 cells. Cell cycle arrest in the G0/G1 phase is mediated by the RB 
gene. RB gene is a tumour suppressor gene. Cell cycle progression into S phase involves 
phosphorylation of Ser780 and Ser807/811, on the Rb gene, by Cdk4/cyclin D. Thus, a 
loss in the Rb-phosphorylation of these sites would result in inhibition of cell cycle 
progression into S phase (Bretones et al., 2014; Shukla and Gupta, 2007). From the data 
obtained, it is possible that asiatic acid downregulates Rb protein thus causing an arrest 
in the G0/G1 phase of cell cycle. Using another novel triterpenoid (25-methoxyhispidol 
A) in a study by Hong et al., (2008), it was shown that G1 phase arrest of the cell cycle 
was due to downregulation of Rb protein coupled with the cdk inhibitor p21
WAF1/Cip1
. 
The same has also been shown in another study involving the use of another triterpene 
from Aesculus hippocastanum (horse chestnut) seed (Patlolla et al., 2006). 
EGF receptor is a member of the Erb family of receptor tyrosine kinases. Its 
activation triggers multiple signal transduction pathways including the MAP-K and the 
PI3/Akt pathway, thus leading to various biological processes associated with tumour 
growth such as cell cycle progression, invasion, metastasis, angiogenesis, and decreased 
apoptosis. Thus, a down-regulation of EGF receptor activity would be considered as a 
potential approach to treat tumours (Pore et al., 2006; Taylor et al., 2012). 
Western blot analysis of cisplatin treated SVGp12 cells under normoxia and 
hypoxia, showed an increase in receptor expression although these differences were 
non-significant. An increase in the expression was observed with asiatic acid under 
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normoxia and decrease under hypoxia (Figs. 4.15 & 4.16), differences were non-
significant again. Cisplatin treated U87-MG cells showed a decrease in EGFR 
expression under normoxia and hypoxia. Asiatic acid showed an increase in EGFR 
expression over time on U87-MG cell line under normoxia and hypoxia both. All these 
differences were non-significant.  
In a study by Benhar et al., (2002), it has been shown that DNA damage due to 
cisplatin activates a signalling pathway that culminates in the activation and expression 
of EGFR, although the exact mechanism is not yet known. Cisplatin mediated EGFR 
activation is slow, occurs once cisplatin-DNA adducts start forming and is kinase 
independent. It has also been suggested that EGFR activation upon cisplatin treatment 
occurs via p38 mitogen-activated kinase and leads to downstream effectors such as 
protein kinase B/AKT. Cisplatin induced EGFR phosphorylation could result in its 
nuclear translocation and lead to interaction with DNA protein kinase, thus mediating 
DNA repair. Thus, cisplatin mediated EGFR activation is a survival mechanism by the 
cell, that in turn, reduces the efficacy of cisplatin (Ahsan et al., 2010).  
It could be said similarly for asiatic acid that, increase in the EGFR expression 
level is a mechanism of cell survival in response to the drug treatment. However, asiatic 
acid inhibits extracellular signal-regulated kinase (ERK) in a variety of tumour cells, 
which in turn prevents the cell from proliferating even with increased EGFR (Wang et 
al., 2013).  
It is known that glioblastoma displays an increased rate of EGFR gene mutation 
and amplification (20-40%) (Franovic et al., 2007). Since U87-MG is a glioblastoma 
cell line, it would only be expected to see an increased expression of EGFR.  On the 
other hand, EGFR expression is also amplified under hypoxia, in a HIF-2α dependent 
manner (Franovic et al., 2007). Thus, even in the absence of EGFR gene mutation, an 
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upregulation in EGFR expression can be observed under hypoxia. However, this was 
not the case for SVGp12 and U87-MG cell lines and the EGFR expression remained 
unchanged. 
As explained earlier, cisplatin exerts its cytotoxic effects by interacting with the 
DNA. Asiatic acid, on the other hand, induces its effects by Bcl-2 inhibition, increased 
mitochondrial membrane potential and increase in intracellular calcium influx. The 
combination study with cisplatin and asiatic acid did not show significant differences in 
cell viability except at 100µM asiatic acid (Fig. 4.26). The EC50 of asiatic acid was 
calculated to be 50µM. 100µM is twice as concentrated as the EC50 of asiatic acid and 
thus is very potent to SVGp12 and U87-MG cell lines. It is due to this reason that a very 
small percentage of viable cells were observed following 100µM asiatic acid and thus 
the significant differences that were observed.  
Asiatic acid, under normoxia, shows S-G2/M phase arrest on SVGp12 cell line 
and G0/G1 phase arrest on U87-MG cell line, whereas cisplatin shows G2/M phase 
arrest, irrespective of the cell line. Due to this reason, a decrease in cell viability that 
was observed with 2µM cisplatin and 100µM asiatic acid, was mainly because of asiatic 
acid. As most of the cells were dead at 24 hours due to asiatic acid, cisplatin could not 
exert its cytotoxicity as cisplatin interferes with DNA replication, which is 
comparatively a slow process.  
Treatment with 100µM cisplatin and 30µM asiatic acid showed a gradual 
decrease in cell viability over time. At a very high concentration, cisplatin is capable of 
inducing DNA damage in a short period of time, in comparison to a low dose of 
cisplatin which takes longer to act. The results observed because of this treatment 
correlated with the results obtained for 100µM cisplatin treatment on its own. However, 
cisplatin treatment on its own showed a smaller percentage of viable cells (p > 0.05), 
161 
 
when compared to 100µM cisplatin and 30µM asiatic acid combination treatment. This 
is because, on the U87-MG cells, asiatic acid induces a G0/G1 phase arrest thus 
preventing the progression of cells into the G2/M phase, where cisplatin shows its 
effects. Thus, the combination treatments did not show any significant differences on 
cell viability due to the reasons explained above. 
Conclusion: Hypoxia reduced the rate of cell growth as confirmed by cell proliferation 
and scratch assay; cisplatin and asiatic acid did not show any significant differences 
between hypoxia and normoxia. Cell cycle analysis revealed a G2/M phase arrest for 
cisplatin treated cells under normoxia and hypoxia, whereas asiatic acid showed S-
G2/M arrest in SVGp12 cells and a G0/G1 phase arrest in U87-MG cells under 
normoxia. Cell cycle arrest due to asiatic acid under hypoxia depended on the cell type 
and the level of oxygen saturation.   
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CHAPTER 5 
5 Nanoparticle Preparation and Characterisation 
  
 
163 
 
5.1 Introduction 
Asiatic acid is a hydrophobic drug, solubility in water 5.98x10
-2
 mg/l at 25°C 
(data from PubChem). Problems with asiatic acid include solubility in water, thus 
making the delivery of asiatic acid difficult (Zhao et al., 2010). In addition, as asiatic 
acid is a herbal compound showing low side-effect profile, it would be an ideal 
candidate in the treatment of cancer. Also, previous literature has shown that asiatic acid 
possesses cytotoxic activity against various cancer cells and can cross the blood brain 
barrier (Cho et al., 2006; Hsu et al., 2004; Kavitha et al., 2011). 
In order to overcome asiatic acid-solubility problem, we formulated asiatic acid-
loaded PCL nanoparticles for effective drug delivery. We chose PCL for this study as it 
is an FDA approved polymer and can be used to formulate nanoparticles in an aqueous 
media containing a hydrophobic drug (Shenoy et al., 2005). PCL has been shown to be 
biocompatible and is applied in medical devices such as intravascular stents and 
external grafting material for broken bones (Sarasam, 2001). 
Objectives: We prepared a drug delivery system for asiatic acid using a synthetic 
polymer poly-ε-caprolactone. Characterisation of the system involved size and surface 
charge measurements, measurement of drug loading and drug release.  
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5.2 Results  
5.2.1 Preliminary Nanoparticle Preparation Studies 
In order to establish a protocol to produce stable NPs, different experimental 
techniques were examined (Section 2.6.2). The ultra-sonification process generates high 
intensity ultra-sonic waves that help reduce the particle size. Nanoparticles obtained by 
this method were monodisperse, PDI 0.09 ± 0.02 to 0.11 ± 0.01 (Table 5.1) and within 
the range of 186.4 ± 2nm to 199 ± 2.5nm in size with a surface charge of -18 ± 0.8mV 
to -22 ± 1.3mV (Figs. 5.1 & 5.2). However, the NPs were not stable and aggregation 
was observed along with precipitation by day 7 of their preparation. Stability of the 
nanoparticles is a measure of the average size, surface charge and the PDI of the 
nanoparticles recorded over a period of time. 
The homogenisation process too, like the ultra-sonification process, generated 
NPs with a size range of 193 ± 1.1nm to 201.7 ± 3.5nm and a surface charge of -18.4 ± 
0.9mV to -23.9 ± 0.8mV (Figs. 5.1 & 5.2). Nanoparticles prepared using this protocol, 
however, were not monodisperse (0.09 ± 0.01 to 0.130 ± 0.01) (Table 5.1) and 
nanoparticle aggregation was observed along with precipitation by day 7 of their 
preparation. 
Nanoparticles prepared by the magnetic stirring process were 196.2 ± 0.9nm to 
202.8 ± 3nm with a surface charge of -19.9 ± 0.86mV to -23.3 ± 0.56mV (Figs. 5.1 & 
5.2). The PDI of these NPs was less than 0.1 (0.06 ± 0.008 to 0.09 ± 0.012) all through 
the 10 days thus showing an improved stability (p < 0.001) (Table 5.1).  
Nanoparticles prepared by magnetic stirring were significantly smaller in size 
from those prepared by ultra-sonification or homogenisation (p < 0.001). The average 
surface charge of three sets of nanoparticles was similar (p > 0.05) however, samples 
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prepared by the magnetic stirring showed a significant reduction in the PDI (p < 0.01). 
Storage time had no difference on the average size of the nanoparticles within each 
group in any of the above experiments (p > 0.05) 
Thus, it was decided to take forward the magnetic stirring method of NP 
preparation. Further changes were carried out on this protocol to achieve an improved 
stability. 
Table 5.1: Polydispersity comparison of blank NPs prepared by the 
homogenisation, ultra-sonification process and magnetic stirring processes 
Day PDI 
 Homogenisation Ultra-sonification Magnetic stirring 
0 0.116 ± 0.009 0.087 ± 0.008 0.082 ± 0.007 
1 0.102 ± 0.021 0.092 ± 0.016 0.058 ± 0.007 
2 0.121 ± 0.012 0.089 ± 0.017 0.074 ± 0.012 
3 0.085 ± 0.008 0.061 ± 0.011 0.087 ± 0.011 
4 0.086 ± 0.013 0.083 ± 0.011 0.065 ± 0.009 
5 0.130 ± 0.013 0.108 ± 0.008 0.058 ± 0.006 
6 0.116 ± 0.005 0.096 ± 0.014 0.086 ± 0.008 
7 0.111 ± 0.014 0.113 ± 0.013 0.054 ± 0.009 
10 No data No data 0.084 ± 0.005 
Average PDI 0.108 ± 0.012 0.09 ± 0.010 0.072 ± 0.008*** 
NPs prepared using the magnetic stirring were more stable compared to NPs prepared 
by homogenisation or ultra-sonification. Nanoparticle prepared by magnetic stirring 
were significantly smaller in size compared to homogenisation and ultra-sonification. 
Values represent mean ± S.E. for three experiments in triplicate. 
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Figure 5.1: Size comparison of blank NPs prepared by the homogenisation, ultra-sonification process and magnetic stirring process 
NPs prepared using the magnetic stirring were more stable compared to NPs prepared by homogenisation or ultra-sonification. Data measurement was 
discontinued due to precipitation in the samples.  Nanoparticles prepared by magnetic were significantly different in size. Values represent mean ± S.E. 
for three experiments in triplicate.  
*** 
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Figure 5.2: Surface charge comparison of blank NPs prepared by the homogenisation, ultra-sonification process and magnetic stirring process 
NPs prepared by all three protocols had a similar average surface charge. No significant differences were observed. Values represent mean ± S.E. for 
three experiments in triplicate. 
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5.2.2 Nanoparticle Filtration Studies 
Systemic delivery of nanoparticles would require their sterilisation. The type of 
filter used for nanoparticle filtration can affect the polymeric associations and chemical 
nature within the nanoparticle structure.  
Blank nanoparticles were prepared (Section 2.6.1) and a volume of 5ml was 
filtered through three different filter types in order to establish the best-suited filter for 
the study. A maximum amount of 2ml from each filter disc could be filtered using the 
Whatman
™
 PES filter and the Whatman
™
 Nylon filters before the filter became clogged, 
whereas a volume of 5mL could be filtered using the Millex
®
 MCE filters. The resulting 
suspension of NPs was measured for a period of 10 days and assessed for their size and 
surface charge. Non-filtered nanoparticles and nanoparticles filtered using Whatman
™
 
Nylon filters precipitated out on the second day after preparation whereas nanoparticles 
filtered using Whatman
™
 PES filters and Millex
®
 MCE filters were stable for a 
minimum period of 10 days (Fig. 5.3 & 5.4). Nanoparticles filtered with the Whatman
™
 
PES filter precipitated out after day 10 of measurement whereas nanoparticles filtered 
using Millex
®
 MCE filters were stable up to a minimum of 10 days following filtration. 
Nanoparticles filtered using Millex
®
 MCE filters were the most stable as compared to 
any of the other methods of filtration (p < 0.001). Storage time had no significant 
difference on the size of NPs within each group (p > 0.05).  
Nanoparticles filtered using Whatman
™
 nylon filters displayed the highest PDI 
whereas samples filtered by other techniques had a similar PDI (Table 5.2). 
Nanoparticles filtered using Millex
®
 MCE filters showed a significant difference (p < 
0.001) in the PDI values compared to non-filtered, Whatman
™
 nylon filters and 
Whatman
™
 PES filters. 
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Figure 5.3: Size comparison of blank NPs filtered using various filters 
Precipitation was observed in samples with no filtration, and those filtered through Whatman
™
 Nylon membrane circles and Whatman™ PES filters, 
after day 10. Nanoparticles filtered using Millex
®
 MCE filters showed a significantly smaller size. Values represent mean ± S.E. for three experiments 
in triplicate. 
*** 
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Figure 5.4: Surface charge comparison of blank NPs filtered using various filters 
Precipitation was observed in samples with no filtration, and those filtered through Whatman
™
 Nylon membrane circles and Whatman™ PES filters, 
after day 10. No significant differences in surface charge were observed. Values represent mean ± S.E. for three experiments in triplicate. 
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Table 5.2: Polydispersity comparison of blank NPs filtered using various filters 
Day PDI  
 
Millex
®
 MCE 
filter 
Whatman
™
 PES 
filter 
Whatman
™
 
nylon filter 
Non-filtered 
0 0.057 ± 0.016 0.092 ± 0.018 0.195± 0.059 0.087 ± 0.01 
1 0.053 ± 0.005 0.048 ± 0.007 0.162  ± 0.026 0.078 ± 0.011 
2 0.072 ± 0.013 0.096 ± 0.015 - - 
3 0.048 ± 0.015 0.076 ± 0.07 - - 
4 0.075 ± 0.010 0.050 ± 0.012 - - 
5 0.035 ± 0.007 0.056 ± 0.015 - - 
6 0.054 ± 0.005 0.082 ± 0.015 - - 
7 0.043 ± 0.008 0.088 ± 0.015 - - 
10 0.033 ± 0.012 0.105 ± 0.012 - - 
14 0.046 ± 0.014 - - - 
21 0.078 ± 0.012 - - - 
28 0.066 ± 0.008 - - - 
38 0.067 ± 0.009 - - - 
50 0.077 ± 0.005 - - - 
60 0.088 ± 0.010 - - - 
Average 
PDI 
0.059 ± 0.010*** 0.077 ± 0.013 0.183 ± 0.042 0.085 ± 0.010 
Average PDI of NPs filtered using Millex
®
 MCE filters was lower than all other types 
of filters used. Nanoparticles filtered using Millex
®
 MCE filters showed a significantly 
smaller PDI. Values represent mean ± S.E. for three experiments in triplicate. 
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5.2.3 Effect of Storage Temperature on Nanoparticle Stability 
Long term storage of nanoparticles requires storage either under room 
temperature or in a refrigerated environment. In order to assess the effects of storage 
temperature on nanoparticle stability, a set of blank NPs (Section 2.6.1) was each 
maintained at room temperature and at 4°C and measurements for size and surface 
charge were performed.  
Nanoparticles stored at room temperature were unstable and precipitated out on 
the tenth day after preparation, whereas nanoparticles stored at 4°C were stable for 60 
days (Fig. 5.5) following preparation. Significant difference in the size of the NPs was 
observed between the two sets of NPs (p < 0.001). Storage time had no significant 
difference on NP size within each group of the two data sets (p > 0.05). 
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Figure 5.5: Size comparison of blank NPs at room temperature and at 4°C 
NPs stored at 4°C were smaller size compared to NPs stored at room temperature. NPs stored at 4°C did not show a difference in their average size and 
were stable for a period of 60 days while the NPs stored at room temperature precipitated out after 10 days; hence, data measurement was discontinued 
for NPs stored at room temperature. Nanoparticles stored at 4°C showed a significant difference in size. Values represent mean ± S.E. for three 
experiments in triplicate. 
*** 
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5.2.4 Calibration Curves Generated using HPLC 
In order to perform drug loading, drug release and to calculate the amount of 
PCL in the blank and asiatic acid-loaded NPs, a calibration curve for asiatic acid and 
PCL (Fig. 5.6) was performed. The percentage loading and the amount of drug loaded 
per milligram of the polymer was determined by injecting the nanoparticle suspension 
through the HPLC.  
 
 
 
Figure 5.6: Calibration curves for asiatic acid and polycaprolactone generated 
using HPLC 
Calibration curve generated for AA using the HPLC protocol described in Section 4.3. 
Values represent mean ± S.E. for three experiments in triplicate.  
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5.2.5 Nanoparticle Drug Loading Studies 
Following the drug loading of asiatic acid into the nanoparticles, it was crucial 
to quantify the amount present in the nanoparticle structure. To assess the effects of 
concentration of asiatic acid on loading efficiency of the nanoparticles, drug loading 
studies were carried out using HPLC. 
The percentage drug loading of the nanoparticles for all four concentrations of 
asiatic acid used was between 2.9 ± 1 to 3.4 ± 0.1% (p > 0.05) when the ratio of 
aqueous phase to organic phase was 1:1 (Fig. 5.7). Different amounts of asiatic acid 
were used to achieve the EC50 value of asiatic acid generated earlier (Section 3.2.3). 
Thus for a 20% uptake of asiatic acid into the nanoparticles, the amount of asiatic acid 
needed was calculated and the following range of concentrations was used. However, as 
the drug loading efficiency of the nanoparticles was very low, attempts were made to 
increase this by bringing some changes in the protocol.  
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Figure 5.7: Comparison of drug loading efficiency of asiatic acid at different 
concentrations using 1:1 ratio of aqueous phase: organic phase 
To increase the amount of drug loaded into the NPs and to determine maximum loading 
efficiency, the amount of AA in the formulation was varied. The percentage loading 
was similar for all three concentrations used. No significant differences were observed. 
Values represent mean ± S.E. for three experiments in triplicate. 
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5.2.6 Maximisation of Nanoparticle Yield  
In an attempt to increase the drug loading efficiency of the nanoparticles, a 
number of individual parameters were modified (Section 2.7.3). An increase in the 
nanoparticle yield would theoretically increase the drug loading efficiency of asiatic 
acid. To measure nanoparticle yield, nanoparticle preparations were injected through the 
HPLC (Table 5.3). Nanoparticle yield (Fig. 5.8) was calculated using the calibration 
curve generated for PCL (Fig. 5.6). 
When the ratio of aqueous phase to organic phase was changed to 2:1, the 
percentage loading of the drug into the nanoparticles increased (Fig. 5.9). The 
maximum loading efficiency obtained was 28.5 ± 1.2% when the initial amount of drug 
added was 20 mg (p < 0.001 for asiatic acid-loaded NPs prepared by using a 2:1 ratio 
against a 1:1 ratio of aqueous phase: organic phase). The drug-loading efficiency 
increased with increasing amount of drug; this correlates with the results produced by 
Chawla & Amiji (2002). The encapsulation efficiency of asiatic acid-loaded 
nanoparticles was calculated to be 72.8 ± 6.5% (Fig. 5.10), which indicates that 72.8% 
of the drug present in the formulation was encapsulated into the formulation whereas 
the remaining drug was the free drug. Encapsulation efficiency of the drug was 
calculated as the percentage drug in the pellet at 0 hours to the total amount of drug 
present in the formulation. 
Please note: Drug loading efficiency refers to the total amount of drug that is 
encapsulated into the nanoparticles and to the amount of drug that may be adsorbed 
onto the surface of the nanoparticles. 
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Table 5.3: A table listing all the changes in the original protocol 
Parameters Original Modifications 
Aqueous: organic phase 1:1 2:1 
Pluronic F-68 150mg 600mg 
Acetone temperature 40°C 20°C 
Stirring time 2 minutes 10 minutes 
Filtration After Before 
The above parameters were modified in order to achieve an improve nanoparticle yield 
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Figure 5.8: Data illustrating the comparison of PCL yield of blank NPs prepared 
by changing various parameters 
To establish a protocol giving the highest NP yield, individual components of the 
preparation protocol were varied. The highest NP yield (20.2 ± 0.4%) was observed 
when the ratio of aqueous phase to organic phase was changed to 2:1 keeping all other 
variables constant. Significant difference was observed with 2:1 ratio of aqueous phase 
to organic phase. Values represent mean ± S.E. for three experiments.  
 
 
  
*** 
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Figure 5.9: Comparison of drug loading efficiency of asiatic acid at different 
concentrations using 2:1 ratio of aqueous phase: organic phase 
The highest NP yield was obtained when the ratio of aqueous phase to organic phase 
was 2:1. Thus, the maximum amount of asiatic acid that could be loaded into the NPs 
was re-established. As no significant differences were observed in the drug loading 
measurement earlier (Fig. 5.7), measurement was only performed at 10 and 20mg of 
asiatic acid upon making changes to the original nanoparticle preparation protocol. A 
significantly higher drug loading was observed at 20mg of asiatic acid. Values represent 
mean ± S.E. for three experiments in triplicate. 
  
*** 
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Figure 5.10: Graph showing the encapsulation efficiency of asiatic acid into the 
NPs 
Amount of asiatic acid recorded in the pellet was the drug encapsulated within the NPs 
whereas amount of drug recorded in the supernatant was free drug in the formulation 
(i.e., un-encapsulated). Encapsulation efficiency of the NPs was 72.8 ± 6.5%, which 
indicates that 72.8% of the drug present in the formulation was encapsulated into the 
NPs, remaining drug was the free drug. Values represent mean ± S.E. for three 
experiments in triplicate.  
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5.2.7 Size, Surface Charge and Polydispersity Measurements of Blank and 
Asiatic acid-loaded Nanoparticles 
It was important to characterise the nanoparticles prepared using the above 
protocol. Characterisation of nanoparticles includes measurements of size, surface 
charge and polydispersity (PDI). Although size and surface charge are understood by 
everyone, PDI is a measure of the homogeneity of the formulation. PDI < 0.1 is 
considered as ideal and indicates a monodisperse formulation. 
Blank and asiatic acid-loaded NPs (Section 2.6.1) were characterised for their 
mean diameter, size distribution and surface charge. Blank and asiatic acid-loaded NPs 
showed a similar average diameter  ranging from 133 ± 1.8nm to 152.5 ± 2.7nm and 
134.4 ± 1.5nm to 150.2 ± 1.2nm respectively (p > 0.05), (Fig. 5.11). The diameter of 
asiatic acid-loaded and blank nanoparticles confirmed the encapsulation of the drug as 
opposed to its surface adsorption (Shah and Amiji 2006). NPs were monodispersed, PDI 
value not exceeding more than 0.1 (Table 5.4), thus confirming the formation of a stable 
suspension (p > 0.05 for average PDI of both sets of NPs).  
Both NPs, blank and asiatic acid-loaded, showed a similar average negative 
surface charge  ranging from -17 ± 1.3mV to -31 ± 2.5mV for blank NPs and -19.8 ± 
1mV to -29.6 ± 0.7mV (p > 0.05) (Fig. 5.12); the negative charge is attributed to the 
carboxylic group present on the PCL chain (Leroueil-Le Verger et al. 1998). The high 
zeta potential values achieved ensure a high-energy barrier thus favouring a good 
stability  (Benita and Levy, 1993) as it allows an ideal stabilization of nanoparticles due 
to prevention of aggregation by strong repulsive forces (Muller 1991). 
Storage time had no significant difference on average nanoparticle size, surface 
charge or PDI within each of group of the two data sets (p > 0.05). 
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Figure 5.11: Size comparison of blank and asiatic acid-loaded NPs at 4°C.  
Both, blank and asiatic acid-loaded NPs were stable at 4°C, showed a similar average diameter and did not show any significant differences in their 
average size over the period of 60 days. Values represent mean ± S.E. for three experiments in triplicate. 
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Figure 5.12: Surface charge comparison of blank and asiatic acid-loaded NPs at 4°C 
Both, blank and asiatic acid-loaded NPs were stable at 4°C, showed a similar average surface charge and did not show any significant differences in 
their average surface charge over the period of 60 days. Values represent mean ± S.E. for three experiments in triplicate. 
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Table 5.4: Polydispersity comparison of blank and asiatic acid-loaded NPs at 4°C 
Day Polydispersity 
 Blank NPs AA NPs 
0 0.057 ± 0.016 0.068 ± 0.011 
1 0.053 ± 0.005 0.055 ± 0.012 
2 0.072 ± 0.013 0.065 ± 0.018 
3 0.048 ± 0.015 0.060 ± 0.012 
4 0.075 ± 0.010 0.067 ± 0.019 
5 0.035 ± 0.007 0.068 ± 0.016 
6 0.054 ± 0.005 0.035 ± 0.006 
7 0.043 ± 0.008 0.063 ± 0.010 
10 0.033 ± 0.012 0.070 ± 0.007 
14 0.046 ± 0.014 0.063 ± 0.011 
21 0.078 ± 0.012 0.061 ± 0.010 
28 0.066 ± 0.008 0.050 ± 0.008 
38 0.067 ± 0.009 0.048 ± 0.007 
50 0.077 ± 0.005 0.060 ± 0.007 
60 0.088 ± 0.010 0.071 ± 0.009 
Average PDI 0.059 ± 0.010 0.060 ± 0.011 
The average PDI of both sets of NPs, blank and AA-loaded, was less than 0.1 over the 
period of 60 days, thus indicating a monodisperse formulation.. No significant 
differences were observed in the PDI of blank and asiatic acid-loaded nanoparticles. 
Values represent mean ± S.E. for three experiments in triplicate. 
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5.2.8 Drug Release in PBS in the Absence and Presence of Lipase 
Following the characterisation of nanoparticles for size, surface charge, PDI and 
drug loading, the need arose to assess the drug release profile. Also, it was important to 
understand the rate of drug release from asiatic acid-loaded nanoparticles to carry out 
further in vitro, cell line-based experiments. 
In vitro drug release of asiatic acid-loaded nanoparticles was performed at 37°C 
in 1X PBS at pH 7.4, maintained on a rocker, in the absence and presence of lipase from 
Pseudomonas sp. Amount of drug released in the supernatant and the amount of drug 
remaining in the pellet after re-centrifugation of the nanoparticles was calculated using 
HPLC. For ease of understanding, concentrations were plotted as a mean percentage of 
the total drug present in the formulation. 
The initial amount of un-encapsulated drug recorded in the absence of lipase, 
immediately after NP preparation, was (30 ± 1.9%) at 0 hours. Drug release plateaued 
after 0 hour, meaning that no additional drug was released from the nanoparticles (p > 
0.05 for asiatic acid release over 24 hours) (Fig. 5.13). Thus, 72.8 ± 6.5% of the drug 
was encapsulated into the NPs and was not released even after 24 hours in 1X PBS 
maintained at 37°C. The total percentage of intact PCL NPs in the pellet was 74 ± 5.6% 
at 0 hours and 71.4 ± 5.1% at the end of 24 hours (Fig. 5.13). Hence PCL did not 
degrade even at the end of 24 hours (p > 0.05). 
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Figure 5.13: Asiatic acid release and PCL breakdown from asiatic acid-loaded NPs 
in PBS (pH7.4) maintained at 37°C on rocker.  
The total percentage of asiatic acid release (A) and PCL breakdown (B) in the 
formulation was measured over a period of 24 hours. No additional drug release after 
the initial record of free drug was observed over 24 hours (p > 0.05). Majority of the 
PCL NPs were intact in the pellet and hence not degraded even at the end of 24 hours (p 
> 0.05). Values represent mean ± S.E. for three experiments in triplicate. 
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To encourage release of asiatic acid from asiatic acid-loaded NPs, 45unts/l lipase 
from Pseudomonas sp. was added to the 1X PBS. Lipase enhanced the rate of drug 
release from the asiatic acid-loaded nanoparticles (Fig. 5.14). Again (as previously seen 
in Fig. 5.13), 30 ± 4.7% of the un-encapsulated drug was measured in the supernatant at 
0 hours. However, the rate of asiatic acid release from the asiatic acid-loaded 
nanoparticles in the presence of lipase increased steadily over a period of 24 hours. The 
total amount of drug released at the end of 24 hours was 65 ± 3.8% (p < 0.001). Results 
show a steady release of asiatic acid from asiatic acid-loaded nanoparticles over a 
period of 24 hours, in the presence of lipase. Measurement of the total percentage of the 
intact PCL nanoparticles in pellet showed an initial amount of 64 ± 6.9% with a steady 
decrease of the amount of PCL nanoparticles in the pellet (Fig. 5.14). The amount of 
PCL nanoparticles in the pellet at the end of 24 hours was 34 ± 4.8% (p < 0.01). 
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Figure 5.14: Asiatic acid release and PCL breakdown from asiatic acid-loaded NPs 
in PBS (pH 7.4) containing Lipase from Pseudomonas sp. maintained at 37°C on 
rocker 
The total percentage of asiatic acid release (A) and PCL breakdown (B) in the 
formulation was measured over a period of 24 hours. A slow steady breakdown of PCL 
NPs along with asiatic acid release in the supernatant was observed, increasing with 
every hour, over a period of 24 hours. Significant differences in drug release and PCL 
breakdown were observed at 24 hours. Remaining drug that was not released into the 
supernatant was encapsulated into the PCL NPs and remained in the pellet even at the 
end of 24 hours. Values represent mean ± S.E. for three experiments in triplicate. 
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5.2.9 Drug release in Cell Culture Medium 
As further experiments of nanoparticles on in vitro cell lines would require the 
use of cell culture medium EMEM, we assessed the rate of drug release from asiatic 
acid-loaded nanoparticles in EMEM.  
Drug release from asiatic acid-loaded nanoparticles was very unstable (p > 0.05 
for asiatic acid release over 24 hours) (Fig. 5.15). Although the experiment was 
performed three times; the inconsistency of the results can be explained by the inability 
of the HPLC to generate well-resolved, identifiable peaks, due to the large number of 
proteins present in the cell culture medium, thus generating a high background signal. 
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Figure 5.15: Asiatic acid release from asiatic acid-loaded NPs in cell culture media 
maintained at 37°C on rocker with 5% CO2 
The results of asiatic acid release from asiatic acid-loaded NPs were inconsistent due to 
the large background noise generated by the proteins present in the cell culture medium 
thus giving unresolved peaks in the HPLC. No significant differences were observed. 
Values represent mean ± S.E. for three experiments in triplicate. 
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5.2.10 Effect of pH on Drug Release from Asiatic acid-loaded Nanoparticles 
As tumour cells display an acidic environment, a pH study was conducted to 
study the drug release characteristics from asiatic acid-loaded NPs in an acidic pH.  
Drug release was performed in 1X PBS at pH5.5 maintained at 37°C. The initial 
amount of un-encapsulated asiatic acid, immediately after NP preparation, was 29 ± 
2.8% at 0 hours (Fig. 5.16). No additional drug was released from the NPs after 24 
hours (p > 0.05). Thus, 70 ± 7.3% of the drug was encapsulated into the NPs and was 
not released even after 24 hours in the 1X PBS maintained at 37°C. Data shows that the 
amount of PCL NPs in the supernatant increased at a very slow rate over the period of 
24 hours (Fig. 5.16), and a significant difference was observed at the end of 24 hours (0 
hours 78.6 ± 4.3%, 24 hours 59.1 ± 2.8%; p < 0.01). 
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Figure 5.16: Asiatic acid release and PCL breakdown from asiatic acid-loaded NPs 
in PBS (pH 5.5) maintained at 37°C on rocker 
The total percentage of asiatic acid release (A) and PCL breakdown (B) in the 
formulation was measured over a period of 24 hours. Although no additional asiatic 
acid was released into the supernatant after the initial record of free drug (p > 0.05); a 
significant increase in the amount of PCL was observed in the supernatant following 
incubation for 24 hours. The remaining drug that was not released was encapsulated 
into the PCL NPs in the pellet. Values represent mean ± S.E. for three experiments in 
triplicate. 
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5.2.11 Freeze Drying 
Long term storage of nanoparticles can either be performed by storage in 
aqueous media or by freeze drying. Although not all nanoparticles are stable in aqueous 
media for a longer duration, freeze drying may not always be necessary. Freeze drying 
is method of water removal from nanoparticles which helps in increasing the shelf life.  
Freeze-dried NPs were re-suspended in 5ml distilled water and analysed for their 
size and surface charge. Size analysis of the nanoparticles using the Malvern Zetasizer 
Nano-ZS showed a 10-fold increase in the size of the particles freeze-dried in the 
absence or presence of 1% and 10% sucrose after re-hydration in distilled water (size 
following re-hydration 905.1 ± 9.11nm). This increase in size is represented in the 
scanning electron microscopy images (Fig. 5.17) where large aggregates of 
nanoparticles can be seen as opposed to the presence of distinct nanoparticles. 
Nanoparticles were greater than 1µm in size and were not accurately measured by the 
zetasizer. Additionally, re-hydration of the freeze-dried particles was difficult as the 
particles settled at the bottom of the vial and large clumps were observed. 
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Figure 5.17: SEM image of freeze-dried blank and asiatic acid-loaded NPs in the 
absence of sucrose 
Images show the formation of distinct spherical blank (A) and asiatic acid-loaded (B) 
NPs with a smooth surface and confirms the size of blank and asiatic acid-loaded NPs to 
be in the range of 130-150nm. 
A 
B 
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5.3 Discussion 
Preliminary Nanoparticle Preparation Studies 
In order to establish a protocol to produce stable nanoparticles, different 
experimental techniques were examined (Section 2.6). Nanoparticles produced by ultra-
sonification and homogenisation processes produced NPs greater than 180nm in size 
(Figs. 5.1 & 5.2; Table 5.1) that were unstable and precipitated out (particle 
aggregation) by the tenth day after preparation. In comparison, nanoparticles prepared 
by magnetic stirring, although similar in size, showed an improved stability (p < 0.001). 
One of the reasons for nanoparticle aggregation is that nanoparticle structure 
breakdown occurs due to the shear forces applied by the homogeniser or the ultra-
sonicator (Konan et al., 2002). The high intensity ultra-sonic waves or the high pressure 
generated by the homogeniser helps breakdown the nanoparticle to a smaller size but 
also increases the temperature of the system thus inducing material degradation leading 
to the loss of nanoparticle stability (Konan et al., 2002; Lamprecht et al., 2000; 
Prombutara et al., 2012). In addition, these techniques lead to reduction in the surface 
charge of the nanoparticle thus making the particles more prone to aggregation due to a 
low electrostatic repulsion (Prombutara et al., 2012). At lower temperatures (ice cooling 
for ultra-sonification and homogenisation processes), the kinetic energy of the particles 
is reduced and the fraction of particles with kinetic energy less than the potential depth 
increases resulting in an increasing particle aggregation (Fiedler et al., 2007). 
Another reason for nanoparticle aggregation can be explained by the DLVO 
(Derjaguin and Landau, Verwey and Overbeek) theory. Brownian motion between 
particles in a nanoparticle suspension causes particle collisions. According to the DLVO 
theory, exposure of particle surfaces to each other upon contact and the short-range 
thermodynamic interactions, such as van der Waals and electrostatic double layer 
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forces, may allow particle-particle attachment to occur resulting in particles over 1µm in 
size (Hosokawa et al. 2007; Hotze et al. 2010). As the ultra-sonification and 
homogenisation methods generate a lot of energy, it leads to a greater Brownian motion 
of the NPs thus causing homoaggregation. As the total kinetic energy of the particles is 
high, particles collide more often and form large dendritic aggregates, thus leading to 
NP aggregation as was observed in this study (Buffle and Leppard, 1995; Hotze et al., 
2010). 
Parenteral route of nanoparticle administration requires sterile and apyrogenic 
products (Goldbach et al., 1995). For the systemic delivery of NPs prepared in this 
study, it would be necessary to filter and create a sterile NP suspension. The type of 
filter used affects the long-term stability of NPs. In order to assess the best type of filter 
for the NPs prepared in this study, three different types of filters were used along with a 
set of unfiltered samples to obtain a comparison. 
Non-filtered samples were not sterile and unstable, while precipitation was 
observed (Figs. 5.3 & 5.4, Table 5.2). Using Whatman
™
 nylon membranes, the filtration 
of nanoparticle suspension was difficult and very small amounts of sample volumes 
(~2ml) could be filtered before changing the membrane. Precipitation after filtration 
was observed in most samples except in the samples where Millex
®
 MCE filters were 
used. In addition, sub 210nm particles were filtered through Millex
®
 MCE membranes 
without any significant change in nanoparticle size or breakage of the nanoparticles. 
The failed attempts of nanoparticle filtration techniques could be due to clogging 
of filtration membranes which is observed when the particle size is too close to the 
membrane pore size (Konan et al., 2002).  
The degradation and stability of the NPs depends on their preparation method, 
polymer properties such as initial molecular weight and physical and chemical 
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parameters such as temperature and pH (Lemoine et al., 1996). To study the effects of 
storage temperature on PCL nanoparticles prepared using the protocol in Section 2.6.1, 
a set of blank nanoparticles was each stored at room temperature and at 4°C. 
Nanoparticles stored at 4°C showed an improved stability over a period of 60 
days with no significant changes in particle size and surface charge while at room 
temperature, the NPs showed rapid particle degradation and aggregation by day 10 (Fig. 
5.5); similar results were also obtained by Lemoine et al., (1996). These results are also 
comparable to those obtained by Coffin and McGinty (1992) where only minor changes 
in the molecular weight of the poly(D,L-lactide) and poly(ε-caprolactone) nanoparticles 
was observed .  
Nanoparticles, in a suspension undergo constant Brownian motion. As the 
temperature of the system increases, the viscosity of the base fluid in the nanoparticle 
suspension decreases, resulting in an increased Brownian motion of the nanoparticles. 
This results in the particles coming into close proximity to each other. Thus, it can be 
speculated that increased Brownian motion increases the size of nanoparticles due to 
particle attachment by short-range thermodynamic interactions (Hotze et al. 2010; 
Sullivan & Edmondson 2008; Jang & Choi 2004). 
In addition, the third law of thermodynamics states ‘The entropy of an object at 
absolute zero is zero, i.e. if an object is cooled down to -273°K, it would cease to have 
any kinetic energy within its molecules’. Thus, at a lower temperature, kinetic energy of 
the particles is lost reducing their Brownian motion and particle collision (Sullivan and 
Edmondson, 2008). Hence, nanoparticles maintained at 4°C showed an improved 
stability over NPs stored at room temperature. 
 
196 
 
Nanoparticle characterisation 
Effective transvascular delivery of therapeutics into malignant glioma cells 
remains challenging due to the presence of the BBB. However, ultra-structural studies 
of the BBB have shown that the size of the fenestrations and gaps in the blood tumour 
barrier increases to 40-90nm and 100-250nm respectively (Sarin et al., 2008). In 
addition, the net charge on the plasma membrane of a cell is -40 to -90mV (Purves et al. 
2001). Hence, nanoparticles with a moderate negative surface charge and a size of less 
than 250nm should, theoretically, be able to move across the plasma membrane of the 
cell, unimpeded.  
PCL NPs were prepared by the solvent displacement method (Section 2.6.1). 
The solvent displacement method is a convenient, reproducible, fast, and economic one-
step manufacturing process for the preparation of monodisperse, polymeric 
nanoparticles in a size range of approximately 50 – 300nm (Beck-Broichsitter et al., 
2010). 
Nanoparticles were characterised for their mean diameter, size distribution and 
surface charge. No significant differences were observed in the size of blank and asiatic 
acid-loaded NPs (Fig. 5.11). The diameter of the drug loaded NPs confirms the 
encapsulation of the drug as opposed to its surface adsorption (Shah and Amiji, 2006). 
As the NP size has remained unchanged and drug release has been observed from asiatic 
acid-loaded NPs, it can be speculated that asiatic acid was incorporated into the matrix 
of the nanoparticles as opposed to its encapsulation in the core of the nanoparticle shell. 
The particles were monodisperse, the PDI value not exceeding more than 0.1, thus 
confirming the formation of a stable suspension (Table 5.4). Factors that are essential 
for the ultimate determination of particle size include polymer concentration in the 
organic phase, polarity of the solvents and the ratio of organic: aqueous phase (Zili et 
al., 2005). 
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Both sets of nanoparticles, blank and asiatic acid-loaded, showed a negative 
surface charge. The negative charge is attributed to the carboxylic group present on the 
PCL chain (Leroueil-Le Verger et al., 1998). Blank and asiatic acid-loaded 
nanoparticles had a similar surface charge, confirming again, the encapsulation of the 
drug as opposed to surface adsorption (Fig. 5.12) (Shah and Amiji, 2006). The negative 
zeta potential values achieved ensured a high-energy barrier of the nanoparticles thus 
favouring a good stability and prevention of aggregation by strong repulsive forces 
(Benita and Levy 1993; Muller 1991).  
In order to increase the encapsulation efficiency of the drug into the NPs, it was 
first necessary to increase the yield of the nanoparticles from the polymer itself (Liu et 
al., 2007). Different variables were altered as previously described (Section 2.7.3). 
Nanoparticle yield increased to 28.5 ± 1.2% upon altering the ratio of aqueous 
phase to organic phase to 2:1 (Fig. 5.8). It was thus decided to prepare nanoparticles 
using a 2:1 ratio of aqueous phase to organic phase for all further experiments. The 
increased yield of the PCL nanoparticles can be explained due to the longer 
hydrophobic PCL block chain that was formed as a result of an increased amount of 
aqueous phase (Feng et al., 2012). PCL, in the presence of PEG, forms amphiphilic 
PEG-PCL structures with a hydrophilic PEG block and a hydrophobic PCL block. 
These amphiphilic PEG-PCL blocks self-assemble in an aqueous environment to form 
micelles. Thus, the increased amount of the aqueous environment increased the 
hydrophobic property of the nanoparticles by producing longer and hydrophobic 
interactions between PCL microdomains in the aqueous environment. In addition, using 
a 2:1 ratio of aqueous phase to organic phase, the total volume of the nanoparticle 
suspension before centrifugation reduced to 75 ml as opposed to 100 ml while using a 
1:1 ratio of aqueous phase to organic phase. This, in turn, increased the concentration of 
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PCL and PEG in the acetone-water environment, thus resulting in an increased number 
of NPs (Choi et al., 2005). 
A drug loading content of the nanoparticles would increase the efficiency of the 
nanoparticles in its systemic administration. It is also important to be able to achieve the 
EC50 concentration of the drug inside the nanoparticles. Thus, in an attempt to increase 
the drug loading efficiency of the nanoparticles, the nanoparticle yield was increased 
(Fig. 5.8). The percentage drug loading of the nanoparticles increased upon altering the 
ratio of aqueous phase to organic phase to 2:1 (Fig. 5.9). The maximum loading 
efficiency was achieved when the initial amount of drug added was 20 mg (Fig. 5.9). 
The loading efficiency increased with increasing amount of drug; a finding similar to 
Chawla & Amiji (2002).  
Encapsulation efficiency of a drug depends on the structure, length, and 
molecular weight of hydrophilic and hydrophobic fragments of the polymer (Wang et 
al., 2011). PCL is a hydrophobic polymer and thus it is insoluble in aqueous phase 
(Shenoy and Amiji, 2005). This insolubility of PCL in water causes it to coagulate and 
form a core-shell structure where the core consists of a hydrophobic PCL chain and the 
shell consists of a hydrophilic PEG chain (Feng et al., 2012; Wang et al., 2011). 
Hydrophobicity of the drug leads to hydrophobic interactions between PCL and asiatic 
acid, while the interaction of the water and hydrophilic PEG allows the drug to dissolve 
in water. This interaction is similar with other hydrophobic drugs such as curcumin used 
in studies by Feng et al (2012). Thus, the drug could be encapsulated into the core of the 
nanoparticle. As asiatic acid is a hydrophobic drug, it would be insoluble in water and 
thus would need a micelle-like system for its delivery. The use of PEG thus allowed 
PCL and asiatic acid to dissolve in water and form nanoparticles consisting of a core of 
the hydrophobic drug- asiatic acid. 
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Drug Release Studies 
The in vitro drug release of asiatic acid-loaded nanoparticles was performed in 
PBS, pH 7.4, maintained at 37°C on a rocker, in the absence and presence of lipase 
from Pseudomonas sp. The amount of drug released in the supernatant and the amount 
of drug remaining in the pellet after re-centrifugation of the nanoparticles was 
determined by the HPLC. The amount of asiatic acid, in both cases, was plotted as a 
mean percentage of the total drug present in the formulation. 
An initial amount of drug was recorded in the absence of lipase at 0 hours, with 
no further asiatic acid release (Fig. 5.13). Lipase enhanced the rate of drug release from 
the asiatic acid-loaded nanoparticles which increased steadily over 24 hours (Fig. 5.14).  
PCL nanoparticles, due to their high crystallinity and hydrophobicity, have a 
slow degradation rate in an aqueous media. This crystallinity of PCL increases with a 
decrease in its molecular weight (Chawla and Amiji, 2002). PCL is available in a wide 
range of molecular weight. The average molar mass distribution of PCL ranges from 
10,000 to 80,000. PCL used for this study has a molecular weight of 14,000 (average 
molar mass distribution (Mn) of 10,000). Due to these properties of PCL, no significant 
amount of degradation of PCL NPs was observed in PBS at pH 7.4 (Fig. 5.13). 
However, in the presence of lipase, the degradation of PCL nanoparticles proceeded 
rapidly as opposed to release in the absence of lipase, (Figs. 5.13 & 5.14). In addition, a 
large amount of the drug was found in the re-centrifuged pellet of the nanoparticle 
suspension with the remaining being present in the supernatant (Figs. 5.10 & 5.13). This 
phenomenon can be explained by the hydrolytic disruption of the ester bonds of 
polymeric nanoparticles, thus allowing drug diffusion. The ester hydrolysis and drug 
diffusion are also controlled by the length of the hydrophobic and hydrophilic chains 
present in the nanoparticle (Feng et al., 2012). Another possible explanation for the 
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presence of the free drug can be explained due to the surface adsorption of the drug onto 
the nanoparticles as opposed to their encapsulation (Shah and Amiji, 2006). 
The presence of lipase enhances the degradation rate of the polymer as 
compared to degradation in an aqueous media (Cho et al., 2002; Shah and Amiji, 2006; 
Wu et al., 2000). PCL degradation begins in the amorphous region prior to degradation 
in the crystalline region (Cho et al., 2002). In the presence of lipase, an increased PCL 
degradation was observed. Gan et al., 1999 have suggested that lipase ‘eats’ up the 
nanoparticles one by one so that the rate of nanoparticle degradation is dependent on the 
enzyme concentration. The healthy adult serum lipase concentration is in the range of 
30-190 units/l which is comparable to the in vitro lipase concentration used for this 
study (45units/l) (Chawla and Amiji, 2002). Since PCL follows surface erosion, the 
steady release of the drug in the presence of lipase could be due to erosion of the 
polymer shell and subsequent release of the drug (Mukerjee et al., 2007). Thus, it can be 
speculated that due to the absence of surface erosion of the polymer by the lipase, drug 
release from the nanoparticles was low in PBS alone. 
As the future study of the nanoparticles involves the use of in vitro cell lines, the 
nanoparticles, blank or asiatic acid-loaded, would have to be suspended into the cell 
culture medium. To assess the stability of asiatic acid-loaded nanoparticles in the cell 
culture medium, we suspended the nanoparticles into EMEM. Drug release from the 
asiatic acid-loaded nanoparticles in the cell culture media was very unstable (Fig. 5.15). 
The experiment was performed three times; however, the inconsistency of the results 
was due to the inability of the HPLC to generate well-resolved, identifiable peaks, due 
to the large number of proteins present in the medium generating a high background 
signal. Although, no similar experiments could be found, this problem might be 
overcome through the use of more sophisticated machines such as gas chromatography. 
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The environmental acidity or pH of living cells and tissues is a major factor 
influencing molecular processes involved in cell cycle progression, cell proliferation, 
and differentiation (Song et al. 2006). Likewise, oncogenesis, malignant transformation, 
metastasis, and angiogenesis are greatly influenced by environmental acidity (Honasoge 
and Sontheimer, 2013; Song et al., 2006). It has been long proposed that the 
microenvironment of tumours is more acidic compared to normal tissues, with the 
extracellular pH being <7 (Gerweck and Seetharaman, 1996; Song et al., 2006). Tumour 
cells show enhanced glycolysis and preferentially convert glucose to lactic acid, thus 
causing a decrease in the pH of the surrounding microenvironment (Griffiths, 1991; 
Honasoge and Sontheimer, 2013). Hence, it was important to study the drug-release 
profile from asiatic acid-loaded nanoparticles in an acidic medium. PBS was used in all 
these experiments as PBS is isotonic and non-toxic to cells. 
Figure 5.16 shows that a large amount of the drug was encapsulated into the 
nanoparticles and was not released even after 24 hours in the 1X PBS maintained at 
37°C. The amount of PCL in the pellet decreased steadily with time, after the 
nanoparticle suspension was re-centrifuged and suspended in 1X PBS pH 5.5. Asiatic 
acid has a pKa of 4.7 and is thus acidic in nature (data from Chemicalize.org). It is due 
to this reason that no drug release was observed even after suspension in acidic PBS for 
24 hours. Thus, the acidic pH did not significantly change the drug release profile from 
the NPs, however, nanoparticle degradation increased significantly, but at a slow rate in 
PBS pH 5.5. 
 
Freeze Drying and Scanning Electron Microscopy 
Freeze-drying is an industrial process of drying by freezing and sublimation of 
ice. It is used to convert solutions of labile materials into solids of sufficient stability for 
distribution and long-term storage (Abdelwahed et al., 2006a). Freeze drying is mainly 
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performed to prevent non-enzymatic polymer hydrolysis and to prevent drug leakage 
out of the nanoparticles. Also, long-term storage of nanoparticles in an aqueous medium 
can lead to particle aggregation. On the other hand, freeze-drying may generate stress 
that could destabilize colloidal suspension of nanoparticles, especially, the stress of 
freezing and dehydration (Abdelwahed et al., 2006b). Thus, in order to prevent the 
collapse of the nanoparticle suspension, addition of a cryoprotectant may be required. 
The most popular cryoprotectants encountered in the literature for freeze-drying 
nanoparticles are sugars: trehalose, sucrose, glucose and mannitol (Abdelwahed et al., 
2006b). 
The freezing step of the freeze-drying process induces dramatic changes on the 
frozen nanoparticle suspension. The ice crystallization leads to a phase separation and 
cryoconcentration of nanoparticles. Such modification induces aggregation or fusion of 
nanoparticles (Abdelwahed et al., 2006a). The use of a suitable cryoprotectant can 
prevent such damage. It has been suggested that stabilisation of liposomes and 
nanoparticles requires their maintenance in a vitrified state (Chasteigner et al., 1996; 
Crowe et al., 1994). Carbohydrates, such as sucrose, are widely used for the protection 
of nanoparticles and liposomes during freeze-drying as they can be easily vitrified 
during freezing and form a protective amorphous matrix around nanoparticles 
(Abdelwahed et al., 2006a). 
Sucrose was chosen as the cryoprotectant in this study as it is often used for the 
freeze-drying of colloidal vectors.  PCL nanoparticles can be freeze-dried giving an 
acceptable product with no macroscopic aggregation when sucrose was used (Saez et 
al., 2000).  
In this study, freeze-drying of the nanoparticles was undertaken in the presence 
and absence of sucrose. However, particle size measurements of the re-hydrated freeze-
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dried nanoparticles showed a 10-fold increase in size, proposing particle aggregation 
due to stress generated during freeze-drying (Fig. 5.17). Nanoparticles have a thin and 
fragile outer envelope that may not always withstand the mechanical stress of freeze-
drying. Thus, the particles collapse and lead to clustering and an increase in the particle 
size (Abdelwahed et al., 2006a).  
Based on the results of this study and the results of nanoparticle stability at 4
o
C 
for 60 days, the decision was made not to freeze dry the nanoparticles but rather store 
them at 4°C, in distilled water, for future studies. Although nanoparticle stability was 
monitored following 90 days of their preparation, fungal growth was observed. Thus it 
was concluded that nanoparticles stable for at 4°C 60 days would be sufficient for 
clinical application. 
SEM imaging of the nanoparticles showed the formation of distinct spherical 
nanoparticles, both blank and drug loaded. The particles were non-porous and had a 
smooth outer surface. SEM also confirmed the size of the nanoparticles to between 130-
150nm (Fig. 5.17).  
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CHAPTER 6 
6 Effect of Nanoparticles on Cell Viability  
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6.1 Introduction  
Polymeric nanoparticles as vehicles of delivery of chemotherapeutic drugs have 
shown great potential and may revolutionize the future of cancer therapy (Ma et al., 
2011). In addition, nanoparticle delivery systems may provide an improved penetration 
of therapeutic drugs along with a reduced risk of drug cytotoxicity in normal tissues in 
comparison to traditional mode of drug delivery. Factors such as reduced drug dose and 
increased pharmacokinetic profile can be achieved using these vectors as mode of 
delivery (Feng et al., 2012; Mei et al., 2009; Shenoy and Amiji, 2005). However, 
problems with nanoparticle delivery include biodegradation time and cellular 
elimination.  
Objectives: We assessed the cytotoxic effects of blank and AA-loaded nanoparticles on 
in vitro cell lines using viability assay and studied differences in cell apoptosis and 
proliferation. Nanoparticle internalisation studies were carried out using microscopy.  
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6.2 Results  
6.2.1 Cellular Uptake of Nanoparticles 
Therapeutic effects of nanoparticles depend upon the extent of internalisation 
and retention by cells. Although in vitro experiments can provide preliminary indication 
to the advantages of nanoparticle formulation versus free drug, in vivo results may not 
necessarily be the same.  
Nanoparticle uptake by monolayers of SVGp12 and U87-MG cell lines was 
examined by microscopy (Figs. 6.1-6.4). The images show fluorescence of coumarin-6 
loaded PCL nanoparticles to be located in the cytoplasm, around the nucleus, thus 
indicating that the nanoparticles were internalised by the cells. Presence of punctate 
fluorescence with coumarin-6 loaded nanoparticles confirms nanoparticle uptake.  
In the SVGp12 cell line, higher uptake was observed following 24 hours of 
incubation with 0.5% coumarin-6 loaded nanoparticles 6.0x10
8
 ± 0.15x10
8
 AU as 
opposed to 4.3x10
8
 ± 0.2x10
8
 AU following 18 hours of incubation. 
In the U87-MG cell line, higher uptake was observed following 24 hours 
incubation with 0.5% coumarin-6 loaded nanoparticles 5.0x10
8
 ± 0.4x10
8
 AU as 
opposed to 2.9x10
8
 ± 0.1x10
8
 AU following 18 hours of incubation, p < 0.05.  
A significant difference in the uptake of 0.05% coumarin-6 loaded nanoparticles 
was observed following 18 hours of incubation (SVGp12 4.9x10
8
 ± 0.3x10
8
, U87-MG 
2.3x10
8
 ± 0.1x10
8
, p < 0.01). 
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Figure 6.1: Cellular uptake of coumarin-6 loaded nanoparticles at 0.05, 0.1 and 
0.5% into SVGp12 cell line following 18 and 24 hours of incubation 
A higher uptake of coumarin-6 loaded nanoparticles was observed at 18 hours compared 
to 24 hours. Nanoparticle internalisation was confirmed due to the fluorescence 
observed in the cell cytoplasm. 
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Figure 6.2: Cellular uptake of coumarin-6 loaded nanoparticles into U87-MG cell 
line following 18 and 24 hours of incubation 
A higher uptake of coumarin-6 loaded nanoparticles was observed at 18 hours compared 
to 24 hours. Nanoparticle internalisation was confirmed due to the fluorescence 
observed in the cell cytoplasm. 
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Figure 6.3: DIC images of SVGp12 and U87-MG cell line showing punctate uptake 
of 0.5% coumarin-6-loaded nanoparticles following 24 hours of incubation. 
(A) SVGp12, (B) U87-MG. A higher nanoparticle uptake was observed following 24 
hours of incubation. 
A 
B 
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Figure 6.4: Data illustrating the uptake of coumarin-6 nanoparticles into SVGp12 
and U87-MG cell lines. 
The total uptake of coumarin-6 loaded nanoparticles into SVGp12 (A) and U87-MG (B) 
cell lines was quantified. Highest uptake was observed at 0.5% coumarin-6 loaded 
nanoparticles following 24 hours of incubation. Values represent mean ± S.E. for three 
experiments in triplicate.  
* 
A 
B 
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6.2.2 Effect of Nanoparticle Treatment on Cell Viability 
Following confirmation of uptake, the effect of nanoparticles on cell viability was 
examined. Blank and asiatic acid-loaded nanoparticles were prepared as described in 
Section 2.6.1. Cell viability in SVGp12 and U87-MG cell lines was assessed following 
nanoparticle treatment. Cell viability was measured using PrestoBlue
®
 where the cells 
were treated for 24, 48, 72, 120 and 168 hours with increasing amounts of the blank and 
drug-loaded nanoparticles (Figs. 6.5 & 6.6).  
Following 24 hours of 22µl blank nanoparticle treatment in SVGp12 cell line, 
75.7 ±3.9% viable cells were measured. The amount of viable cells recorded at the end 
of 168 hours, following the same treatment was 57.3 ± 4%. The asiatic acid-loaded 
nanoparticles, at 22µl, showed a viability of 53.5 ±4.1% in the SVGp12 cell line, and 
this changed to 64.6 ± 12.3% following 168 hours of the treatment. Nanoparticle 
treatments did not show any significant differences. 
In the U87-MG cell line, a viability of 79.8 ± 9.1% was measured at the end of 24 
hour upon treatment with 22µl of blank nanoparticle treatment, and was 93.3 ± 15.9% at 
the end of 168 hours. Asiatic acid-loaded nanoparticles showed a similar viability of the 
cells, which was 74.7 ± 7% at the end of 24 hours and increased to 86.1 ± 8.2% 
following 168 hours of treatment. Nanoparticle treatments did not show any significant 
differences. 
Statistical analysis of the data did not show any significant differences between 
the two cells following incubation with any treatment. 
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Figure 6.5: Data illustrating the effect of blank & loaded nanoparticle treatments 
on the viability of SVGp12 cell line 
Cell viability was measured in SVGp12 cell line 24, 48, 72, 120 and 168 hours after 
incubation with the treatments. (A) Control treatments, (B) blank, (C) asiatic acid-
loaded nanoparticle treatments. Asiatic acid and cisplatin showed a reduction in cell 
viability over time, however, no effect was seen with the nanoparticle treatments, blank 
or asiatic acid-loaded, on SVGp12 cell line. No significant differences were observed. 
Values represent mean ± S.E. for three experiments in triplicate. 
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Figure 6.6: Data illustrating the effect of blank & loaded nanoparticle treatments 
on the viability of U87-MG cell line 
Cell viability was measured in U87-MG cell line 24, 48, 72, 120 and 168 hours after 
incubation with the treatments. (A) Control treatments, (B) blank, (C) asiatic acid-
loaded nanoparticle treatments. Asiatic acid and cisplatin showed a reduction in cell 
viability over time, however, no effect was seen with the nanoparticle treatments, blank 
or asiatic acid-loaded, on U87-MG cell line. No significant differences were observed. 
Values represent mean ± S.E. for three experiments in triplicates. 
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6.2.3 Nanoparticle Cell Proliferation Assay using CFDA-SE 
To investigate the effect of nanoparticle treatments on cell proliferation, analysis 
using CFDA-SE as a marker was performed in SVGp12 and U87-MG cell lines. 
Independent treatments with 10µM cisplatin, 50µM asiatic acid and blank and asiatic 
acid-loaded nanoparticle treatments at 6µl and 22µl were performed. 
The proliferation assay on SVGp12 cell line did not show any differences in the 
rate of proliferation of cells when treated blank and asiatic acid nanoparticles as it can 
be seen from Figs. 6.7 & 6.9. A reduction in CFDA-SE fluorescence with 22µl blank 
nanoparticles from 30.9 ± 1.2% at 24 hours to 1.8 ± 0% at 120 hours was observed. 
Asiatic acid-loaded nanoparticles at 22µl showed a reduction in CFDA-SE fluorescence 
from 37.1 ± 2.1% at 24 hours to 2.2 ± 0% at 120 hours. None of these differences were 
significant when compared to the control. 
The proliferation assay on U87-MG cell line did not show any differences in the 
rate of proliferation of cells when treated blank and asiatic acid nanoparticles as it can 
be seen from Figs. 6.8 & 6.10. A reduction in CFDA-SE fluorescence with 22µl blank 
nanoparticles from 32.3 ± 1.1% at 24 hours to 2.6 ± 0.2% at 120 hours was observed. 
Asiatic acid-loaded nanoparticles at 22µl showed a reduction in CFDA-SE fluorescence 
from 37.2 ± 1.5% at 24 hours to 3.1 ± 0.3% at 120 hours. None of these differences 
were significant when compared to the control. 
Statistical analysis of the data did not show any significant differences between 
the two cells following incubation with any treatment. Thus, cells proliferated at a 
similar rate in the absence and presence of nanoparticles. 
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Figure 6.7: Flow cytometric plots showing cell proliferation using CFDA-SE on 
SVGp12 cell line following 120 hours of incubation. 
24 hours (A), 48 hours (B), 72 hours (C), 120 hours (D). Non-treated (black), cisplatin 
(red), asiatic acid (green), 22µl blank nanoparticles (blue), 22µl asiatic acid-loaded 
nanoparticles (orange). Cisplatin treatment reduced the rate of proliferation of SVGp12 
cells. No difference in the rate of proliferation of SVGp12 was observed with any other 
treatments. 
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Figure 6.8: Flow cytometric plots showing cell proliferation using CFDA-SE on 
U87-MG cell line following 120 hours of incubation. 
24 hours (A), 48 hours (B), 72 hours (C), 120 hours (D). Non-treated (black), cisplatin 
(red), asiatic acid (green), 22µl blank nanoparticles (blue), 22µl asiatic acid-loaded 
nanoparticles (orange). Cisplatin treatment reduced the rate of proliferation of U87-MG 
cells. No difference in the rate of proliferation of U87-MG was observed with any other 
treatments.  
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Figure 6.9: Data illustrating the effect of blank & asiatic acid-loaded nanoparticle 
treatments on SVGp12 cell line using CFDA-SE  
 Cell proliferation assay on SVGp12 cell line following 24, 48, 72 and 120 hours of 
incubation with the respective treatment was performed using CFDA-SE. (A) Control 
treatments, (B) nanoparticle treatments. A decrease in fluorescence indicates a higher 
rate of cell proliferation. Nanoparticle treatments, blank and asiatic acid-loaded, did not 
show any difference in the rate of cell proliferation of SVGp12 cells. Values represent 
mean ± S.E. for three experiments in triplicate. 
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Figure 6.10: Data illustrating the effect of blank & asiatic acid-loaded nanoparticle 
treatments on U87-MG cell line using CFDA-SE  
 Cell proliferation assay on U87-MG cell line following 24, 48, 72 and 120 hours of 
incubation with the respective treatment was performed using CFDA-SE. (A) Control 
treatments, (B) nanoparticle treatments. A decrease in fluorescence indicates a higher 
rate of cell proliferation. Asiatic acid and the nanoparticle treatments, blank and asiatic 
acid-loaded, did not show any difference in the rate of cell proliferation of SVGp12 
cells when compared to control, however, a reduction in proliferation was observed with 
cisplatin treatment. Values represent mean ± S.E. for three experiments in triplicate. 
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6.2.4 Nanoparticle Apoptosis Assay 
The cell proliferation assay did not show any significant differences in the rate 
of proliferation following nanoparticle treatments. We thus decided to assess the effect 
of nanoparticles on cell death using flow cytometry.  
The treatments with blank and asiatic acid-loaded nanoparticles at both the 
volumes, i.e., 6µl and 22µl did not show any significant differences on the cell lines as 
the proportion of cells in each stage were equivalent to the control treatment. 
Again, a minimal effect of blank and asiatic acid-loaded nanoparticle treatment 
can be seen at both the volumes, i.e., 6µl and 22µl and the proportion of cells in each 
stage were equivalent to the control treatment (Figs. 6.11 & 6.13). In the SVGp12 cell 
line, blank nanoparticle treatment at 22µl showed 64.6 ± 1.9%, 1.1 ± 0.3%, 2.8 ± 0.9% 
and 31.4 ± 0.9% of live, early apoptotic, late apoptotic and necrotic cells, respectively, 
following 120 hours of incubation. Asiatic acid loaded nanoparticles at 22µl showed 
71.2 ± 1.7%, 0.7 ± 0.3%, 1.6 ± 0.7% and 26.5 ± 0.7% of live, early apoptotic, late 
apoptotic and necrotic cells following 120 hours of incubation. The nanoparticle 
treatments did not show any significant differences in the SVGp12 cell line. 
In the U87-MG cell line, blank nanoparticle treatment at 22µl showed 93.3 ± 
1.2%, 1.6 ± 0.8%, 1.6 ± 0.9% and 3.4 ± 0.6% of live, early apoptotic, late apoptotic and 
necrotic cells, respectively, following 120 hours of incubation (Figs. 6.12 & 6.14). 
Asiatic acid loaded nanoparticles at 22µl showed 92.4 ± 1.4%, 7.7 ± 0.8%, 1.6 ± 0.8% 
and 4.2 ± 0.2% of live, early apoptotic, late apoptotic and necrotic cells following 120 
hours of incubation. The nanoparticle treatments did not show any significant 
differences in the U87-MG cell line. 
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Figure 6.11: Flow cytometric plots showing cell apoptosis, following blank and 
loaded nanoparticle treatments, using Annexin V/Alexa Fluor 488
®
 and propidium 
iodide on SVGp12 cells following 120 hours of incubation, under normoxia 
(A) Non-treated cells, (B) 22 µl blank nanoparticles and (C) 22 µl asiatic acid-loaded 
nanoparticles. Nanoparticle treatments did not show any significant differences in the 
cell populations when compared to control. 
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Figure 6.12: Flow cytometric data showing cell apoptosis, following blasnk and 
loaded nanoparticle treatments, using Annexin V/Alexa Fluor 488
®
 and propidium 
iodide on U87-MG cells following 120 hours of incubation, under normoxia 
(A) Non-treated cells, (B) 22 µl blank nanoparticles and (C) 22 µl asiatic acid-loaded 
nanoparticles. Nanoparticle treatments did not show any significant differences in the 
cell populations when compared to control.  
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Figure 6.13: Data illustrating the effect of blank & loaded nanoparticle treatments 
on SVGp12 cell line using annexin V/alexa fluor 488
®
 and propidium iodide, under 
normoxia  
 Cell apoptosis study following 24 (A), 48 (B), 72 (C) and 120 (D) hours of incubation 
with the respective treatment was performed on SVGp12 cell line. Data shows relative 
proportions of live (colourless), necrotic (light grey), early apoptotic (dark grey) and 
late apoptotic cells (black). Nanoparticle treatments, blank and asiatic acid-loaded, did 
not show any significant differences in cell populations when compared to control. 
Values represent mean ± S.E. for three experiments in triplicate. 
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Figure 6.14: Data illustrating the effect of blank & loaded nanoparticle treatments 
on U87-MG cell line using Annexin V/Alexa Fluor 488
®
 and propidium iodide, 
under normoxia 
 Cell apoptosis study following 24 (A), 48 (B), 72 (C) and 120 (D) hours of incubation 
with the respective treatment was performed on U87-MG cell line. Data shows relative 
proportions of live (colourless), necrotic (light grey), early apoptotic (dark grey) and 
late apoptotic cells (black). Nanoparticle treatments, blank and asiatic acid-loaded, did 
not show any significant differences in cell populations when compared to control. 
Values represent mean ± S.E. for three experiments in triplicate. 
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6.3 Discussion  
Therapeutic effects of drug loaded nanoparticles depend on the internalisation 
and sustained retention of the nanoparticles by diseased cells (Ma et al., 2011). Not only 
nanoparticle internalisation, but also its metabolism and distribution largely depend on 
the size and surface charge of the nanoparticles (Gao et al., 2013). 
As seen from Figs. 6.1-6.4, nanoparticle internalisation was observed upon the 
addition of coumarin-6-loaded nanoparticles to both cell lines. Nanoparticle 
internalisation was observed at 18 hours, however, it was higher following 24 hours of 
incubation. 
Endocytosis is the main pathway for cellular uptake of nanoparticles (Gao et al., 
2013). The endocytosed nanoparticles are then either confined within endo-lysosomes 
and are unable to reach into the cytosol, or are exported back to the exterior of the cell 
by exocytosis (Panyam and Labhasetwar, 2003; Verma and Stellacci, 2010). A study by 
Haursh-Frenkel and his associates investigated the internalisation mechanism of 
positively and negatively charged nanoparticles using a negative mutant of dynamin I-
K44A, (a GTPase responsible for endocytosis), lacking the GTPase activity of dynamin. 
Their results established that the internalisation of negatively charged nanoparticles was 
due to pathways other than the clathrin and caveolin (Harush-Frenkel et al., 2007).  
Another factor affecting nanoparticle internalisation is the negatively charged 
cell membrane. This results in a very low interaction and internalisation of negatively 
charged nanoparticles into the cell. However, some nanoparticles may be internalised 
through nonspecific binding and clustering of the particles on cationic sites on the 
plasma membrane (pinocytosis) (Agrawal et al., 2009; Kelf et al., 2010; Verma and 
Stellacci, 2010).  
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Figures 6.5 & 6.6 show the effect of blank and asiatic acid-loaded nanoparticles 
on cell viability of SVGp12 and U87-MG. It can be seen from the figure that neither of 
the nanoparticle formulations had an effect on cell viability of U87-MG.  
Although PCL has been approved by the FDA for clinical use, the degradation 
of PCL is a very slow process, and thus only suitable for a long term drug delivery 
system (Shenoy and Amiji, 2005; Sinha et al., 2004). PCL degradation can be affected 
by its molecular weight, crystallinity, environment and temperature (Coombes et al., 
2004; Passaglia et al., 2006). PCL degradation occurs by two mechanisms, the internal 
non-enzymatic cleavage and the enzymatic degradation. The non-enzymatic cleavage of 
PCL is an extremely slow process and takes 4-6 months to start. Enzymatic degradation, 
on the other hand, depends on the lipase concentration and takes about 3-4 weeks for the 
degradation to take place, depending on crystallinity (Hakkarainen and Albertsson, 
2002; Sinha et al., 2004; Woodruff and Hutmacher, 2010). In a study performed by 
Chen et al., 2000 it was demonstrated that the degradation of PCL microspheres 
initiated in 3 weeks in the presence of lipase, however, it showed no signs of 
degradation even after 9 weeks, in the absence of lipase (Chen et al., 2000). Lipophilic 
drugs in a PCL based formulation are generally distributed in the matrix, while the 
hydrophilic drugs move towards the interface and tend to be in the adsorbed state in the 
formulation. PCL based formulations have been shown to release hydrophilic drugs at a 
much higher rate than lipophilic drugs by burst release (Chen et al., 2011; X. Wang et 
al., 2009). Asiatic acid is a lipophilic drug and thus only a slow release would be 
expected. 
It has been suggested by Woodruff and Hutmacher, 2010 that PCL can only be 
bio-degraded by bacteria and fungi but not by humans or animals. This is due to the lack 
of the particular kind of lipase which is required for PCL bio-degradation. Although, 
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keeping this in mind, it is not to say that PCL is incompatible with humans, but rather it 
takes a very long time to hydrolyse. PCL can be degraded in the human body via bio-
resorption; however the process may take 2-4 years to end, and depends on the 
molecular weight (Woodruff and Hutmacher, 2010). This rate of degradation can be 
readily altered by copolymerisation with other polymers or lactides and glycolides 
(Pulkkinen et al., 2009).  
As asiatic acid is a lipophilic drug, it means that asiatic acid was dispersed in the 
matrix of the nanoparticles as opposed to surface adsorption. Within the limits of this 
project, this phenomenon has been confirmed by the in vitro drug release experiments 
that were performed on the nanoparticles (Sections 5.2.8-5.2.10). This information 
provides an explanation as to why the asiatic acid-loaded nanoparticles did not show an 
effect on cell viability (Figs. 6.5 & 6.6), cell proliferation (Figs. 6.7-6.10) or cell 
apoptosis (Fig. 6.11-6.14), in vitro.  
In addition to this, even though no significant reduction in cell viability was 
observed with the asiatic acid-loaded nanoparticles, an increase in the viability of cells 
was observed following blank nanoparticle treatment (although these differences were 
non-significant too) (Figs. 6.5 & 6.6). The monomeric and oligomeric fragments 
generated by any surface erosion/non-enzymatic degradation within the cellular system 
in vitro, are taken up in the TCA cycle (Dash and Konkimalla, 2012). TCA cycle 
generates NADH and FADH2 from acetyl CoA; NADH in turn provides cellular energy 
in the form of ATP, thus increasing cellular metabolism and ultimately cell growth and 
proliferation (Mailloux et al., 2007). This provides an explanation for the increase in 
cell viability that was observed with the blank nanoparticles.  
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GBM is the most aggressive form of glioma and represents up to 50% of all 
primary brain tumours. It is caused by many genetic and epigenetic alterations in the 
glial cells (Kanu et al., 2009). Some of these genetic alterations involve p53 mutation, 
loss of heterozygosity, PTEN mutation, MGMT methylation and EGFR amplification 
(Hegi et al., 2005; Hervey-Jumper and Berger, 2014; Kanu et al., 2009; Kleihues and 
Ohgaki, 1999). According to Cancer Research UK, the current survival rate for all types 
of brain tumours in England and Wales is 40% for one year post-diagnosis. Of this, only 
20% of patients survive for 5 years and approximately 15% survive for 10 years 
(information from Cancer Research, UK. 2014). Although most GBMs develop rapidly 
without any clinical, radiological, or morphologic evidence, secondary GBM arises 
from the primary tumours such as WHO grade II and III tumours, may look 
histologically similar but affect different age groups (Ohgaki et al., 2004). 
GBM symptoms includes headache which is not taken seriously by the patient 
leading to a late diagnosis of the tumour, making patient recovery difficult. Other 
symptoms include fits and seizures. Patients with high grade tumours show more 
serious symptoms such as epilepsy and high intra-cranial blood pressure (Klein et al., 
2010; Preusser et al., 2011). Management of GBM involves radiation and surgery 
followed by chemotherapy, although most patients do not survive more than 2 years 
(Preusser et al., 2011; Stupp et al., 2009). Although proposed therapies vary greatly, 
radiotherapy with concomitant temozolomide is the preferred mode of treatment (Mandl 
et al., 2008). Despite this, patient prognosis remains poor and radiation along with 
chemotherapy reduce the overall immunity of the patient (Chamberlain et al., 1998).  
Cisplatin, is also widely used for the treatment of brain tumours (Frezza et al., 
2010). However, the use of cisplatin is very limited due to its toxicity on normal tissue 
and adverse side effects which include immunosuppression and inhibition of platelet 
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count in the bone marrow (Florea and Büsselberg, 2011; Momekov et al., 2006; Ramesh 
and Reeves, 2002; Sheleg et al., 2002).  
More recently, interstitial brachytherapy with iodine and the use of permanent 
low-activity implants are being used as an adjuvant treatment for malignant brain 
tumours (Orringer et al., 2012; Pelloski and Gilbert, 2007; Schwarz et al., 2012; Zhang 
et al., 2012). Additionally, carmustine wafer implants following surgery are used in 
patients to prevent tumour resurrection, although it may delay wound healing and is 
associated with a higher risk of oedema (Preusser et al., 2011; Reithmeier et al., 2010; 
Wang et al., 2002).   
A great interest has arisen in the use of herbal products with anti-cancer activity 
in the treatment of cancers such as glioblastoma and breast cancer. One such drug, 
asiatic acid, is extracted from Centella asiatica and shows properties such as wound 
healing and anti-angiogenesis demonstrating low or no side effects (Gohil et al., 2010; 
Hsu et al., 2004; Kavitha et al., 2011; Singh and Rastogi, 1969).  
Tumours generally demonstrate a hypoxic microenvironment. Oxygen 
consumption in tumours is erratic due to the heterogeneity of the tumour micro-
vasculature giving rise to hypoxic micro-regions (Dewhirst et al., 1994; Gnaiger, 2003; 
Maxwell et al., 2001). Although mammalian tissue can tolerate a wide range of oxygen 
tension, a drop in the partial pressure of oxygen leads to the activation of the hypoxia 
inducible factor. The HIF system comprises of the α and β (also known as ARNT) units. 
While the β unit is continually expressed, stability of the α subunit is mediated by the 
oxygen dependent domain (ODD) and the α subunit undergoes rapid degradation by the 
product of the tumour suppressor gene called the von Hippel-Lindau tumour suppressor 
gene (VHL). Thus, the α-subunits are undetectable when the oxygen tension is high 
(21%). When the oxygen tension is reduced, a stabilisation and an increase in the HIF-
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1α level occurs, HIF-1α translocated into the nucleus where dimerisation with the 
ARNT via the PAS (basic helix-loop-helix DNA binding motif) domain occurs, leading 
to the transcription of a wide array of genes (e.g. EGF, PDGF, VEGF and lactate 
dehydrogenase) that are involved in the cell’s adaptation to hypoxia (Giaccia et al., 
2003; Liu and Simon, 2004; Maxwell, 2003; Semenza et al., 2000). 
As the gene expression and hence cellular metabolism is altered under hypoxia, 
we investigated the effects of asiatic acid under hypoxia along with our control drug-
cisplatin. The effects of cisplatin and asiatic acid on cell viability, proliferation, cell 
cycle, apoptosis and the generation of reactive oxygen species were studied. 
As we already know, HIF-1α  is an important regulator of transcription under 
hypoxia and so, an initial increase in HIF-1α is important for cell’s adaptation to 
hypoxia (Strese et al., 2013). Cell’s adaptation to hypoxia involves angiogenesis 
stimulation via VEGF, apoptosis inhibition via Bcl-2, modification of glucose 
metabolism and upregulation of proteins involved in metastasis. Thus, it is not 
surprising that cells under hypoxia show a slower rate of proliferation. This was 
demonstrated by the results obtained in this study where a reduction in the rate of cell 
growth and proliferation (using CFDA-SE) was observed for control treatments of both, 
SVGp12 and U87-MG cell lines. The wound healing assay, too, confirmed again that 
proliferation was slower under hypoxia as opposed to normoxia where a complete 
closure of the wound was observed. 
We also demonstrated that cisplatin cytotoxicity was significantly reduced under 
hypoxia compared to normoxia. As cisplatin works by forming DNA adducts in the cell, 
proliferation of the cell is important. However, as a decrease in cell proliferation was 
observed under hypoxia, cisplatin cytotoxicity reduced. This was confirmed by the cell 
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apoptosis study for cisplatin that was carried out under hypoxia (Koch et al., 2003; 
Rohwer et al., 2010; Song et al., 2006; Yao et al., 2005).  
On the other hand, asiatic acid did not show any differences in the rate of cell 
proliferation under normoxia or hypoxia, when compared to their respective controls. 
Cell apoptosis study showed, yet again, that the efficacy of asiatic acid was reduced 
under hypoxia as a large number of live cells were observed. Wound healing under 
hypoxia, using microscopy, showed rounded cells which are a characteristic of 
apoptosis. A partial closure of the wound for asiatic acid treatment under normoxia was 
observed. No significant differences were observed between any two cell lines with 
asiatic acid treatment. 
Cell proliferation under hypoxia is inhibited by the cyclin-dependent kinase 
inhibitor p27
Kip1
 which inhibits the activation of cyclin E-Cdk2 or cyclin D-Cdk4 
complexes thus controlling cell cycle progression at G1. Also, it has been demonstrated 
that hypoxia can decrease cell-senescence caused due to drug treatments (Chang et al., 
1999; d’Adda di Fagagna, 2008; Sullivan et al., 2008; Wartenberg et al., 2003). This 
leads into development of resistance towards anti-cancer drugs, under hypoxia.  In 
addition, as cell proliferation is slower under hypoxia, drug cytotoxicity is reduced 
(Koch et al., 2003; Rohwer et al., 2010; Song et al., 2006). This would explain the 
reason behind the results obtained for cisplatin and asiatic acid under hypoxia where a 
reduction in cytotoxicity was observed. 
Signal transduction pathways leading to various biological processes, is 
triggered by the EGFR and is associated with tumour growth such as cell cycle 
progression, invasion, metastasis, angiogenesis, and decreased apoptosis (Pore et al., 
2006; Taylor et al., 2012). In order to investigate whether asiatic acid mediates its 
cytotoxicity via modulation of EGFR expression, we measured the EGFR expression in 
232 
 
SVGp12 and U87-MG cell lines. No significant differences in receptor expression of 
SVGp12 and U87-MG cell lines were observed under normoxia or hypoxia following 
cisplatin or asiatic acid treatments.  
It has been shown previously that DNA damage due to cisplatin activates a 
signalling pathway culminating in the activation of EGFR, through an unknown 
mechanism. Cisplatin mediated EGFR activation is slow, only occurring when cisplatin-
DNA adducts start forming (Benhar et al., 2002). This EGFR activation has been shown 
to occur via p38 mitogen-activated kinase and works in a SOS-type response, activating 
DNA protein kinase mediating DNA repair and working as a survival mechanism in 
response to cisplatin (Ahsan et al., 2010). Keeping this is mind, it can only be 
speculated that cells respond in a similar fashion to asiatic acid treatment increasing 
EGFR level as a survival mechanism. Although EGFR activity may be increased 
following asiatic acid treatment in cells, asiatic acid inhibits extracellular signal-
regulated kinase (ERK) in a variety of cells, thus preventing cell proliferation despite 
the increase in EGFR (Wang et al., 2013). In addition to this, hypoxia also induces 
amplification of gene transcription and translation of EGFR. The results obtained in this 
study suggest that increased EGFR expression depends not only on drug treatments but 
also upon hypoxia and hypoxia induced amplification of EGFR. 
Cell cycle progression is a controlled and an important biochemical process. 
Cell cycle regulation is crucial and only cells that do not exhibit deleterious genetic 
mutations progress through the cell cycle. In order to investigate the effects of cisplatin 
and asiatic acid on cell cycle progress, we performed a cell cycle analysis of SVGp12 
and U87-MG cell line. Cell cycle analysis of cisplatin treated SVGp12 and U87-MG 
cells under normoxia showed G2/M phase arrest, although under hypoxia, a transient S 
phase arrest was seen for SVGp12 cells, however, the U87-MG cells showed a large 
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population of cells under G0/G1 phase which shifted towards the apoptotic population 
at 120 hours. Under hypoxia, cells accumulate p53 through a HIF-1α-dependent 
mechanism causing G0/G1 phase arrest in the cell cycle through a non-p53-mediated 
pathway (Shannon et al., 2003). It has been demonstrated previously that hypoxia 
results in a slower cell cycle progression whereas extreme hypoxia induces a pre S-
phase arrest in cells. However,  cells in the other phases of cell cycle continue to 
progress to late G1 phase before being arrested in the cell cycle progression (Amellem 
et al., 1994). Cells in the S phase of the cell cycle are more sensitive to DNA injuries 
under hypoxia. The transient G1 phase arrest is thus a possible mechanism designed to 
prevent DNA injuries due to hypoxia (Graeber et al., 1994).  
Asiatic acid treatment in SVGp12 cell line showed S-G2/M arrest under 
normoxia and G0/G1 arrest under 1% and 5% hypoxia. On the U87-MG cell line, 
G0/G1 arrest was seen under normoxia and 5% hypoxia, whereas under 1% hypoxia, S-
G2/M arrest was seen. In a study performed on breast cancer cell line, MCF-7 and 
MDA-MB-231, by Hsu et al., (2004), it was demonstrated that asiatic acid decreased the 
expression of cyclin B1, cyclin A, Cdc25c, and Cdk2, whereas it increased the 
expression of p21/WAF1  and phosphorylation of Cdk2, as well as phospho-Cdc25c. 
Cdc25c is an M phase inducer causing de-phopshorylation of cyclin B-Cdk1 complex. 
However, DNA damaged cells fail to express Cdc25c in its peak hyper-phosphorylated 
state (Shackelford et al., 1999). Thus from these studies, it can be suggested that asiatic 
acid does not induce cell cycle arrest due to DNA damage and other mechanisms may 
be involved, and thus need further investigation. 
The RB tumour suppressor gene is involved in cell cycle progression into S 
phase by phosphorylation of serine residues on the RB gene product by Cdk4/cyclin D. 
A loss in the Rb-phosphorylation of these sites would result in inhibition of cell cycle 
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progression into S phase (Bretones et al., 2014; Shukla and Gupta, 2007). Thus, it can 
be speculated that asiatic acid causes cell cycle arrest due to the downregulation of Rb 
protein causing an arrest in the G0/G1 phase of cell cycle, although other mechanisms 
may be involved. 
We also performed combination studies using cisplatin and asiatic acid, under 
normoxia only, in order to study any synergism that may be involved. The combination 
treatments showed a reduction in cell viability that was comparable to individual drug 
treatments at the same time points. It has been shown as a part of this study that asiatic 
acid causes S-G2/M in SVGp12 and G0/G1 arrest in U87-MG cells. The cytotoxicity 
observed in cells was mainly due to asiatic acid as this is a fast acting drug and induces 
cell cycle arrest along with apoptosis within 24 hours of treatment. Thus, as the cells are 
already arrested in one of the phases of cell cycle, cell proliferation slows down and 
cisplatin fails to create DNA adducts in the cell.  
Cell death can occur due to apoptosis or necrosis. We investigated the effects of 
cisplatin and asiatic acid on cell apoptosis SVGp12 and U87-MG cells under normoxia 
and hypoxia. Cisplatin treatment under normoxia showed cell death mainly due to 
apoptosis, although the number of apoptotic cells under hypoxia was less compared to 
normoxia. Asiatic acid, too, mainly caused cell death due to apoptosis, however, a 
smaller fraction of cells underwent necrosis. 
Cisplatin causes cell death mainly via the mitochondrial signalling pathway 
through activated caspase-3 (Cummings and Schnellmann, 2002; Florea and 
Büsselberg, 2006; Jiang et al., 2004). Other factors involved in cisplatin mediated 
cytotoxicity include increased efflux and decreased influx of the drug, increased cellular 
glutathione and metallothionein levels, increased DNA repair, and oncogene expression 
(Gonzalez et al., 2001). 
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Asiatic acid-mediated cell death is cell-type specific in the U87-MG cell line and 
involves caspase -9 and -3 activation (Bunpo et al., 2004; Cho et al., 2006; Kavitha et 
al., 2015). However, there are other mechanisms involved in cell death due to asiatic 
acid and these include reduction in mitochondrial membrane potential due to 
endoplasmic reticulum stress, inhibition of Bcl-2 expression in cells and intracellular 
calcium release. Asiatic acid also causes a loss in the phophatidylserine (PS) asymmetry 
in cells leading to exposure of PS on the outer membrane of the cell. In addition, asiatic 
acid also leads to DNA fragmentation in some cells (Bunpo et al., 2004; Cho et al., 
2006; Hsu et al., 2004; Kavitha et al., 2015). Asiatic acid mediated necrotic cell death is 
mainly due to the release of the enzyme lactate dehydrogenase, where a rapid release 
causes traumatic cell death (Cho et al., 2006; Scaffidi et al., 2002). 
We observed that apoptotic activity under hypoxia was significantly less 
compared to normoxia, following treatments with both, cisplatin and asiatic acid. 
Hypoxia has a tendency to select cells with a low p53 expression, where a post-
translational modification of the p53 gene occurs, making it active and promoting 
transcription of cell cycle regulating or apoptotic genes, thus reducing cell apoptosis 
(Brown and Wilson, 2004; Graeber et al., 1996; Zhou et al., 2006). Also, under hypoxia, 
cellular restoration following DNA injuries is common as opposed to normoxia, where 
these injuries are more permanent.  
In addition, an increase in the expression of MDR1 gene is observed under 
hypoxia. The MDR1 gene encodes membrane-resident P-gp protein where P-gp acts as 
an efflux pump in various types of cancers including glioma, thus causing resistance 
towards various drugs (Comerford et al., 2002; Gottesman, 2002; Liu et al., 2008). 
Hypoxia also reduces cell-senescence due to chemotherapeutic drugs, as mentioned 
earlier.  
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Hypoxia can also modulate mitochondrial activity in a cell via the suppression 
of the TCA cycle following the inhibition of pyruvate shuttling into mitochondria. The 
resultant deactivation of pyruvate dehydrogenase initiates mitochondrial autophagy by 
suppressing mitochondrial biogenesis. This ultimately causes a reduction in cell death 
and increased drug resistance (Galluzzi et al., 2008; Kim et al., 2006; Papandreou et al., 
2006; Zhang et al., 2007). It can thus be speculated that the absence of a huge 
population of apoptotic cells under hypoxia was due to hypoxia-related biochemical 
changes in the cell that have been explained above. 
We also observed that apoptosis due to cisplatin under hypoxia showed a 
percentage of apoptotic cells that did not change over time. Hypoxia creates an 
environment of stress. An approximate of 50% of all tumours contains hypoxic or 
anoxic regions. It has been demonstrated that following the introduction of a hypoxic 
environment, cells undergo an initial acclimatisation period (Grayson et al., 2006). 
Under hypoxia, the hydration of carbon dioxide is catalysed by carbonic anhydrase IX 
(CAIX), which acts to maintain the extracellular pH environment in tumour cells. Thus, 
CAIX allows the adaptation of tumour cells to hypoxia and a slow release of the 
enzyme leads to cell death under hypoxia. In this manner, due to the acclimatisation of 
cells, a small number of apoptotic cells were observed, however, as hypoxia also 
downregulates p53 promoting cell proliferation and inhibiting apoptosis, no further 
increase in the apoptotic percentage of cells was observed (Korkolopoulou et al., 2007; 
Pantuck et al., 2003; Yamagata et al., 1998).  
It is known that reactive oxygen species (ROS) play an important role in tumour 
metastasis and ROS generation can mediate cell apoptosis (Ma et al., 2009). Cancer 
cells show an increased basal level of ROS activity and are also involved in the 
activation of HIF (Huang et al., 2008; Kolamunne et al., 2013).  
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In order to understand the relationship between cell survival and ROS, we 
examined the ROS activity in cells following cisplatin and asiatic acid treatments. 
Results did not show any significant differences in the ROS activity in SVGp12 and 
U87-MG cell lines following drug treatments.  
ROS are mainly generated in the mitochondria due to aerobic respiration. In 
tumour cells, anaerobic respiration takes place, producing lactate instead of glucose as a 
source of energy. Also, HIF is a negative regulator of mitochondrial activity (Kim and 
Dang, 2006; Kim et al., 2006; Papandreou et al., 2006; Zhang et al., 2007). This could 
be a possible reason why we did not observe a change in ROS production in this study. 
Although cisplatin has been shown to mediate cell apoptosis due to ROS, 
cisplatin induced ROS generation mainly occurs in c-Myc low-expressing cells 
(Berndtsson et al., 2007; Biroccio et al., 2001; Pelicano et al., 2004). While cisplatin has 
been shown to increase ROS activity, asiatic acid has been shown to suppress ROS 
production. This is because, asiatic acid interference with the mitochondrial membrane 
potential stimulates cytochrome c release which initiates caspase signalling pathways 
(Lee et al., 2002; Tang et al., 2009). Transcription, upregulation and translocation of 
cytochrome c, into cell cytosol from the mitochondria, results in dynamic changes 
including downregulation Bcl-2 proteins, opening of permeability transition pore and 
loss of mitochondrial membrane potential, ultimately causing cell death (Chandra et al., 
2002; O’Brien and Kirby, 2008). Thus, we speculate that asiatic acid causes cell death 
via downregulation of ROS.  
Keeping in mind the results generated above, problems with asiatic acid 
administration involve reduced solubility due to its hydrophobicity thus potentially 
decreasing its bioavailability (Cho et al., 2006; Lee et al., 2002; Zhao et al., 2010).  In 
order to overcome this problem, we formulated asiatic acid-loaded nanoparticles using 
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the synthetic polymer poly-ε-caprolactone. PCL is a non-toxic polymer approved by the 
FDA for clinical use and the applications include suture coating and surgical stent 
supports (Cho et al., 2002; Sarasam, 2001; Shenoy and Amiji, 2005; Tarafder et al., 
2013).  
Blood brain barrier is the biggest challenge to the delivery of chemotherapeutic 
drugs into the brain. We speculated that the preparation of nanoparticles smaller than 
the pore size of the BBB fenestrations would theoretically allow the free movement of 
nanoparticles into the brain microenvironment.  
We prepared monodisperse, negatively charged asiatic acid-loaded nanoparticles 
with a smooth spherical surface. These particles were stable at 4°C for a minimum of 60 
days and were characterised for drug loading and drug release. We demonstrated a 
steady drug release in PBS containing lipase due to the enzymatic PCL degradation; no 
drug release was observed in the absence of lipase. As PCL is hydrophobic, it degrades 
slowly in an aqueous medium, in the absence of lipase. The presence of lipase causes 
disruption of ester bonds, thus degrading the polymer and leading to drug release. It is 
also known that cancer cells have an acidic microenvironment; thus we also investigated 
drug release in PBS pH 5.5. Although we observed PCL degradation at pH 5.5, drug 
release into the supernatant did not occur. This can be attributed to the 4.7 pKa value of 
asiatic acid which can cause repulsive forces in the acidic medium, thus preventing drug 
release from the nanoparticles. 
Although we demonstrated that the nanoparticles were stable for a minimum of 
60 days in aqueous medium at 4°C, an even longer storage of nanoparticles involves 
freeze drying. Freeze drying of blank and asiatic acid-loaded nanoparticles showed a 
10-fold increase in size and re-hydration was difficult as the particles settled at the 
bottom of the vial and large clumps were observed. We thus decided to not freeze dry 
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the formulation for any further experiments but continue long term storage in distilled 
water.  
Following nanoparticle characterisation, we investigated the effects of 
nanoparticles on in vitro cell lines, SVGp12 and U87-MG. As the cytotoxic effects of 
nanoparticles would depend upon nanoparticle internalisation into the cells, we 
investigated this using microscopy. Nanoparticle internalisation into SVGp12 and U87-
MG cells was observed at 18 hours and was higher at 24 hours. Cell membranes carry a 
negative charge on the outside. This leads to a low interaction between the cell 
membrane and the negatively charged nanoparticles and thus nanoparticle 
internalisation is reduced. However, some nanoparticles may be internalised through 
nonspecific binding and clustering of the particles on cationic sites on the plasma 
membrane (pinocytosis) (Agrawal et al., 2009; Kelf et al., 2010; Verma and Stellacci, 
2010).  
Following nanoparticle internalisation studies, we investigated the effects of 
nanoparticle formulations on cell viability. Neither of the nanoparticle formulations, 
blank or asiatic acid-loaded, had an effect on cell viability of SVGp12 and U87-MG. 
This can be explained due to the fact that PCL degradation, due to hydrolysis, is a slow 
process and depends on the molecular weight and the crystallinity of the compound 
(Coombes et al., 2004; Passaglia et al., 2008). PCL hydrolysis is an extremely slow 
process and takes 4-6 months to start (Hakkarainen and Albertsson, 2002; Sinha et al., 
2004; Woodruff and Hutmacher, 2010). In addition, it was brought to our attention by 
Woodruff and Hutmacher, (2010) that PCL can only be bio-degraded by bacteria and 
fungi but not by humans or animals and this is due to the lack of the particular kind of 
lipase required for PCL bio-degradation. Although PCL can undergo degradation due to 
hydrolysis, this is a very slow process and take can up to 4 years in the human body 
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(Woodruff and Hutmacher, 2010). As asiatic acid is a hydrophobic drug, it was mainly 
encapsulated due to dispersion in the nanoparticle matrix and as a result of no/low 
degradation of PCL by in vitro cells, drug could not be released into the medium. Thus, 
asiatic acid-loaded nanoparticles did not show an effect on cell viability, cell 
proliferation or cell apoptosis in vitro. 
 
8 CONCLUSION 
Asiatic acid has demonstrated cytotoxic activity in the glioblastoma cell line, in 
vitro. An increased apoptosis under hypoxia, in comparison to cisplatin was observed. 
Although asiatic acid did not show any effects on cell proliferation, cell cycle arrest was 
observed. Results of this study have also shown that asiatic acid possess a higher 
cytotoxicity compared to cisplatin under hypoxia. In addition, as asiatic acid is a herbal 
compound with low side-effects, it could possibly replace the use of chemotherapeutic 
drugs in the market, and the results from study have demonstrated the anti-cancer 
effects. 
Results of this study have also demonstrated that PCL nanoparticles cannot be 
used a short term delivery mode in humans due to the lack of degradation following 
uptake into cells.  
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9 FUTURE WORK 
  
242 
 
In an attempt of cell survival as result of hypoxia, various gene expressions are 
modulated due to oxygen stress. Keeping in mind the time scale of this project, we did 
not have the opportunity to acclimatise cells to hypoxia prior to performing drug 
treatments. In order to study the effects of hypoxia on cellular response to drug 
treatments, it is important to acclimatize cells to hypoxia in order to optimise energy 
metabolism and protein expression due to mitochondrial alteration, and reduce oxidative 
stress (Levett et al., 2012; Watson et al., 2009). Future studies could involve 
acclimatisation of cells to hypoxia for a minimum period of 8-10 weeks. Cells can be 
introduced to hypoxia from normoxia and the oxygen tension can be gradually 
decreased over a period of 10 weeks in order to reduce the effect of oxygen stress on the 
cells. Protein measurements including caspases, p53, P-gp and cyclins levels can be 
checked at each stage to give an idea of the change in cellular metabolism resulting due 
to oxygen stress. This would help obtain a better understanding of the effects of asiatic 
acid under hypoxia.  
In addition, it has been estimated that tumour areas are exposed to cycling 
hypoxia that can range from 12-43%. This has direct consequences on tumour 
behaviour and promotes spontaneous metastasis. In this manner, the effectiveness of 
anti-cancer therapies is affected and the cells are more chemo- and radio-resistant 
(Cairns et al., 2001; Olbryt et al., 2014; Rofstad et al., 2007). Also, oxygen level in 
tumours is found to be heterogeneous. Thus it would be beneficial to expose cells to 
cycling hypoxia and measure the levels of different proteins that are affected by 
hypoxia. This would expand the knowledge towards understanding the behaviour of 
cells under hypoxia and help in designing strategies to overcome this. 
As cellular metabolism is altered under hypoxia, it would be useful to study the 
differences in cellular metabolism of non-treated and asiatic acid treated cells under 
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normoxia and hypoxia. This would be beneficial in understanding the mechanism of 
increased tumour cell survival and decreased cytotoxicity of drugs under hypoxia and 
can be performed using the Seahorse Biosciences. Cells can be examined for 
mitochondrial stress by measuring mitochondrial respiration and glycolysis; this would 
help assess cellular metabolism and characterise the metabolic phenotypes by enabling 
real time measurement of intact cells (Parks et al., 2013; Verduzco et al., 2015).  
Although physiologically relevant information on cellular behaviour due to 
various treatments is generated through 3D live animal studies, this can sometimes be 
too far-fetched an idea. An alternative approach to this can be applied using ex vivo 3D 
cellular models in the form of cell culture spheroids, as opposed to 2D monolayers. Due 
to the formation of large cellular aggregates, the mutual contacts can be re-established 
thus generating specific micro-environments allowing them to express a tissue-like 
phenotype. In addition, 3D cell cultures provide a deeper insight into cell adhesion and 
migration (Antoni et al., 2015; De Witt Hamer et al., 2008; Pampaloni et al., 2007). Due 
to the different levels of cell depth in a spheroid, the amount of oxygen reaching each 
cell differs thus altering hypoxia conditions within the spheroid. Spheroids mimic the in 
vivo tumour masses closely and can thus provide more accurate results towards the 
behaviour of these cells in response to drug treatments. 
The results of this study have demonstrated the anti-cancer effects of asiatic acid 
under normoxia and under hypoxia. Although it has been mentioned in the literature 
that apoptosis due to asiatic acid is via caspase activation, ER stress and an increase in 
intracellular calcium, however, these studies have only been carried out under normoxic 
conditions. Therefore, it would be interesting to study the mechanism of action of 
asiatic acid under hypoxia. This could involve the use of caspase inhibitors, 
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measurement of mitochondrial membrane potential and measurement of intracellular 
calcium release.  
Immunoblotting for caspases can be carried out and relative levels can be 
quantified. However, this would require the use of high-quality antibodies that react 
with specific individual caspases. An increase in caspase level following asiatic acid 
treatment would indicate the activation of caspases for apoptosis. Caspase activation can 
also be investigated by flow cytometric analysis using anti-CD95 (Bantel et al., 2001). 
Another method of caspase detection is via measurement of cleavage of synthetic 
substrates upon their incubation with lysates of apoptotic cells. Specific substrates for 
caspases are commercially available in the market and are tagged with fluorescent 
compounds thus making measurement easy. Caspase activity can also be measured 
using caspase inhibitors. Commercially available caspase inhibitors work by reversible 
or irreversible binding to caspases, forming adducts in the cysteine residues of the 
caspases. A few examples of caspase inhibitors include zvad-fmk, YV(biotin)KD-aomk, 
biotin-YVAD-aomk, DEVD-amc and z-EK(biotin)D-aomk (Borutaite and Brown, 
2001; Cho et al., 2006; Köhler et al., 2002; Pennington and Thornberry, 2015). 
Mitochondrial membrane potential can be measured using fluorescent dyes such 
as tetramethylrhodamine methyl and ethyl ester, rhodamine 123, 3,3′-
dihexyloxacarbocyanine iodide and 5,5′,6,6’-tetrachloro-1,1’,3,3′-
tetraethylbenzimidazolylcarbocyanineiodide. Mitochondrial accumulation of these dyes 
can be visualised by microscopy or quantified using flow cytometry and fluorescent 
plate reader. As these dyes are cationic, the amount of mitochondrial accumulation of 
these dyes will provide an inverse proportion to the measure of the mitochondrial 
membrane potential (Ly et al., 2003; Nicholls and Ward, 2000; Perry et al., 2011).  
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Apoptosis due to calcium release can be using TMB-8, dantrolene, Fura-2 and 
EGTA, all of which are calcium channel blockers. TMB-8, Fura-2 and dantrolene are 
intracellular calcium channel blockers, whereas EGTA is an extracellular calcium 
channel blocker. The use of specific blockers would answer if apoptosis due to asiatic 
acid is via intracellular or extracellular calcium release or neither (Hsu et al., 2004; 
Wertz and Dixit, 2000). In addition, immunoblotting can also be used. 
The results of this study have been unable to clearly identify cell cycle arrest 
mechanisms. It would be beneficial to study the effects of asiatic acid on cell 
proliferation and cell cycle arrest mechanisms, under normoxia and hypoxia. The results 
of this study have shown that asiatic acid does not affect cell proliferation. Also, cell 
cycle arrest due to asiatic acid is cell type specific and may depend on oxygen level, as 
has been observed in the results obtained. Cell cycle arrest due to asiatic acid can be 
confirmed by using high quality cyclin-specific antibodies for immunoblotting. 
Measurements of cyclin A, B and E, p21/WAF1,p38 kinase, MAPK, p53, Cdc2 and 
Cdc25c could provide a further insight into the arrest mechanisms.  
It would also be beneficial to study the downregulation of apoptosis due to 
hypoxia in asiatic acid treated cells. DNA breaks due to asiatic acid can be studied 
through southern blotting and would provide an insight into the direct effects of asiatic 
acid on cellular DNA.  
Although we did not see any degradation of PCL nanoparticles in the absence of 
lipase, alternative approaches can be applied. Conversion of PCL nanoparticles prepared 
in this study into a hydrogel formulation could be a useful tool in the post-operative care 
of brain tumours. As PCL can take up to 4 years to degrade, the slow drug release from 
the resultant hydrogel degradation over time would be helpful in preventing relapse 
following tumour removal (Woodruff and Hutmacher, 2010). In addition, modification 
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of the preparation technique to allow a higher drug loading might be extremely 
beneficial in long term hydrogel implantation into the tumour site. 
Modification of PCL nanoparticles, for rapid degradation, using natural 
polymers can also be investigated. Few examples of natural polymers include chitosan, 
alginate, hyaluronan, albumin and dextran (Almond et al., 2003; Augst et al., 2006; Cai 
et al., 2010; Gurski et al., 2010; Souza et al., 2010; Susa et al., 2009; Ta et al., 2008; van 
Dijk-Wolthuis et al., 1995). On the other hand, asiatic acid loaded nanoparticles using 
only natural polymers can be investigated. 
The transport of asiatic acid-loaded nanoparticles across the blood brain barrier 
and its effects in a flow-based 3D cell culture apparatus can be studied using the Flocel 
Dynamic in vitro Blood Brain Barrier (DIV-BBB) model (FlocelInc, Ohio, USA). The 
Flocel apparatus mimics the blood brain barrier in vitro, and can be a helpful tool in 
assessment of asiatic acid toxicity. Other models of in vitro drug transport evaluation 
include using filter inserts allowing the growth of endothelial cells on one surface and 
astrocytes on the other. Although the formation of tight junctions is observed, this is a 
static model lacking the presence of dynamic pulsatile flow and also the capillary 
endothelial monolayer is 150 times more permeable than BBB in vivo. The lack of 
pulsatile flow leads to an inability to produce active transport mechanisms and 
metabolic transformations. This is a major drawback in assessing drug transport across 
the BBB as the bioavailability of the drug is reduced (Cecchelli et al., 1999; Deli et al., 
2005; Naik and Cucullo, 2012; Pardridge et al., 1990).  
The advantage of using the Flocel DIV-BBB model over any other BBB model 
is that it replicates the physiological levels of shear stress experienced by in situ 
endothelial cells. It also allows the formation of physiological trans-endothelial 
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resistance, and formation of gap junctions. Thus, this BBB model resembles closely to 
the in vivo BBB, both functionally and anatomically (Naik and Cucullo, 2012). 
PCL nanoparticles that were prepared in this study can be injected through the 
BBB system to investigate the transport of these particles across the barrier. The 
dynamic flow of the system and the resultant movement of nanoparticles may lead to a 
mechanical stress causing some breakdown of the nanoparticles allowing drug release.  
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